Factors Regulating Features of Metabolic Syndrome by Pijut, Sonja S.
University of Kentucky 
UKnowledge 
Theses and Dissertations--Pharmacy College of Pharmacy 
2017 
Factors Regulating Features of Metabolic Syndrome 
Sonja S. Pijut 
University of Kentucky, srhee2@uky.edu 
Digital Object Identifier: https://doi.org/10.13023/ETD.2017.044 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Pijut, Sonja S., "Factors Regulating Features of Metabolic Syndrome" (2017). Theses and Dissertations--
Pharmacy. 70. 
https://uknowledge.uky.edu/pharmacy_etds/70 
This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It 
has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Sonja S. Pijut, Student 
Dr. Gregory A. Graf, Major Professor 
Dr. David J. Feola, Director of Graduate Studies 
 
 
 
 
 
 
 
 
 
 
FACTORS REGULATING FEATURES OF METABOLIC SYNDROME 
 
 
 
 
 
 
____________________ 
DISSERTATION 
____________________ 
 
 
 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
Graduate School at the University of Kentucky 
By 
Sonja Sheena Pijut 
Lexington, Kentucky 
Director: Dr. Gregory A. Graf, Professor of Pharmaceutical Sciences 
Lexington, Kentucky 
2017 
Copyright © Sonja Sheena Pijut 2017 
  
 
 
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
FACTORS REGULATING FEATURES OF METABOLIC SYNDROME 
The collective presence of central obesity, low HDL-cholesterol, and elevated triglycerides, blood 
pressure, and fasting blood glucose constitutes Metabolic Syndrome (MetS), a disease state that 
increases the risk of cardiovascular disease (CVD) and Type 2 Diabetes Mellitus (T2DM). 
Nonalcoholic fatty liver disease (NAFLD), present in up to 90% of obese adults, is also linked to 
MetS. As in CVD, disruptions in cholesterol metabolism play a contributing role in the 
development of T2DM and NAFLD. Genes involved in cholesterol synthesis, secretion, and 
catabolism are diurnally regulated in the liver and adipose. Disruptions in the sleep-wake cycle 
are thought to potentiate metabolic disorders associated with CVD, thus revealing a potential role 
of disrupted circadian rhythms in the development of MetS phenotypes. 
We initially observed that a group of clock-controlled genes in the Par bZip family were 
downregulated in adipose tissue of obese mice and humans. Further studies revealed that deletion 
of the core clock gene, Bmal1, from adipose tissue alone (ABKO mice) or in combination with 
the liver (LABKO mice) altered feeding behavior and locomotor activity. Obesity was increased 
in LABKO mice but there were no further detrimental effects in either ABKO or LABKO mice. 
Interestingly, high-fat diet suppressed Bmal1 transcript levels in adipose tissue suggesting that the 
muted effects observed with genetic Bmal1 deletion were likely due to the overpowering effects 
of a high-fat diet. 
Cholesterol metabolizing and bile acid synthesizing enzymes oscillate diurnally at the 
transcriptional level. Promoting cholesterol elimination through bile acid synthesis and biliary 
secretion is essential for reducing hepatic cholesterol, a perpetrating factor in the progression of 
NAFLD. Previous studies in animal models demonstrated that deletion of the hepatic cholesterol 
transporters, Abcg5 and Abcg8 (G5G8), decreased biliary cholesterol secretion and increased 
obesity and hepatic steatosis. Ursodiol (Urso) increased G5G8 protein expression and in 
combination with ezetimibe, a cholesterol-lowering agent, showed promise as a therapeutic for 
NAFLD. However, bile acid synthesis was suppressed in the presence of Urso and ezetimibe, 
suggesting that the overall effect on cholesterol elimination was minimized. The increase in 
G5G8 and decrease in bile acid synthesis was associated with an increase in Fgf15/19, a 
suppressor of bile acid synthesis. In order to determine if and how FGF15/19 regulates G5G8, 
mice were injected with FGF19. G5G8 protein expression and biliary total cholesterol were 
increased. Additionally, G5G8 localized to the canalicular surface of hepatocytes. Urso caused a 
similar localization of G5G8 that appeared to be dependent of the FGF15/19-FGFR4 signaling 
 
 
pathway. Interestingly, G5G8 was not required for maintaining cholesterol homeostasis in the 
presence of FGF15/19. 
Data from murine models suggest Urso and ezetimibe promote cholesterol elimination, though 
the effects may be limited by the suppression of bile acid synthesis. Nonetheless, there may be a 
therapeutic window in which optimal cholesterol elimination can be reached. Additionally, the 
effects of Urso and ezetimibe are variable between mice and humans. Given the clinical 
availability of the two drugs, the translatability into humans and the potential to address whether 
Urso and ezetimibe can minimize NAFLD is great. 
KEYWORDS: Obesity, Insulin Resistance, NAFLD, Circadian rhythm, G5G8, FGF15/19
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CHAPTER 1: INTRODUCTION 
Cardiovascular disease (CVD), the leading cause of death worldwide, is significantly increased 
with obesity, Type 2 Diabetes Mellitus (T2DM), dyslipidemia, and hypertension. The cumulative 
presence of these CVD-related risk factors is described as Metabolic Syndrome (MetS). 
Emerging as an associated feature of MetS is nonalcoholic fatty liver disease (NAFLD). NAFLD 
is highly prevalent in obese individuals and is likely an independent risk factor for CVD as well 
[1]. As in CVD, disruptions in cholesterol metabolism play a causative role in the development 
and progression of NAFLD.  
Glucose and lipid metabolism display diurnal rhythmicity, suggesting the importance of circadian 
rhythms in maintaining energy homeostasis. Studies reveal that altered sleep-wake cycles are 
associated with features of MetS including obesity and dyslipidemia [2, 3]. Additionally, glucose 
and lipid metabolizing enzymes, including those involved in cholesterol synthesis, secretion, and 
catabolism, exhibit diurnal regulation. This reveals a potential role of disrupted circadian rhythms 
in the development of MetS phenotypes. 
Overview of Metabolic Syndrome 
The group of risk factors that constitute Metabolic Syndrome (MetS) include central obesity, low 
HDL-cholesterol, and high triglycerides, fasting blood glucose, and blood pressure. These risk 
factors tend to occur in combination, and the presence of three or more defines MetS. Individuals 
with MetS have an even greater risk of CVD compared to the sum of the risk associated with each 
risk factor. As the prevalence of obesity continues to rise, a similar trend is observed with MetS. 
Approximately 35% of adults in the United States were thought to have MetS between 2011 and 
2012, though the prevalence is highly variable between sex, age, and ethnic groups [4]. MetS is 
more prevalent in females, adults 60 years of age and older, and in Hispanics [4]. Nonetheless, 
MetS is consistently higher in overweight and obese individuals within each group underscoring 
the important relation between obesity and MetS [5, 6]. 
History 
Features of MetS were first described in the 1920s by two groups of physicians observing an 
association between T2DM and hypertension in their patients [7]. Subsequently, a number of 
researchers made similar observations linking various metabolic disorders. In 1988, it was 
proposed that the common factor in individuals with impaired glucose tolerance, 
hyperinsulinemia, elevated very low density lipoprotein (VLDL)-triglycerides, elevated high 
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density lipoprotein (HDL)-cholesterol, and hypertension was insulin resistance [7, 8] . Central 
obesity was later included as part of the cluster of risk factors [7]. Though MetS centers around 
the core disease states of obesity, insulin resistance, dyslipidemia, and hypertension, the criteria 
for diagnosis by the World Health Organization, the National Cholesterol Education Program 
Adult Treatment Panel III, the European Group for the Study of Insulin Resistance, the American 
Association of Clinical Endocrinologists, and the International Diabetes Federation vary slightly 
[7]. Thus, there is not one well-established definition for MetS. 
Etiology and Pathophysiology 
The presence of multiple diseases states as part of the diagnostic criteria gives an indication of the 
complex nature of MetS. The phenotypic presentation of MetS may also vary greatly as there are 
lean individuals who are considered “metabolically-obese” and vice versa. Therefore, the etiology 
and pathophysiology of MetS are likely explained by various interconnected physiological and 
biochemical mechanisms involving multiple organs. 
It is widely thought that obesity and insulin resistance are the underlying insults that link the 
features of MetS together. Initial efforts identified the relationship between insulin resistance and 
metabolic disorders. In a cohort of subjects from the San Antonio Heart Study followed for 8 
years, elevations in fasting insulin as a marker of insulin resistance were observed to precede the 
development of T2DM, decreased HDL-cholesterol, increased triglycerides, and hypertension [9]. 
In an insulin resistant state, impaired insulin signaling in tissues such as the liver, skeletal muscle, 
and adipose tissue reduces the glucose uptake capability of these tissues. This necessitates 
increased insulin secretion from the β-cells of the pancreas in order to maintain normal plasma 
glucose levels. Persistently increased insulin secretion leading to β-cell failure coupled with 
decreased insulin sensitivity result in the development of T2DM.  
The adipose tissue plays a key role in storing excess free fatty acids (FFAs) as triglycerides in 
adipocytes. Over-expansion of adipocytes as seen in obesity leads to adipose dysfunction 
characterized by increased inflammation and impaired insulin sensitivity. Insulin normally 
inhibits lipolysis. However, in the setting of adipose dysfunction, lipolysis and mobilization of 
FFAs to peripheral tissues are increased. FFAs are thought to increase hepatic glucose production 
and inhibit insulin-mediate glucose uptake into cells, further precipitating the insulin resistant 
state [10]. Additionally, studies reveal that visceral adipose, associated with central obesity, 
produces more inflammatory cytokines than subcutaneous adipose, leading to ectopic fat 
accumulation and insulin resistance [11, 12].  
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Clinical Significance and Treatment 
Individuals with MetS are twice as likely to develop CVD over the following 5 to 10 years and 
five times as likely to develop T2DM [13]. Features of MetS, particularly obesity and insulin 
resistance, have also been associated with NAFLD. Approximately 90% of obese individuals 
have NAFLD, though NAFLD is highly prevalent with insulin resistance independent of obesity 
as well [14]. 
Treatment for MetS involves management of individual risk factors using both non-
pharmacological and pharmacological modalities. Lifestyle modifications through diet and 
exercise remain an essential component for treatment, particularly during the initial stage. In a 
systematic review, lifestyle modification programs were found to improve quality of life and have 
beneficial effects on features of metabolic syndrome [15]. However, adapting and maintaining 
non-pharmacological, lifestyle modifications is challenging.  
Obesity 
Over one-third of adults in the United States are considered obese. Obesity, defined as having a 
body mass index (BMI) of  >30 kg/m2, precipitates a number of disease states such as T2DM, 
hypertension, CVD, sleep apnea, osteoarthritis, depression, and cancer [16]. Obesity increases 
morbidity and mortality, thus complicating all aspects of clinical care.  
Adipose Tissue and Obesity 
Adipose tissue has traditionally been viewed solely as a storage place for FFAs as triglycerides. 
While this is an important function for storing excess energy and providing insulation and 
protection, adipose tissue is now viewed as a highly metabolically active organ responsible for 
the synthesis of multiple cytokines and hormones involved in energy regulation. Adipose tissue is 
comprised of adipocytes, the site of energy storage, as well as stromal vascular cells including 
fibroblasts, endothelial cells, preadipocytes, and macrophages that support its dynamic role [17].  
The regulation of energy storage and release in adipose tissue is dependent on a series of 
pathways that occur in response to feeding and fasting. Following food intake, FFAs are 
transported through the circulation by VLDLs and chylomicron remnants. Triglycerides are 
hydrolyzed by lipoprotein lipase (LPL) located on the surface of endothelial cells of capillaries 
lining tissues such as adipose to facilitate uptake and storage of FFAs as triglycerides. Glucose is 
converted into FFAs for long term storage as triglycerides in a process called lipogenesis. When 
energy demand is high during the fasted state, lipolysis occurs. Stored triglycerides are 
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hydrolyzed to FFAs by adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) 
for release back into the circulation. Insulin and glucagon are two primary hormones essential for 
the regulation of these processes. Insulin is released during the fed state to stimulate glucose 
uptake into adipocytes as well as lipogenesis while inhibiting lipolysis. Glucagon opposes insulin 
and induces lipolysis during the fasted state. 
Adipose tissue plays a role as an endocrine organ by synthesizing and releasing cytokines and 
hormones referred to as adipocytokines. Adipocytokines are involved in regulating food intake, 
glucose and lipid metabolism, blood pressure, and immunity. Two of the more well-defined 
adipocytokines in regulating energy homeostasis include leptin and adiponectin. Leptin is 
stimulated by insulin and signals to the brain to suppress food intake and increase energy 
expenditure, mediating between feeding behavior and energy homeostasis. Peripherally, leptin 
increases hepatic lipid oxidation and lipolysis [18-20]. Accordingly, leptin-deficient (ob/ob) and 
leptin receptor-deficient (db/db) mice become morbidly obese [21, 22]. As food intake increases 
and adipocytes enlarge, leptin production increases in an effort to decrease food intake, increase 
energy expenditure and regulate fat mass. In obesity, increased leptin is ineffective in 
implementing these changes; therefore, obese individuals become leptin resistant despite having 
increased leptin. Unlike leptin, adiponectin is conversely related to fat mass. Adiponectin 
stimulates glucose uptake and fatty acid oxidation and inhibits hepatic glucose production. 
Metabolic disorders including MetS, obesity, and T2DM are associated with decreased 
adiponectin while administration of adiponectin in mouse models of obesity improves insulin 
sensitivity [23-28]. 
Adipocyte expansion during the development of obesity is also accompanied by the accumulation 
of macrophages and the release of inflammatory adipocytokines including tumor necrosis factor 
alpha (TNF-α) and interleukin 6 (IL-6). Although adipocytes produce and release TNF-α, 
macrophages within adipose tissue are the major source contributing to the increased 
inflammatory adipocytokine [29]. TNF-α has been shown to impair insulin signaling and is a 
proposed mechanism linking obesity and insulin resistance [30]. Similar to TNF-α, IL-6 inhibits 
insulin signaling and is associated with T2DM. Although doses of IL-6 administered peripherally 
increases blood glucose in humans, mice deficient of IL-6 develop obesity [31, 32]. These data 
suggest that IL-6 may induce differing effects centrally versus peripherally [32]. The release of 
inflammatory adipocytokines during the development of obesity results in a chronic inflammatory 
state that leads to adipose dysfunction and subsequently insulin resistance. 
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Adipose Tissue Depots 
Adipose tissue depots have anatomical and functional differences that become relevant in 
metabolic disease states. Subcutaneous adipose tissue is distributed throughout the peripheral, 
gluteo-femoral region and expands under normal physiological conditions to store excess FFAs. 
In contrast, visceral adipose tissue is distributed throughout the central, abdominal region and 
thought to be highly pathogenic. While subcutaneous adipose tissue produces higher levels of 
leptin and adiponectin, visceral adipose tissue produces more macrophages and inflammatory 
adipocytokines, IL-6 and fatty acid binding protein 4 (FABP-4) [11, 12]. The anatomical location 
may also contribute to the pathological tendency of visceral adipose tissue. Close proximity to the 
portal circulation suggests a greater impact of adipocytokines and FFAs from visceral adipose 
tissue on glucose and lipid metabolism in the liver. In a study measuring splanchnic FFAs in 
obese and lean humans, the proportion of hepatic FFA delivery increased with increasing visceral 
fat indicating a greater exposure of FFAs to the liver in centrally obese individuals [33]. Adipose 
tissue dysfunction that occurs in obesity can lead to the deposition of fat in tissues that do not 
normally accumulate large quantities of fat. This process, known as ectopic lipid accumulation, 
can lead to increased visceral adipose tissue as well as lipid accumulation in the liver, skeletal 
muscle, and heart. Ectopic lipid accumulation impairs the homeostatic functions of the affected 
tissues and leads to the metabolic disturbances observed in diseases such as T2DM and NAFLD.  
Insulin Resistance 
Early studies in humans provided evidence that insulin resistance, rather than insulin deficiency is 
the initiating abnormality associated with T2DM. This concept was suggested in 1936 when it 
was observed that diabetic patients had varying responses to insulin [34]. Subsequent studies 
supporting this notion revealed that insulin levels were increased with T2DM [35, 36]. Insulin 
resistance is characterized by decreased glucose uptake into tissues and increased hepatic glucose 
production resulting in hyperglycemia and hyperinsulinemia. Insulin resistance is of great clinical 
significance because it is now widely accepted that the eventual fate of insulin resistance is the 
development of T2DM. Additionally, insulin resistance and T2DM are highly associated with 
obesity, NAFLD, and other metabolic disorders known to increase the risk of CVD.  
Mechanisms of Obesity-Induced Insulin Resistance 
The mechanisms involved in obesity-induced insulin resistance include a number of alterations 
(e.g. FFA accumulation, inflammation) that converge to impair insulin signaling in adipose tissue, 
liver, and skeletal muscle. In obesity, hypertrophic adipocytes release more FFAs and 
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inflammatory adipocytokines. Accordingly, increased FFAs are observed in obese individuals 
[37]. Elevated FFAs lead to ectopic lipid accumulation and impair insulin signaling thereby 
increasing lipolysis, increasing hepatic glucose production, and inhibiting glucose uptake into 
tissues. FFAs also induce inflammation by activating Toll like receptor 2 (TLR2) and TLR4 [38]. 
Together with the increased release of adipocytokines, FFA-induced inflammatory cytokines 
promote recruitment of macrophages and other immune cells to further increase inflammation. 
Both pro- and anti-inflammatory cytokines have been identified to modulate the insulin signaling 
pathway. Some examples include TNF-α, IL-1α, and IL-10. TNF-α and IL-1α impair insulin by 
decreasing phosphorylation of insulin receptor substrate 1 (IRS-1) while IL-10 reduces 
inflammation by inhibiting NF-κB activity [39-41]. 
As in adipose tissue, excess glucose neither used for energy nor stored as glycogen are stored in 
the liver as triglycerides by undergoing lipogenesis and triglyceride synthesis. Glucose and 
insulin induce lipogenesis by regulating carbohydrate responsive element binding protein 
(ChREBP) and sterol regulatory element binding protein 1c (SREBP-1c), respectively [42-44]. 
ChREBP and SREBP-1c activate transcription of lipogenic genes in response to high-
carbohydrate diets [44, 45]. In the insulin resistant state, insulin is unable to promote glucose 
uptake and suppress hepatic glucose production though lipogenesis in the liver persists. This 
paradox, called selective hepatic insulin resistance, is thought to mediate the phenotypes 
associated with MetS. Thus, increased hepatic lipogenesis is observed in humans with insulin 
resistance or NAFLD [46, 47]. Ectopic lipid accumulation in the liver results in increased FFAs 
and lipid metabolites such as ceramides and DAG that promote mitochondrial dysfunction and 
ER stress, inducing insulin resistance [48].  
Skeletal muscle is the primary site for insulin-mediated glucose uptake and glycogen storage. As 
a result, impaired insulin signaling in skeletal muscle can have overt effects on whole-body 
glucose metabolism. Similar to other tissues, FFAs have been implicated in the development of 
skeletal muscle insulin resistance by inducing inflammation and modulating mitochondrial 
function [49]. Additionally, lipid metabolites produced as a result of ectopic lipid accumulation 
have been implicated in skeletal muscle insulin resistance [50, 51]  
Nonalcoholic Fatty Liver Disease 
NAFLD has become increasingly more prevalent over the past couple of decades and is now the 
leading cause of chronic liver disease in the United States [52]. NAFLD is the accumulation of 
≥5% liver fat not caused by known factors of fatty liver such as alcohol consumption, viral 
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hepatitis, autoimmune disease, and certain drugs. It is characterized by a continuum of disease 
severity ranging from hepatic steatosis to nonalcoholic steatohepatitis (NASH). While hepatic 
steatosis is common and relatively benign, NASH involves inflammation, fibrosis, and hepatocyte 
damage that lead to cirrhosis [53]. 
The prevalence of NAFLD ranges from 15-40% in the general population and is even greater in 
disease states that increase CVD risk including obesity, T2DM, dyslipidemia, hypertension, and 
MetS [54-57]. Indeed, NAFLD is associated with increased carotid-artery intimal medial 
thickness and carotid atherosclerotic plaques, markers of CVD [58]. Although it is more likely for 
NAFLD to be present in combination with other metabolic disease states known to increase CVD, 
NAFLD is also thought to be an independent CVD risk factor [59-61]. 
Current treatment strategies for NAFLD include lifestyle modifications for weight loss such as 
diet and exercise. Various studies show that weight loss is effective in reducing aminotransferase 
levels and hepatic steatosis as well as improving features of MetS that are commonly associated 
with NAFLD. Accordingly, the American Association for the Study of Liver Diseases 
recommends a minimum weight loss of 3-5% of body weight in order to improve steatosis [62]. 
Aside from lifestyle modifications, there are currently no pharmacologic agents approved for the 
treatment of NAFLD and NASH. 
The Hypothesis of the Two-hit Model 
Given the close association, it is likely that similar physiological and biochemical alterations are 
implicated in the pathogenesis of NAFLD and features of MetS. The pathophysiology of NAFLD 
is often explained by the two-hit model that includes two distinct mechanisms that first induce 
fatty liver (steatosis) then fatty liver with the presence of inflammation (steatohepatitis). The 
initial insult is ectopic lipid accumulation in the liver. As in obesity and insulin resistance, 
excessive FFAs are stored in the liver as triglycerides. FFAs in the liver are derived from 1) the 
release of FFAs from adipose tissue, 2) lipogenesis in the liver, and 3) the diet. Although hepatic 
lipogenesis is a minor source of FFAs in healthy individuals, it is significantly increased in 
NAFLD and insulin resistance [46, 47]. The secondary insult required for the progression of 
hepatic steatosis to NASH involves the development of inflammation and fibrosis induced by 
inflammatory cytokines, mitochondrial dysfunction, and oxidative stress. FFAs play a direct role 
by stimulating the inflammatory cytokine, TNF-α, and promoting oxidative stress [63, 64]. 
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Dyslipidemia in NAFLD 
Similar to the plasma lipoprotein profile observed in MetS, NAFLD is often associated with 
increased triglycerides and decreased HDL-cholesterol [65]. Dyslipidemia in NAFLD can be 
explained in part by mechanisms involved in insulin resistance [66]. Insulin resistance increases 
the FFA flux into the liver by inducing lipolysis in adipose tissue. Additionally, upregulation of 
SREBP-1c and ChREBP increases hepatic lipogenesis. Microsomal triglyceride transfer protein 
(MTP) and apolipoprotein CIII (apoCIII), required for VLDL synthesis, are increased in insulin 
resistance through a mechanism involving the disinhibition of forkhead box protein O1 (FOXO1) 
[67, 68]. Together, these alterations promote VLDL synthesis and secretion. In the plasma, 
circulating VLDL bind to LPL in tissues for hydrolysis and uptake of triglycerides. LPL activity 
is decreased in insulin resistance, impairing the clearance of VLDL triglycerides. Decreased 
HDL-cholesterol is commonly observed in association with increased triglycerides. It is 
hypothesized that this is mediated by the lipid transfer protein, cholesteryl ester transfer protein 
(CETP). CETP facilitates the transfer of triglycerides from triglyceride-rich lipoproteins such as 
VLDL to HDL in exchange for cholesterol, resulting in decreased HDL-cholesterol. This transfer 
is dependent on the concentration of plasma triglycerides, thus it is plausible that CETP activity is 
increased in disease states that induce hypertriglyceridemia [66, 69]. Indeed, CETP activity is 
increased in NAFLD and MetS [70]. Elevated triglycerides and decreased HDL-cholesterol are 
significant risk factors for CVD and likely to contribute to the increased risk of CVD-related 
deaths associated with NAFLD. 
Hepatic Free Cholesterol in NAFLD 
Elevated FFAs in the liver have been established to induce oxidative stress and apoptosis in 
NAFLD [63]. However, studies suggest that free cholesterol may play a role in the development 
of NAFLD and progression to NASH. A lipidomic analysis of livers from subjects with suspected 
NAFLD has revealed a significant increase in free cholesterol with NASH while cholesterol ester 
levels remain unchanged [71]. Increases in free cholesterol that correspond with Srebp-2 
expression are observed in NASH [72]. Similarly, cholesterol synthesis determined by serum 
desmosterol to cholesterol ratio as well as transcript levels of HMG-CoA reductase (Hmgcr) and 
Srebp-2 are increased with NAFLD [73]. In low density lipoprotein (LDL) receptor-deficient 
mice, the addition of cholesterol to a high-fat, high-carbohydrate diet exacerbates hepatic 
steatosis while dietary cholesterol in humans is associated with cirrhosis [74, 75]. Free cholesterol 
can form crystals within hepatocyte lipid droplets, activating Kupffer cells to promote the 
9 
 
progression of steatosis to NASH [76]. Minimizing the accumulation of excess free cholesterol in 
the liver may be effective in both the treatment and prevention of NAFLD. 
Overview of Circadian Rhythms 
Virtually all organisms regulate behavior and physiological processes such as glucose and lipid 
metabolism in synchrony to the environment. When the availability and abundance of resources 
are variable, coordination to the environment is necessary in order to optimize energy utilization. 
Modern conveniences allow availability of food and light throughout the day and night, creating 
an opportunity where rhythmic behaviors and processes become asynchronous to the intrinsic 
circadian rhythms of organisms. Consequently, waking and eating during typical rest periods are 
thought to exacerbate metabolic disorders. 
Circadian rhythms refer to patterns that occur ‘around the day’ from the Latin word circa 
meaning ‘around’ and diēm meaning ‘day.’ Circadian rhythms occur with a periodicity of 
approximately 24 hours. The period or tau (τ) is defined as the time between two recurring points 
of a cycle and the amplitude is defined as the degree of difference between the peak or trough and 
the mean value of the cycle (Figure 1.1). Circadian rhythms have the intrinsic property of 
maintaining rhythmicity independent of influences by the environment. This can be observed by 
measuring wheel running activity in mice housed in either constant dark or constant light ‘free-
running’ conditions. However, external cues (zeitgebers) have the capability to entrain the clock 
to align with the environment and play an important role in maintaining synchrony of clocks in 
varying tissues. 
Figure 1.1 
 
Figure 1.1. Pictorial representation of circadian rhythms. The mean value is the average of all 
oscillating values within a circadian cycle. The period or tau (τ) is the time between two 
consecutive peaks, troughs, or recurring point of a cycle. The amplitude is the difference between 
the peak or trough and the mean value of the cycle.  
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Molecular Components of the Circadian Clock 
The circadian clock network is comprised of transcription factors that oscillate through a 
transcriptional/translational feedback loop (Figure 1.2). BMAL1 and CLOCK, components of the 
positive arm of the loop, heterodimerize and bind to E-box sequences in the promotors of target 
genes to activate transcription. The period (Per) and cryptochrome (Cry) families are such genes 
that are upregulated by BMAL1 and CLOCK. The PER and CRY proteins in turn inhibit BMAL1 
and CLOCK, serving as the negative arm of the loop. Through this cyclic manner, the core clock 
genes—Bmal1, Clock, Per1/2, and Cry1/2—auto-regulate their own expression. Genetically 
engineered mice either lacking or with mutated forms of core clock genes exhibit varying degrees 
of impaired gene expression of core clock and clock-controlled genes as well as arrhythmic 
behavior [77-79]. Interestingly, detrimental phenotypes such as premature aging, infertility, and 
altered glucose regulation are also observed, signifying the importance of clock genes in whole 
body physiology [80-82].  
Figure 1.2 
 
Figure 1.2. Molecular components of the circadian clock network. BMAL1 and CLOCK 
heterodimerize and bind to E-box sequences to activate transcription of period, cryptochrome, 
Rev-erbα, Rorα, and the PAR bZip family. PER and CRY heterodimerize and inhibit BMAL and 
CLOCK, suppressing their own transcription. REV-ERBα and RORα bind to the retinoic acid-
related orphan receptor response element (RORE) sequence of Bmal1 to inhibit and activate 
Bmal1 transcription, respectively. Core clock and clock-controlled genes in peripheral tissues 
regulate metabolic processes.  
Downstream of the core clock genes are clock-controlled genes including nuclear receptor 
subfamily 1, group D, member 1 (Rev-erbα), retinoic acid receptor-related orphan receptor alpha 
(Rorα), and the proline- and acid-rich basic region leucine zipper (PAR bZip) family (Figure 2). 
Rev-erbα and Rorα are of particular significance as they are involved in creating an accessory 
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loop that further regulates the circadian cycle. The Rev-erbα promotor contains an E-box 
sequence recognized by BMAL1 and CLOCK. Consequently, Clock mutant mice have decreased 
Rev-erbα gene expression. REV-ERBα inhibits the transcription of Bmal1 through the recognition 
of retinoic acid-related orphan receptor response elements (ROREs). Mice deficient of Rev-erbα 
have decreased amplitude of Bmal1 mRNA and protein oscillations. RORα and REV-ERBα are 
coordinately regulated yet have opposing functions. While REV-ERBα inhibits Bmal1, RORα 
activates Bmal1 transcription. Cells deficient of Rorα have dampened oscillations of Bmal1 and 
Rorα-deficient mice have altered locomotor activity and rhythm. 
The expression of PAR bZip genes, Dbp, Hlf, and Tef, exhibit robust diurnal patterns and is 
dependent on BMAL1 and CLOCK activity. The PAR bZip proteins act as functionally redundant 
homo- and heterodimers. While phenotypes observed with the deletion of one or two PAR bZip 
genes are relatively modest, deletion of all three genes elicits epileptic seizures and impaired 
xenobiotic metabolism resulting in premature aging and mortality [83-86]. 
The Network of Central and Peripheral Clocks 
The suprachiasmatic nucleus (SCN) houses the central clock, also known as the master regulator. 
Early studies in rats with SCN lesions have linked this region of the brain to rhythmic locomotor 
activity, drinking behavior, and corticosterone secretion [87, 88]. The SCN is located in the 
hypothalamus and receives entrainment signals from the environment to cue the circadian cycle. 
While both photic and non-photic signals are received by the SCN, light is the predominant 
zeitgeber for the central clock. Light enters the retina of the eye and signals to the SCN through 
the retinohypothalamic tract [89, 90]. Neurons within the SCN undergo synchronized 
depolarization to maintain the transcriptional/translational feedback loop of the circadian cycle. 
The central clock is the pacemaker for clocks located outside of the SCN both within the brain 
and in other peripheral tissues. Neuronal and humoral signals are sent from the central clock to 
downstream peripheral clocks in order to synchronize oscillations. Transplantation of a functional 
SCN can establish rhythmicity in a mouse with disrupted circadian rhythms, demonstrating the 
hierarchical organization of circadian clocks [91]. 
As mentioned previously, peripheral clocks are regulated by signals from the central clock. 
However, circadian rhythms in peripheral tissues can oscillate independent of the central clock. 
This uncoupling of the central clock from peripheral clocks is observed in food restriction studies. 
In nocturnal mice, restricting food to the daytime under both light-dark and constant dark 
conditions reverses the rhythmic pattern of core clock and clock-controlled genes in the liver but 
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not the SCN [92]. As this study suggests, food is the main zeitgeber for peripheral clocks but not 
the central clock. Although rhythmicity in the central and peripheral clocks is coordinated in part 
through distinct mechanisms, the convergence of behavior regulated by the central clock and 
metabolism regulated by peripheral clocks in maintaining energy homeostasis necessitates 
communication between the brain and the periphery. Hormones released diurnally from the 
periphery signal to the brain to facilitate the regulation of the feeding/fasting cycle. Ghrelin is 
released from the stomach and binds to its receptor in the brain during the fasted state to stimulate 
appetite while leptin, released from adipose tissue, has an opposite effect. Insulin and leptin 
regulate neurotransmitters in the hypothalamus essential for modulating food consumption and 
energy expenditure [93]. Food consumption, regulated by the feeding/fasting cycle via the central 
clock, is associated with food anticipatory activity (FAA) that occurs immediately prior to food 
availability. FAA is observed in SCN-lesioned rats as well as mice with global disruptions in 
circadian rhythms, suggesting the role of clock-independent modalities in FAA [94, 95]. The 
integrated relationship between circadian rhythms and metabolic processes foretell the 
importance of rhythmicity in maintaining energy homeostasis. 
Circadian Dysfunction: A Contributing Factor in Features of MetS 
A relationship between impaired circadian rhythms and the development of features of MetS has 
been observed in a number of epidemiological studies. Shift workers are particularly susceptible 
to disruptions in sleep and eating cycles that contribute to misalignments between behavioral and 
physiological rhythms [96]. Increased risk of CVD has been associated with shift work, 
suggesting that maintaining synchrony between daily activities and environmental cues is 
essential for metabolic homeostasis [97]. In a cross sectional, population-based study of 27,485 
participants, obesity, high triglycerides, and low HDL-cholesterol were more common in shift 
workers compared to day workers [2]. In another study of 7,839 participants followed from birth 
to age 45, BMI, abdominal circumference, and C-reactive protein were higher in shift workers 
after adjusting for confounders [98]. The relative risk of T2DM in women was found to be higher 
with shift work in a study comparing day workers to rotating night shift workers [99]. Night 
eating syndrome is another condition that has been associated with T2DM. Although it has been 
reported that sleep onset, offset, and duration are not impaired, individuals with night eating 
syndrome have an altered feeding pattern and significantly increased caloric consumption during 
the night [100, 101]. 
In an effort to explore the cause and effect relationship between disrupted circadian rhythms and 
various aspects of metabolic disease, several genetic models targeting core clock or clock-
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controlled genes have been generated (Table 1.1). Studies from these models demonstrate the 
physiological significance of clock components on regulating energy homeostasis. While whole 
body knockout (KO) models reveal significant defects in circadian behavior regulated by the 
central clock, much interest has been gained in elucidating the importance of peripheral clocks 
with respect to metabolism.  
Table 1.1 
Gene Mutation Metabolic Defects Reference 
Bmal1 whole body KO 
Ectopic lipid accumulation; Elevated triglycerides, 
FFAs, and cholesterol; impaired gluconeogenesis 
[82, 102] 
Bmal1 liver KO Fasting hypoglycemia [103] 
Bmal1 adipose KO Increased adiposity; decreased polyunsaturated FAs [104] 
Clock whole body loss of 
function 
Obesity; hyperphagia; hyperleptinemia; 
hyperglycemia; hypoinsulinemia; hyperlipidemia; 
hepatic steatosis 
[105] 
Per2 whole body KO  
Altered lipid metabolism; Reduced epididymal fat 
pad; impaired glucocorticoid rhythm 
[106, 107] 
Cry1/Cry2 whole body, 
double KO 
Hyperglycemia; glucose intolerance; elevated 
corticorsterone levels; decreased body weight;  
[108, 109] 
Rev-erbα whole body KO Increased adiposity; hyperglycemia [110] 
Rorα whole body KO 
Atherosclerosis; hypoalphalipoproteinemia; 
decreased HDL-cholesterol 
[111] 
    
Table 1.1. Genetic mouse models of circadian dysfunction and the corresponding metabolic 
defects. Deletion or mutation of core clock and clock-controlled genes leads to alterations in 
glucose and lipid metabolism. 
The liver and adipose tissue are essential for the signaling of substances involved in glucose and 
lipid metabolism. These substances including glucose, insulin, leptin, glucocorticoids, and lipids, 
exhibit diurnal oscillations in the plasma that occur in coordination with nutrient availability, thus 
allowing energy utilization to be optimized  [82, 112-118]. Additionally, transcriptome and 
metabolome profiling studies in the liver have revealed a large portion of diurnally expressed 
transcripts and metabolites, respectively [119-121]. Approximately 10% of transcripts in the liver, 
many of which are involved in glucose, lipid, bile acid and xenobiotic metabolism, are 
rhythmically expressed [119, 121]. Liver-specific Bmal1 KO mice become hypoglycemic during 
fasting due to defects in hepatic glucose export and gluconeogenesis [103]. Liver-specific 
deletion of Bmal1 in the setting of apolipoprotein E (Apoe) whole body deletion induces 
hyperlipidemia and atherosclerosis while suppressing gene expression of the sterol half 
transporters, ATP binding cassette subfamily G, member 5 (Abcg5) and ATP binding cassette 
subfamily G, family 8 (Abcg8) (G5G8), and biliary cholesterol secretion [122]. Additionally, 
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REV-ERBα has been shown to be a regulator of bile acid synthesis [123]. The PAR bZip 
transcription factor, d site albumin promotor binding protein (DBP), is thought to regulate the 
circadian expression of cholesterol 7α-hydroxylase (Cyp7a1) in rats and has been demonstrated to 
activate phosphoenolpyruvate carboxykinase (PEPCK) in hepatoma cells [124, 125]. Together, 
these data demonstrate the role of core clock and clock-controlled genes in mediating metabolic 
processes in the liver.  
In adipose tissue, deletion of Bmal1 leads to alterations in circulating polyunsaturated FAs and 
feeding behavior, resulting in obesity [104]. Food is a potent zeitgeber for peripheral clocks and 
the timing of food intake can have significant impacts on metabolic homeostasis. Food intake 
during the rest phase induces obesity while food intake during the active phase has protective 
effects [126-130]. Furthermore, in a clinical trial assessing the influence of food timing on weight 
loss, participants consuming more calories during the early part of the day lost more weight than 
those consuming more later in the day despite similar overall caloric intake [131]. Current data 
from animal models and humans provide convincing evidence of a direct role of peripheral clocks 
in regulating energy homeostasis.  
Overview of Cholesterol Metabolism 
Cholesterol is essential for many biological functions as a component of the cell membrane and 
as a precursor for vitamin D, steroid hormones, and bile acids. Cholesterol can either be derived 
from dietary sources or endogenous cholesterol synthesis. The majority of cholesterol in the body 
comes from cholesterol synthesis, making this pathway a favorable target for regulating plasma 
cholesterol levels. Too much cholesterol can be detrimental as observed in the development of 
atherosclerosis. A physiological level is dependent on the coordinated regulation between 
cholesterol absorption, synthesis, and elimination. 
Cholesterol Synthesis, Transport, and Regulation 
Sterol homeostasis in the liver is largely maintained by processes regulating cholesterol synthesis, 
plasma lipoprotein uptake, VLDL secretion, biliary cholesterol secretion, and bile acid synthesis. 
Cholesterol synthesis is transcriptionally regulated by SREBP-2. In the setting of sufficient 
cellular sterol content, SREBP cleavage-activating protein (SCAP) binds cholesterol and forms a 
complex with insulin-induced protein 1 and 2 (INSIG1 and 2) to retain SREBP-2 in the 
endoplasmic reticulum (ER). SCAP does not interact with INSIG1 and 2 when cellular sterol 
content is low, allowing SCAP to facilitate SREBP-2 mobilization from the ER to the Golgi. 
Proteolysis of SREBP-2 in the Golgi results in transcriptional activation of cholesterol 
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synthesizing genes such as Hmgcr. Hmgcr, the rate-limiting enzyme of the cholesterol synthesis 
pathway, is a key step for regulation and the target for the cholesterol-lowering agents referred to 
as statins. Statins modulate plasma cholesterol levels by inhibiting HMGCR in hepatocytes. 
Decreases in HMGCR activity leads to a reduction in intracellular cholesterol, creating an 
environment favorable for SREBP-2 mobilization. In addition to inducing Hmgcr, SREBP-2 
increases the expression of LDL receptor (Ldlr). Upregulation of LDLR promotes the clearance 
of apo-B-containing lipoproteins thus lowering plasma cholesterol. Statins are effective in 
lowering LDL-cholesterol by as much as 60%, has been demonstrated to decrease CVD-related 
morbidity and mortality, and is the recommended treatment for primary and secondary prevention 
of atherosclerotic CVD [132]. 
Intestinal absorption of cholesterol is also a therapeutic target for dyslipidemia. Ezetimibe (EZ) 
inhibits the sterol transporter Niemann-Pick C1-like 1 (NPC1L1) to decrease plasma LDL-
cholesterol by approximately 18% [133, 134]. Interestingly, a counter-relationship between 
cholesterol absorption and synthesis has been demonstrated, suggesting a regulatory interplay 
between the two sources of cholesterol. Several studies have found that statins increase 
cholesterol absorption while EZ increases synthesis [135-138]. In the Scandinavian simvastatin 
survival study (4S), a subgroup of patients with low baseline cholesterol absorption benefited 
from simvastatin treatment by experiencing less coronary events compared to those with high 
cholesterol absorption [137, 139]. A subsequent study in the 4S subgroup revealed that 
simvastatin is more effective in suppressing cholesterol synthesis in those with higher baseline 
cholesterol synthesis [137]. Together, these data suggest that the addition of EZ to offset the 
increase in cholesterol synthesis by a statin may be more beneficial. While the clinical 
significance of a statin combined with other non-statin therapies has been conflicting, the recent 
findings from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial 
(IMPROVE-IT) have demonstrated that the addition of EZ to simvastatin not only further reduces 
LDL-cholesterol but also reduces the risk of cardiovascular events [140]. 
Endogenously-derived cholesterol along with dietary cholesterol within the liver are packaged 
into VLDL and transported into the circulation. VLDL interacts with LPL in the periphery 
resulting in the depletion of triglycerides and the conversion of VLDL to remnant particles. The 
remnant particles bind to receptors in the liver (e.g. LDLR) for removal from the circulation 
while a portion of the remnant particles are repackaged into other lipoproteins. The majority of 
plasma cholesterol is carried within LDL and is removed from the circulation via LDLR. LDL 
and other apoB-containing lipoproteins in the plasma can undergo oxidation and accumulate 
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within endothelial cells of arteries, leading to the development of atherosclerosis and increased 
CVD risk. In contrast, HDL mediates reverse cholesterol transport (RCT), a multi-step process 
that promotes the transport of cholesterol from peripheral tissues through the circulation to the 
liver for elimination. Pre-β HDL particles containing apoA1 acquire free cholesterol from 
peripheral tissues via ATP binding cassette subfamily A, member 1 (ABCA1). Upon activation 
by apoA1, lecithin:cholesterol acyltransferase (LCAT) esterifies free cholesterol associated with 
pre-β HDL resulting in the formation of mature HDL. Scavenger receptor B1 (SR-B1) mediates 
the selective uptake of cholesteryl ester from HDL into the liver. HDL can also interact with 
CETP to transfer cholesteryl ester to apoB-containing lipoproteins in exchange for triglycerides. 
Through this process, cholesterol is transported to the liver via LDLR. Cholesterol within the 
liver can then be secreted into the bile by G5G8 as free cholesterol or converted into bile acids.  
ABCG5 ABCG8: A Regulator of Sterol Homeostasis 
The ABC half transporters, G5G8, promote sterol efflux from hepatocytes and enterocytes. G5G8 
in the liver is responsible for the secretion of up to 90% of the free cholesterol entering the bile 
and involved in the final step of RCT. In the intestine, G5G8 promotes the efflux of plant sterols 
(phytosterols) and cholesterol absorbed via NPC1L1. Studies have revealed G5G8 to be direct 
targets of liver X receptor alpha (LXRα), a nuclear receptor that is activated by oxysterols and 
regulates the expression of genes involved in lipid metabolism [141, 142]. Upon transport into the 
enterocytes, cholesterol is esterified with FAs by acetyl-CoA acetyltransferase 2 (ACAT2), 
packaged into chylomicrons, and secreted through the basolateral side to be transported into the 
circulation. Phytosterols are poor substrates for ACAT2 and therefore, the majority are secreted 
from enterocytes into the intestinal lumen by G5G8. Defects in G5G8 result in a rare autosomal 
recessive disease called sitosterolemia. Characteristics of sitosterolemia include tendon 
xanthomas, arthralgias, and premature coronary artery disease that occur as a result of increased 
plasma phytosterol levels. Normally, only about 5% of ingested phytosterols are absorbed and 
retained compared to 15-60% with sitosterolemia. Plasma cholesterol levels are also increased 
due to increased intestinal absorption and decreased biliary secretion rates. Similarly in mice, 
disruptions in G5G8 leads to increased fractional absorption and plasma levels of phytosterols 
while biliary cholesterol is decreased [143]. In transgenic mice, overexpression of G5G8 yields 
an opposite effect, decreasing plasma phytosterol levels and increasing biliary cholesterol [144]. 
The role of G5G8 in governing sterol homeostasis has attracted interest as a potential therapeutic 
target for CVD-related disease states such as atherosclerosis, NAFLD, and MetS. Indeed, 
overexpression of both intestinal and hepatic G5G8 in Ldlr-/- mice placed on a high-fat, high-
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cholesterol diet increases biliary cholesterol and fecal neutral sterols and decreases fractional 
absorption of cholesterol [145]. Hepatic cholesterol as well as LDL-cholesterol and VLDL-
cholesterol fractions of plasma cholesterol are reduced and correlated with a decrease in 
atherosclerotic lesion area [145]. Liver-specific overexpression of G5G8 in Ldl-/- mice increases 
biliary cholesterol secretion but decreases fractional absorption, lesion area, LDL-cholesterol and 
VLDL-cholesterol only when intestinal absorption is inhibited by EZ [146]. Similarly, increasing 
biliary cholesterol secretion through adenoviral vectors encoding G5G8 in db/db mice leads to a 
paradoxical increase rather than a decrease in plasma cholesterol, an effect alleviated by the 
addition of EZ [147]. Together, these studies suggest that biliary secretion and intestinal 
absorption of cholesterol act cooperatively to regulate cholesterol elimination.  
Hepatic free cholesterol is thought to promote the development of NAFLD and progression to 
NASH [71-76]. Studies in mice suggest that G5G8 may play a role in modulating NAFLD and 
features of MetS [147-149]. Mice deficient of G5G8 become obese, insulin resistant, and have 
decreased biliary cholesterol secretion and increased hepatic free cholesterol when fed a high-fat 
diet [149]. In obese, insulin resistant ob/ob and db/db mice, G5G8 is decreased [148]. 
Overexpression of G5G8 in db/db mice decreases plasma triglycerides, insulin resistance, and ER 
stress [147]. Therefore, promoting G5G8 and biliary cholesterol secretion may be effective in 
alleviating features of MetS.  
The pharmacologic bile acid, ursodiol (Urso), has been shown to increase G5G8, biliary 
cholesterol secretion, and fecal neutral sterols [150]. Urso has anti-apoptotic and anti-
inflammatory properties among a number of other effects [151]. However, it is not entirely 
known what the mechanisms are for G5G8 regulation. Tauroursodeoxycholic acid (TUDCA) is 
the taurine-conjugated metabolite of Urso that acts as a molecular chaperone and also increases 
G5G8. Thus, Urso may similarly regulate G5G8 post-transcriptionally by acting as a chaperone to 
alleviate ER stress. Proper formation of G5G8 is dependent on N-linked glycosylation facilitated 
by the lectin chaperones, calnexin and calreticulin within the ER [152-154]. G5G8 is then 
transported to the canalicular surface of hepatocytes to facilitate sterol efflux [152-154]. 
Bile Acid Synthesis and Signaling 
Bile acid synthesis is essential for facilitating solubilization of dietary cholesterol, lipids, and fat-
soluble vitamins and nutrients in micelles for absorption. An equally important role of bile acid 
synthesis is cholesterol catabolism. Bile acid synthesis is the major route by which excess 
cholesterol is eliminated from the body [155]. Cholesterol is converted to bile acids by a series of 
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enzymes in the neutral or acidic pathways. Bile acids are predominantly synthesized via the 
neutral pathway involving CYP7A1. CYP7A1 catalyzes the formation of 7-α-hydroxycholesterol 
and is the rate-limiting step of bile acid synthesis [155, 156]. The two primary bile acids that are 
synthesized within the neutral pathway are cholic acid (CA) and chenodeoxycholic acid (CDCA) 
[155, 156]. CA and CDCA have differing signaling properties and the relative abundance is 
determined by sterol 12α-hydroxylase (CYP8B1) [156]. Sterol 27-hydroxylase (CYP27A1) and 
25-hydroxycholesterol 7α-hydroxylase (CYP7B1) are involved in the synthesis of bile acids 
through the acidic pathway [155, 156]. Bile acids synthesized in the liver are secreted into the bile 
canaliculi by ATP binding cassette, subfamily B, member 11 (ABCB11). Bile acids, along with 
phospholipids transported by ATP binding cassette, subfamily B, member 4 (ABCB4) and free 
cholesterol transported by G5G8, are stored in the gallbladder and released into the duodenal 
lumen in response to hormones secreted upon food consumption. Approximately 95% of bile 
acids are reabsorbed in the ileum, cycling through the enterohepatic circulation [157]. Bile acid 
absorption occurs in the ileum, mediated by the apical sodium-dependent bile acid transporter 
(ASBT) and the organic solute transporter alpha/beta (OSTα/β) located on the apical and 
basolateral surfaces, respectively [158-161]. 
With the discovery of the nuclear receptor, farnesoid X receptor (FXR), much as been revealed 
about the signaling properties of bile acids. Bile acids are ligands for FXR in the intestine and 
liver, participating in the feedback mechanism for regulating the bile acid pool [162]. FXR forms 
a heterodimer with retinoid X receptor (RXR) and binds to target genes with FXR response 
elements (FXREs) including small heterodimer partner (Shp) and fibroblast growth factor 15 
(Fgf15) [156]. SHP is a transcriptional co-repressor that indirectly binds and suppresses Cyp7a1, 
thus decreasing bile acid synthesis [163]. Mouse FGF15 and human FGF19 (FGF15/19) are 
orthologous proteins that only share about 50% amino acid sequence yet are functionally similar 
[164]. FGF15/19, stimulated in the intestine in response to FXR activation, travels to the liver via 
the enterohepatic circulation where it binds to the fibroblast growth factor receptor 4 (FGFR4) 
and β-Klotho complex. The role of FGF15/19 in regulating bile acid homeostasis via the gut-liver 
axis was evaluated in a series of experiments demonstrating that 1) FXR activation stimulates 
FGF15 in the intestine but not the liver, 2) FGF15 suppresses Cyp7a1, and 3) mice deficient of 
FGF15 have increased Cyp7a1 [163].  
Research in the field of FXR as a regulator of lipid and glucose metabolism shows promise of 
FXR as a therapeutic target for disease states associated with MetS. Initial evidence was 
established by the role of bile acid sequestrants in lowering plasma cholesterol levels. Bile acid 
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sequestrants prevent intestinal absorption of bile acids, disrupting the enterohepatic circulation of 
bile acids as well as cholesterol to the liver. CYP7A1 is stimulated to increase bile acid synthesis 
and as a result, hepatic cholesterol decreases. Decreased hepatic cholesterol leads to the activation 
of SREBP-2 to increase cholesterol synthesis and LDLR expression. Consequently, bile acid 
sequestrants are effective for reducing total cholesterol and LDL-cholesterol [165, 166]. 
Modulation of FXR is associated with changes in glucose metabolism in the liver, adipose tissue, 
and skeletal muscle [167-169]. FXR-deficient mice are hyperglycemic and exhibit impaired 
peripheral insulin sensitivity [167-169]. Activation of FXR in db/db mice suppresses hepatic 
gluconeogenesis and increases glycogen synthesis, improving insulin sensitivity [169]. In mouse 
embryonic fibroblasts, FXR deficiency impairs adipocyte differentiation, linking FXR to 
adipocyte function [167]. Interestingly, insulin signaling is impaired in skeletal muscle of FXR-
deficient mice despite the lack of FXR expression in skeletal muscle of wildtype mice [168]. 
While the effect of FXR deficiency on skeletal muscle is attributed to the increase in triglycerides 
and FFAs, the possible role of FGF15 cannot be ruled out [168]. Recently, promising results were 
demonstrated from clinical trials assessing the safety and efficacy of a synthetic, potent FXR 
agonist, obeticholic acid (OCA), in the treatment of NAFLD and NASH [170, 171]. OCA 
increases FGF19, a direct target of FXR [170]. In addition to regulating bile acid synthesis and 
stimulating gallbladder filling, FGF15/19 is involved in regulating energy homeostasis [172-174]. 
FGF19 transgenic mice have decreased fat mass and hepatic steatosis, increased energy 
expenditure, and are protected from diet-induced obesity [174]. In obese mice, FGF19 treatment 
increases metabolic rate, reducing weight gain [173]. FGF15/19 has also been shown to decrease 
hepatic gluconeogenesis and increase protein and glycogen synthesis [175, 176]. Thus, the role of 
FGF15/19 in the gut-liver axis is not limited to the regulation of bile acid synthesis but includes 
governing glucose and lipid metabolism. 
Circadian Regulation of Cholesterol and Bile Acid Metabolism 
Aspects of cholesterol and bile acid metabolism are governed by circadian rhythms. It has been 
shown in rodents that cholesterol synthesis, mediated by HMGCR, exhibits a diurnal pattern in 
the liver and intestine and appears to be highly dependent on food intake [177-179]. Similarly, 
bile acid synthesis is variable throughout a 24-hour period [180, 181]. Additional evidence of 
circadian regulation is demonstrated by the diurnal oscillations of Abcg5, Abcg8, Ldlr, Abcb4, 
Abcb11, and Cyp8b1 transcript levels in mouse liver that have been identified in the open access 
bioinformatics database, CircaDB.  
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It appears that the core clock gene, Clock, plays an essential role in the liver expression of several 
genes related to cholesterol and bile acid metabolism. In Clock mutant mice, Hmgcr, Ldlr, and 
Cyp7a1 expression are muted [182]. Furthermore, Clock mutant mice fed a diet supplemented 
with cholesterol and cholic acid accumulate more hepatic cholesterol than wildtype mice 
suggesting that cholesterol homeostasis requires functional circadian clocks [182]. Indeed, it has 
previously been reported that Clock mutant mice exhibit features of MetS including obesity, 
hyperglycemia, and hyperlipidemia [105].  
Diurnal regulation of genes involved in cholesterol and bile acid metabolism allows for 
coordination with nutrient availability that is necessary for efficient maintenance of energy 
homeostasis. In addition to modulating the cholesterol-bile acid axis for the regulation of glucose 
and lipid metabolism, targeting core clock genes to maintain rhythmicity is a potential therapeutic 
strategy for MetS and other related disease states such as NAFLD. This dissertation will explore 
the effects of peripheral circadian dysfunction particularly in the adipose and liver on the 
development of features of MetS [183]. Additionally, the role of the bile acid-FGF15/19 axis in 
sterol metabolism will be studied in order to identify a therapeutic regimen that may be effective 
in the treatment of NAFLD. 
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CHAPTER 2: ROLE OF CLOCK-CONTROLLED PAR BZIP GENES IN OBESITY AND 
INSULIN RESISTANCE 
Introduction 
Obesity is observed at higher rates in individuals with altered sleep-wake cycles, suggesting a 
causal relationship between disrupted circadian rhythms and metabolic disease. As a result, much 
attention has been focused on understanding the role of circadian clocks in energy homeostasis, 
particularly in highly metabolic tissues such as the adipose. Adipose tissue has a wide array of 
functions critical for energy regulation. Adipocytes expand to store excess FFAs as well as 
secrete hormones involved in regulating appetite, body weight, and glucose and lipid metabolism. 
These processes occur in coordination with the diurnal pattern of the feeding/fasting cycle. Thus, 
the regulation of energy homeostasis is tightly coupled to circadian rhythms.  
The circadian clock is regulated by transcriptional/translational feedback loops involving the core 
clock components, BMAL1, CLOCK, PER, and CRY. BMAL1 and CLOCK bind to E-box 
sequences of Per and Cry to stimulate transcription. In turn, PER and CRY auto-suppress 
transcription by inhibiting BMAL1 and CLOCK. When PER and CRY concentrations decrease 
below the threshold for auto-suppression, BMAL1 and CLOCK activity resumes. D-site binding 
protein (Dbp), hepatic leukemia factor (Hlf), and thyrotroph embryonic factor (Tef), members of 
the proline- and acid-rich basic regoin leucine zipper (PAR bZip) family, are direct downstream 
targets of the circadian clock network. The role of PAR bZip genes have been revealed in 
pathways involved in xenobiotic metabolism, gluconeogenesis, bile acid synthesis, and lipid 
metabolism [86, 124, 125, 184, 185]. PAR bZip triple knockout mice are prone to epilepsy and 
accelerated aging partly due to altered expression of detoxification enzymes such as constitutive 
androstane receptor (CAR) [86]. In adipose tissue, Dbp was found to regulate oscillations of 
peroxisome proliferator activated receptor gamma (PPARγ), a nuclear receptor essential for 
adipocyte differentiation and glucose metabolism [185]. Additionally, gene expression of Dbp in 
subcutaneous adipose tissue was either negatively or positively correlated to BMI depending on 
the degree of obesity [186].  
In the current study, transcriptome profiling of white adipose tissue (WAT) from wildtype and 
ATP binding cassette, subfamily D, member 2 (ABCD2)-deficient mice fed control or erucic 
acid-supplemented diets was conducted in an effort to identify potential genes implicated in the 
development of obesity. ABCD2 is a lipid transporter involved in the transport of long chain 
monounsaturated fatty acids into the peroxisome for β-oxidation [187-189]. Mice deficient of 
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ABCD2 exhibit obesity and insulin resistance only in the presence of erucic acid [187]. In this 
unique model of obesity, there was an overrepresentation of circadian-regulated genes, including 
the PAR bZip family, that were significantly deregulated in WAT of ABCD2-deficient mice fed 
erucic acid. Further analyses in other models of obesity confirmed the observation that PAR bZip 
genes are altered in WAT during obesity. 
Methods 
Animals 
Mice (n=2-6) used for the microarray study came from a previously reported study [187]. Briefly, 
8-week-old wild type and Abcd2 knockout mice were fed standard or erucic acid-enriched diets 
for 8 weeks. Lean and obese mice used to measure transcript levels of PAR bZip genes came 
from a cohort of mice from a previously reported study [149]. Mice were anesthetized by a 
ketamine/xylazine solution and euthanized by exsanguination at termination. Tissues were 
dissected, snap frozen in liquid nitrogen, and stored in -80ºC. 
Real Time-PCR 
RNA was isolated from frozen tissues using RNA STAT-60 (Tel-Test, Inc.) and the RNeasy Mini 
Kit (Qiagen). cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad). De-
identified human cDNA samples were donated by the laboratory of Dr. Philip Kern of the 
Department of Internal Medicine (University of Kentucky). Quantitative real time-PCR was 
conducted using the 7900HT Fast Real Time-PCR System (Applied Biosystems) and SYBR 
Green or Taqman assays. CT values of measured transcripts were normalized to that of Gapdh or 
Hprt. 
Statistical Analyses 
Comparisons between two groups defined by one factor were performed using unpaired t-test. 
Comparisons defined by two factors were performed using two-way ANOVA. Statistical analyses 
were conducted using GraphPad Prism (version 6). For the microarray, analyses were conducted 
by the laboratory of Dr. Arnold Stromberg of the Department of Statistics (University of 
Kentucky). Data are summarized as mean ± SEM, and statistical significance is defined by 
p<0.05. 
 
 
23 
 
 
Results 
Circadian genes are differentially deregulated in white adipose tissue of obese, ABCD2-deficient 
mice fed erucic acid. 
A genome-wide microarray of adipose tissue was conducted in wild type and Abcd2 KO mice fed 
either a standard diet or a diet enriched with erucic acid in order to identify genes involved in 
explaining the observed obesity phenotype. Of the 35,549 probes screened, 1,916 probes had a 
main effect of genotype, 4,032 probes had a main effect of diet, and 566 probes had an interaction 
effect between the two factors of genotype and diet (Figure 2.1).  
Figure 2.1 
Figure 2.1. Diagram of statistically significant and non-significant probes from a 2x2 
factorial microarray study of wild type and ABCD2 KO mice fed standard or eruric acid-
enriched diets. 566 probes were significantly deregulated by an interaction between genotype 
and diet (p<0.01). 1,916 probes had a main effect of genotype and 4,032 probes had a main effect 
of diet (p<0.01). 
The list of 566 probes that were differentially deregulated by interaction were processed through 
the Database for Annotation, Visualization, and Integrated Discovery (DAVID) version 6.7 for 
functional annotation clustering [190, 191]. The genes that were most overrepresented were 
clustered into annotation sources defined by the terms ‘rhythmic process’, ‘biological rhythms’, 
and ‘circadian rhythm’ (Table 2.1).  
 
 
35,549 probes
Interaction p-value 
<0.01
566 probes
Interaction p-value 
≥0.01
34,983 probes
Genotype p-value 
<0.01
1,916 probes
Diet p-value <0.01
4,032 probes
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Table 2.1. 
Annotation Source Terms p-value 
GOTERM_BP_FAT Rhythmic process 6.0E-5 
SP_PIR_KEYWORDS Biological rhythms 8.6E-4 
KEGG_PATHWAY Circadian rhythm 2.7E-3 
GOTERM_BP_FAT Circadian rhythm 8.7E-3 
 
Table 2.1. Functional annotation clustering output from DAVID Bioinformatics Database. 
The list of 566 probes that were differentially deregulated by an interaction between genotype and 
diet were most highly associated with ‘rhythmic process’, ‘biological rhythms’, and ‘circadian 
rhythm’ terms. The p-value represents the significance of the association measured by the 
DAVID Fisher Exact test. 
Two sets of probes for both Dbp and Tef were identified within the list of 566 probes. After 
ranking the probes from lowest to highest p-value, both sets of Dbp probes were included in the 
list of the top 20 probes with the lowest p-value (Table 2.2). 
Table 2.2 
Gene Symbol ProbF 
Per3 1.52645E-06 
Slc30a1 2.78176E-06 
Hspa1b 1.01351E-05 
Zcchc14 1.11562E-05 
Cstb 1.91807E-05 
Hist1h3b 2.12286E-05 
Nedd8 2.42598E-05 
S100a16 2.82557E-05 
Snx33 3.36851E-05 
Dbp 5.16747E-05 
Per3 5.81648E-05 
Dbp 6.26626E-05 
Trim8 6.31615E-05 
Mrps6 6.41546E-05 
Nr1d2 6.83611E-05 
Per3 7.42258E-05 
4933424C09Rik 9.60619E-05 
Fam110c 0.000119221 
Kctd6 0.000124885 
Ndrg1 0.000139583 
 
Table 2.2. Gene symbols of the top 20 probes with the lowest p-value. The effect of a 
genotype by diet interaction is highly significant in two sets of Dbp probes.  
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Dbp, Hlf, and Tef are decreased in white adipose tissue of obese mice. 
To confirm the findings from the microarray analysis in another mouse model of obesity, gene 
expression of Dbp, Hlf, and Tef were measured using real time-PCR in WAT of lean and obese 
ABCG5 ABCG8 (G5G8) knockout mice. All three members of the PAR bZip family, Dbp, Hlf, 
and Tef were significantly downregulated in obese G5G8 knockout mice compared to lean G5G8 
knockout mice (Figure 2.2). Pparα, Pparγ, and Tnfα were measured as positive controls and as 
expected, expression of Pparα and Pparγ were decreased in obese mice while Tnfα expression 
was increased (Figure 2.2). 
Figure 2.2 
 
Figure 2.2. Gene expression of PAR bZip genes in WAT of 24-week-old male G5G8 
knockout mice fed a low-fat diet (lean) or a high-fat diet (obese). Dbp, t=2.472, df=9, 
p=0.0354; Hlf, t=2.866, df=9, p=0.0186; Tef, t=3.326, df=9, p=0.0088; Pparα, t=2.825, df=9, 
p=0.0199; Pparγ, t=8.100, df=9, p<0.0001; Tnfα, t=4.450, df=9, p=0.0016. n=5 for lean, n=6 for 
obese. *p<0.05, **p<0.01.  
Dbp and Hlf are decreased in white adipose tissue of obese, insulin-resistant humans. 
Although the suppression of all three PAR bZip genes was observed in WAT of a mouse model 
of obesity, the clinical significance of this in humans is unclear. In order to better understand 
whether the clock-controlled PAR bZip genes are regulated by obesity in humans, gene 
expression was measured using RT-PCR in subcutaneous WAT in lean/insulin sensitive (IS) and 
obese/insulin resistant (IR) humans. The mean age between lean/IS and obese/IR subjects were 
similar while BMI and SI, a measure of insulin sensitivity, were significantly increased in obese, 
insulin resistant subjects (Table 2.3). 
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Table 2.3 
Lean/IS 
 Age (years) BMI (kg/m2) SI (min-1/μU/mL) 
 26 19 15.248 
 51 23 6.276 
 29 20 13.64 
 48 22 5.068 
 34 19 5.456 
 35 26 8.31 
Mean ± SEM 37.2±15.2 21.5±8.8 9.0±3.7 
Obese/IR 
 34 36 1.2 
 35 35 1.979 
 36 36 1.299 
 38 37 2.15 
 48 38 2.04 
 49 37 1.008 
Mean ± SEM 40.0±16.3 36.5±14.9**** 1.6±0.7** 
 
Table 2.3. Human subject characteristics. Age measured in years, body mass index (BMI) 
measured in kg/m2, and insulin sensitivity index (SI) of lean/insulin sensitive (IS) and 
obese/insulin resistant (IR) human subjects. SI was calculated using the minimal model 
methodology. Age, t=0.5702, df=10, p=0.5812; BMI, t=12.53, df=10, p<0.0001; SI, t=4.093, 
df=10, p=0.0022. n=6 per group. **p<0.01, ****p<0.0001. 
Gene expression of two of the PAR bZip genes, Dbp and Hlf, as well as the positive control, 
PPARG coactivator 1 alpha (Pgc1α), were significantly decreased in WAT of obese/IR subjects 
compared to lean/IS subjects (Figure 2.2). Tef expression tended to be decreased as well; 
however, the decrease was not statistically significant (Figure 2.3).  
Figure 2.3 
 
Figure 2.3. Gene expression of PAR bZip genes in WAT of lean/IS and obese/IR female 
human subjects. Dbp, t=2.338, df=10, p=0.0415; Hlf, t=2.892, df=10, p=0.0161; Tef, t=1.677, 
df=10, p=0.1244; Pgc1α, t=2.362, df=10, p=0.0398. n=6 per group. *p<0.05.  
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Discussion 
Our interest in the PAR bZip family of transcription factors was driven by the results from the 
microarray study comparing gene expression in WAT of wildtype and ABCD2 knockout mice 
fed control or erucic acid-supplemented diets. The MetS-like phenotypes observed with erucic 
acid feeding in ABCD2 knockout mice included obesity, hepatic steatosis, and insulin resistance 
[187]. The purpose of the microarray study was to identify genes that may be mechanistically 
involved in precipitating these phenotypes. Several core clock and clock-controlled genes were 
significantly deregulated when comparing wildtype mice fed a control diet versus ABCD2 
knockout mice fed an erucic acid-supplemented diet including Dbp and Tef of the PAR bZip 
family. In our study, PAR bZip genes were decreased in a diet-induced model of obesity, 
confirming the findings of the microarray analysis. Furthermore, two members of the PAR bZip 
family, Dbp and Hlf, were decreased in humans with obesity and insulin resistance as well. 
Our study provides evidence that PAR bZip genes in adipose tissue are inversely correlated with 
obesity and insulin resistance in both mice and humans. This suggests the notion that peripheral 
clocks are key factors involved in maintaining energy homeostasis. Indeed, the circadian clock 
has been found to regulate adipogenesis, lipogenesis, lipolysis, and fatty acid oxidation [106, 184, 
185, 192, 193]. However, it cannot be concluded from our current study whether altered PAR 
bZip gene expression is simply an associated outcome of obesity or if it plays a pathogenic, 
causative role in adipose dysfunction. In order to better understand the impact of the PAR bZip 
family in adipose tissue function, further studies would need to be conducted in a tissue-specific 
PAR bZip knockout model. 
In our study, we were able to translate our findings from mouse models of obesity to a human 
population of obese/IR subjects. While all three members of the PAR bZip family were 
significantly downregulated in mice, decreases in only Dbp and Hlf were significant in humans. 
This may be due to several limitations of the study including the use of a small sample size and 
the measurement of gene expression at only one time point. Another limitation of the study was 
the use of only males in the mouse experiment and only females in the human experiment. There 
are established sex differences in the characteristics of the circadian cycle, body temperature, 
melatonin release, feeding behavior, and sleep-wake cycles [194-198]. Additionally, differences 
in clock gene and protein expression have been observed in adipose tissue between morbidly 
obese males and females [199]. A more expansive study including measurements in both sexes 
during multiple time points is needed to get a better appreciation of the impact of suppressed PAR 
bZip gene expression on metabolic disease. 
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In summary, PAR bZip genes were downregulated in adipose tissue of multiple mouse models of 
obesity. These results were confirmed in human subjects, further suggesting the role of PAR bZip 
genes in adipose function. Taken together, our study extends findings from preclinical studies to 
humans and provides potential for identifying novel targets for the treatment of obesity.   
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CHAPTER 3: EFFECT OF PERIPHERAL CIRCADIAN DYSFUNCTION ON METABOLIC 
DISEASE IN RESPONSE TO A DIABETOGENIC DIET 
Introduction 
The liver and adipose tissue house peripheral clocks that regulate diurnal oscillations of factors 
involved in energy homeostasis such as glucose, insulin, and leptin [82, 115, 118]. Coordination 
between the liver and adipose tissue is essential for the regulation of glucose and lipid 
metabolism. This allows proper storage and release of fatty acids and glucose in response to the 
nutrient status. In the setting of disrupted peripheral clocks, it is thought that processes necessary 
for maintaining energy homeostasis is impaired [82, 105, 107, 192, 200]. Deletion of the core 
clock gene, Bmal1, specifically from the liver suppresses rhythmic expression of genes involved 
in glucose transport and gluconeogenesis while deletion specifically from adipose tissue alters 
feeding behavior and induces obesity [103, 104]. Given the interplay of adipose tissue and the 
liver, we hypothesized that the disruption of circadian clocks in both tissues would potentiate 
features of MetS.  
Methods 
Animals 
Mice with loxP sites flanking exon 8 (Bmal1f/f) were generously donated by Dr. Karyn Esser of 
the University of Kentucky and transgenic mice hemizygous for a Cre recombinase transgene 
driven by the adipocyte fatty acid binding protein promoter (aP2-Cre+/0) were purchased from 
Jackson Laboratory (Bar Harbor, ME). Female Bmal1f/f were bred to male Bmal1f/f-aP2-Cre+/0 
mice using trio breeding to obtain adipose-Bmal1 deletion. Recombinant adenoviral vectors 
containing no insert (Ad-Empty) or cDNA for Cre recombinase (Ad-Cre) were amplified in 
HEK293Q cells, purified on cesium chloride gradients and dialyzed against PBS. Mice were 
injected with 4x1012 particles/kg via tail vein injection. Bmal1f/f mice without the aP2-Cre allele 
were injected with Ad-Empty virus (control). Bmal1f/f mice with the aP2-Cre allele were injected 
with either Ad-Empty virus or Ad-Cre virus to generate adipose-Bmal1 knockout (ABKO) and 
liver- and adipose-Bmal1 knockout (LABKO) mice, respectively.   
Mice were maintained on a C57BL/6J background and housed 2-4 mice per cage in individually 
ventilated cages in a temperature-controlled room with access to standard rodent chow (Teklad 
2918). For breeding, mice were maintained on a 14-hour light/10-hour dark cycle. Following 
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adenoviral injection at 7-weeks old, mice were transferred to a 12-hour light/12-hour dark cycle 
for the duration of the study. 
All animal procedures were conducted conforming to Public Health Service policies for humane 
care and use of laboratory animals and were approved by the University of Kentucky Institutional 
Animal Care and Use Committee. 
Indirect Calorimetry 
Measurements for indirect calorimetry were performed on the TSE System (Chesterfield, MO). 
This system includes 24 chambers plus a reference chamber. O2 (%), CO2 (%), food intake and 
locomotor activity were directly measured from each chamber in sequence in 30 minute intervals. 
Reference measurements from room air were also taken in 30 minute intervals. The length of 
each measurement and reference measurement were determined by the measurement interval 
divided by the number of active chambers. Flow rate to the chambers was 0.45 L/min. 
Respiratory exchange ratio (RER) and energy expenditure (EE) were calculated by the system 
using measured values [CO2%, O2%, flow (L/min)]. Resting energy expenditure (REE) was 
defined as EE during the resting period (10:00 to 18:00) with a total activity count less than 150 
beam breaks/30 min. Locomotor activity is defined as the number of times a mouse breaks two 
adjacent beams in succession or breaks the same beam twice. Mice were acclimated to chambers 
for 7 days then transferred to clean chambers immediately prior to the start of measurements. 
Data from the first and last days of measurements were not included in the analyses. Data across 
three days were averaged for each mouse. 
Diet and Physiological Measurements 
For 24-hour blood glucose measurements, mice 13-24-weeks old on standard rodent chow in 12-
hour light/12-hour dark conditions were provided food only during the dark cycle for a 24-hour 
period. Blood glucose from tail vein pricks was measured every four hours for 24 hours 
beginning at circadian time 0, defined as the beginning of lights-on. 
For the diet intervention study, male mice 8-weeks old were fed either a control diet (CD) 
comprised of 63% carbohydrate, 16% fat and 21% protein (Bio-Serv F4031) or a diabetogenic 
diet (DD) comprised of 26% carbohydrate, 59% fat and 15% protein (Bio-Serve F3282). Body 
weight was measured weekly and body composition was determined by EchoMRI-100 (Echo 
Medical Systems) during weeks 8, 12, 16, 20 and 24. Adiposity was calculated by dividing fat 
mass by total body mass. 
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During weeks 12, 16, 20 and 24, fasting glucose was measured following a 4-hour fast beginning 
at lights-on. Glucose tolerance and insulin sensitivity tests (GTT and IST) were conducted during 
weeks 16 and 24. For the GTT, 10 μL/g body weight of a 20% glucose solution was injected 
intraperitoneally following a 4-hour fast beginning at lights-on. For the IST, 10 μL/g body weight 
of insulin 0.2 IU/mL was injected intraperitoneally following a 1-hour fast beginning at lights-on. 
Blood glucose levels were measured before and 30, 60, 90 and 120 minutes after the injection 
from blood obtained from a tail-vein prick. All blood glucose measurements were conducted 
using a standard glucometer. 
At the termination of the study, mice were administered ketamine/xylazine solution for sedation 
and euthanized by exsanguination. For the 24-hour gene expression, mice were sacrificed every 
four hours for 24 hours beginning at circadian time 0. For the diet intervention study, mice were 
sacrificed at circadian time 0. Blood was stored at 4ºC for four hours, centrifuged at high speed 
for 10 minutes then serum collected and stored at -80ºC. Tissues were dissected and immediately 
frozen in liquid nitrogen. For histological analysis, pieces of liver and adipose tissue were fixed in 
10% formalin for 24 hours at room temperature then transferred to 70% ethyl-alcohol for long-
term storage at 4ºC. 
Histology 
Liver and epididymal fat sections were embedded in paraffin and cut into 5 μm-thick sections. 
Sections stained with hematoxylin and eosin and Picrosirius Red were imaged at a 10x 
magnification. Adipocyte size and number were quantified using the NIS Elements software 
(Nikon Instruments, Inc., Tokyo, Japan). The image threshold and object count features were 
used to quantify three 700x700 μm areas to represent each section (2 sections per mouse).  
Hepatic Lipid Extraction and Lipid Measurements 
Hepatic lipids were extracted from 100 μg of tissue using the Folch method. Extracts were 
solubilized in 1% Triton in water as previously described [149]. Total cholesterol, triglycerides 
and non-esterified fatty acids (NEFAs) were measured using enzymatic, colorimetric assays 
(Wako Chemicals). 
Real Time-PCR 
RNA was isolated from frozen tissues using RNA STAT-60 (Tel-Test, Inc.) and the RNeasy Mini 
Kit (Qiagen). cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad). 
Quantitative real time-PCR was conducted using SYBR Green and the 7900HT Fast Real Time-
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PCR System (Applied Biosystems). For markers of lipolysis, TaqMan (Applied Biosystems) 
assays were used. Primer sequences for SYBR Green assay are listed in Table 3.1. CT values of 
measured transcripts were normalized to that of Gapdh and expressed relative to control mice on 
control diet using the ΔΔCT method. 
Table 3.1  
Gene Primer sequence 
Bmal1 
Forward 5’-ACACCAAGGAAGGATCAAGA-3’ 
Reverse 5’-GGTACCAAAGAAGCCAATTCA-3’ 
Dbp 
Forward 5’-ACCGGCCAGCTGTCTCCTGA-3’ 
Reverse 5’-CCACAGCAGCGGCGCAAAAA-3’ 
Pparg 
Forward 5’-CACAATGCCATCAGGTTTGG-3’ 
Reverse 5’-GCTGGTCGATATCACTGGAGATC-3’ 
C/ebpa 
Forward 5’-GACATCAGCGCCTACATCGA-3’ 
Reverse 5’-TCGGCTGTGCTGGAAGAG-3’ 
C/ebpb 
Forward 5’-ATTTCTATGAGAAAAGAGGCGTATGT-3’ 
Reverse 5’-AAATGTCTTCACTTTAATGCTCGAA-3’ 
Zfp423 
Forward 5’-TGGCCTGGGATTCCTCTGT-3’ 
Reverse 5’-CTCTTGACTTGTCACGCTGTT-3’ 
Hsl 
Forward 5’-GGAAAGAATTGATGGAGCCGGC-3’ 
Reverse 5’-TCCATGCTGTGTGAGAACGCT-3’ 
F4/80 
Forward 5’-CTTTGGCTATGGGCTTCCAGTC-3’ 
Reverse 5’-GCAAGGAGGACAGAGTTTATCGTG-3’ 
Mcp-1 
Forward 5’-TTAAAAACCTGGATCGGAACCAA-3’ 
Reverse 5’-GCATTAGCTTCAGATTTACGGGT-3’ 
Hmgcr 
Forward 5’-CTTGTGGAATGCCTTGTGATTG-3’ 
Reverse 5’-AGCCGAAGCAGCACATGAT-3’ 
Hmgcs 
Forward 5’-GCCGTGAACTGGGTCGAA-3’ 
Reverse 5’-GCATATATAGCAATGTCTCCTGCAA-3’ 
Abcg5 
Forward 5’-TGGATCCAACACCTCTATGCTAAA-3’ 
Reverse 5’-GGCAGGTTTTCTCGATGAACTG-3’ 
Abcg8 
Forward 5’-TGCCCACCTTCCACATGTC-3’ 
Reverse 5’-ATGAAGCCGGCAGTAAGGTAGA-3’ 
Ldlr 
Forward 5’-AGGCTGTGGGCTCCATAGG-3’ 
Reverse 5’-TGCGGTCCAGGGTCATCT-3’ 
Srb1 
Forward 5’-TCCCCATGAACTGTTCTGTGAA-3’ 
Reverse 5’-TGCCCGATGCCCTTGA-3’ 
Cyp7a1 
Forward 5’-TAGTGGCGGGCGTCCCTATT-3’ 
Reverse 5’-GCCCAGAGGATCACGAGGTG-3’ 
Cyp8b1 
Forward 5’-GCCTTCAAGTATGATCGGTTCCT-3’ 
Reverse 5’-GATCTTCTTGCCCGACTTGTAGA-3’ 
Gapdh 
Forward 5’-TGTGTCCGTCGTGGATCTGA-3’ 
Reverse 5’-CCTGCTTCACCACCTTCTTGAT-3' 
 
Table 3.1. Sequences for primers. Forward and reverse primer sequences of SYBR Green 
assays. 
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Immunoblot Analysis 
SDS-PAGE and immunodetection of proteins was conducted as previously reported [148]. To 
enrich for nuclear proteins, frozen tissues were homogenized in buffer containing Tris 
hydrochloride 20 mM, magnesium chloride 2 mM, sucrose 0.25 M and protease inhibitors. The 
homogenate was centrifuged at 2,000 g for 10 minutes and the remaining pellet was solubilized in 
protein sample buffer. An insulin syringe was used to shear DNA. For measuring total and 
phosphorylated AKT (p-AKT), the supernatant of the homogenate was collected. Protein 
concentrations were measured by BCA assay. The following primary antibodies were used: 
BMAL1 at 1:2000 dilution (Bethyl Laboratories A302-616A), total AKT at 1:5000 dilution (Cell 
Signaling Technology 4685), p-AKT at 1:5000 dilution (Cell Signaling Technology 9271), 
histone H3 at 1:2000 dilution (Cell Signaling Technology 4499), GAPDH at 1:200 dilution 
(Chemicon Internation MAB374). The secondary antibodies used were a goat anti-rabbit IgG 
horseradish peroxidase (HRP) conjugated antibody (Pierce Biotechnology 31460) and a horse 
anti-mouse IgG HRP conjugated antibody (Cell Signaling Technology 7076) at a 1:1000 dilution. 
Statistical Analyses 
Comparisons across groups defined by one factor (e.g., genotype) were performed using t-test or 
one-way ANOVA, and across groups defined by two factors (e.g., genotype and diet) using two-
way ANOVA. For gene expression measured over a 24-hour period, variances across groups 
differed. Comparisons across groups defined by one factor (e.g., genotype) while accounting for 
lean mass were performed using one-way ANCOVA. Comparisons across groups defined by two 
factors (e.g., genotype and diet) while accounting for 8-week body weight were performed using 
two-way ANCOVA. Comparisons across groups in which time was a factor were performed 
using repeated measures ANOVA. Statistical analyses were conducted using GraphPad Prism 
(version 6) and SAS (version 9.3). Data are summarized as mean ± SEM, and statistical 
significance is defined by P<0.05. 
Results 
Liver and adipose peripheral clocks mediate centrally-regulated functions. 
We generated adipose-Bmal1 knockout (ABKO) and liver- and adipose-Bmal1 knockout 
(LABKO) mice in order to study the role of adipose and liver peripheral clocks in metabolic 
disease. (Fig. 1). Peak mRNA and protein expression were blunted in adipose tissue of female 
ABKO and LABKO mice expressing the aP2-Cre transgene while mRNA and protein expression 
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were blunted in liver of LABKO mice injected with the Ad-Cre virus (Fig. 3.1A and B). 
Furthermore, the diurnal mRNA expression of Dbp, a BMAL1 target gene, was disrupted in 
adipose of ABKO and LABKO mice and in liver of LABKO mice (Fig. 3.1C).  
Figure 3.1 
 
Figure 3.1. Deletion of Bmal1 in WAT and liver of 13-24-week-old female mice on standard 
rodent chow. Hour 0 represents the beginning of lights-on. n=3-9 per group. A) Bmal1 
expression in white adipose tissue (WAT), genotype F(2, 49)=18.23, p<0.0001; time F(5, 
49)=29.76, p<0.0001; interaction F(10, 49)=6.604, p<0.0001, and in liver, genotype F(2, 
55)=8.709, p=0.0005; time F(5, 55)=22.75, p<0.0001; interaction F(10, 55)=1.860, p=0.0714. B) 
Western blot and densitometry analyses of BMAL1 in WAT of mice negative or positive for the 
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aP2-Cre transgene, t=4.944, df=6, p=0.0026, and in liver of mice injected with Ad-empty or Ad-
Cre virus, t=7.732, df=6, p=0.0002, at hour 0. C) Dbp expression in WAT, genotype F(2, 
49)=2.481, p=0.0941; time F(5, 49)=6.358, p=0.0001; interaction F(10, 49)=2.223, p=0.0317, and 
in liver, genotype F(2, 55)=0.9127, p=0.4075; time F(5, 55)=11.35, p<0.0001; interaction F(10, 
55)=1.874, p=0.0695. *=Comparison between control and ABKO, #=Comparison between 
control and LABKO, +=Comparison between ABKO and LABKO for Figures 1A and C. 
*,#,+p<0.05, **,##p<0.01, ***,###p<0.001, ****,####p<0.0001. 
To determine whether peripheral Bmal1 regulates behavioral changes related to metabolism, 
measures of food intake, locomotor activity and energy expenditure were taken in female mice 
maintained on a standard rodent chow diet (Fig. 3.2). Both ABKO and LABKO mice had 
increased total food intake. The increase was observed in both the light and dark phase, although 
the increase did not reach statistical significance in the dark phase in ABKO mice. (Fig. 3.2A and 
B). Total locomotor activity was increased in ABKO mice compared to control mice. This was 
due to increased activity predominantly in the light phase and tended to be increased in the dark 
phase (Fig. 3.2C and D). Further deletion of Bmal1 in the liver reversed this effect (Fig. 3.2D). 
Other differences in activity patterns were also observed. Compared to control and LABKO mice, 
ABKO mice had a greater and more prolonged peak in activity following the onset of the dark 
phase. ABKO mice also exhibited bursts of activity midway through the light and dark phases 
(Fig. 3.2C). 
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Figure 3.2 
 
Figure 3.2. Food intake, physical activity and energy expenditure changes in 12-week-old 
female mice on standard rodent chow. Hour 0 represents the beginning of lights-on. n=7-9 per 
group. A) Food intake over 24 hours, genotype F(2, 3842)=10.28, p<0.0001; time F(47, 
3842)=3.594, p<0.0001; interaction F(94, 3842)=1.361, p=0.0124. B) Food intake during the 
light phase, F(2, 20)=9.791, p=0.001; dark phase, F(2, 20)=5.956, p=0.0093; both phases, F(2, 
20)=16.65, p<0.0001. C) Locomotor activity defined as the sum of ambulatory (break of two 
adjacent beams in succession) and fine (break of the same beam twice) activity over 24 hours, 
genotype F(2, 3888)=54.14, p<0.0001; time F(47, 3888)=16.03, p<0.0001; interaction F(94, 
3888)=1.741, p<0.0001. D) Locomotor activity during the light, F(2, 20)=7.541, p=0.0036; dark 
phase, F(2, 20)=3.555, p=0.0477; both phases, F(2, 20)=5.853, p=0.01. E) Resting energy 
expenditure (REE) relative to lean mass, slope p=0.458; intercept p=0.171. F) Respiratory 
exchange ratio (RER) during the light and dark phase, genotype F(2, 42)=29.12, p<0.0001; phase 
F(1, 42)=13.01, p=0.0008; interaction F(2, 42), p=0.0546. Effects of genotype are indicated by 
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horizontal lines terminating in vertical lines. *=Comparison between control and ABKO, 
#=Comparison between control and LABKO, +=Comparison between ABKO and LABKO for 
Figures 2A and C. *,#,+p<0.05, **,##,++p<0.01, ***,###,+++p<0.001, ****,++++p<0.0001. 
Resting energy expenditure (REE) was analyzed using lean mass as a covariate. After controlling 
for lean mass, there were no significant differences among genotypes on REE (Fig. 3.2E). The 
respiratory exchange ratio (RER) was higher overall in the dark phase and highest in ABKO mice 
within both light and dark phases indicating a greater utilization of glucose for energy (Fig. 3.2F). 
Body weight, lean mass, fat mass and adiposity were all increased in LABKO mice compared to 
control and ABKO mice (Fig. 3.3A-D).  
Plasma glucose oscillates following a diurnal pattern [82, 104, 115]. ABKO mice had higher 
blood glucose concentrations throughout the light phase which was maintained upon feeding 
during the dark phase. The increase in glucose was reversed in LABKO mice, resulting in a 
similar blood glucose pattern between control and LABKO mice (Fig. 3.3E). 
Figure 3.3 
 
Figure 3.3. Body weight, body composition and blood glucose of 13-24-week-old female mice 
fed a standard rodent chow. n=7-9 per group. A) Body weight, F(2, 20)=37.99, p<0.0001. B) 
Lean mass, F(2, 20)=10.63, p=0.0007. C) Fat mass, F(2, 20)=124.9, p<0.0001. D) Percent 
adiposity, F(2, 20)=106.3, p<0.0001. E) Blood glucose measured beginning at circadian time 0, 
genotype F(2, 74)=10.72, p<0.0001; time F(5, 370)=65.51, p<0.0001; interaction F(10, 
370)=1.058, p=0.3938. n=17-31 per group. Effects of genotype are indicated by horizontal lines 
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terminating in vertical lines. *=Comparison between control and ABKO, +=Comparison between 
ABKO and LABKO for Figure 3E. *,+p<0.05, ***p<0.001, ****p<0.0001. 
Disruptions in liver and adipose peripheral clocks lead to increased body weight and adiposity. 
To assess the development of obesity and obesity-related phenotypes, a second cohort of male 
mice was fed a low-fat, control diet (CD) or high-fat, diabetogenic diet (DD) for 16 weeks. The 
diabetogenic diet itself decreased Bmal1 mRNA expression in epididymal adipose tissue but not 
in the liver (Fig. 3.4A and C). However, this decrease was not reflected in BMAL1 protein levels 
observed at hour 0 (Fig. 3.4B). 
Figure 3.4 
 
Figure 3.4. Deletion of Bmal1 in WAT and liver of 24-week-old male mice on control diet 
(CD) or diabetogenic diet (DD) for 16 weeks. A) Bmal1 expression at circadian time 0 in WAT, 
genotype, F(2, 39)=8.433, p=0.0009; diet F(1, 39)=9.94, p=0.0031; interaction F(2, 39)=4.676, 
p=0.0151. n=4-11 per group. B) Western blot analysis of BMAL1 in WAT of control mice on CD 
or DD. C) Bmal1 expression at circadian time 0 in liver, genotype F(2, 37)=8.64, p=0.0008; diet 
F(1, 37)=2.305, p=0.1374; interaction F(2, 37)=2.611, p=0.0869. n=5-9 per group. Effects of 
genotype are indicated by horizontal lines terminating in vertical lines. Effects of diet are 
indicated by brackets terminating in horizontal lines. *p<0.05, **p<0.01, ***p<0.001. 
As in the cohort of female mice, male LABKO mice were slightly heavier prior to the initiation of 
diet at 8-weeks old (Fig. 3.5A and B). At 24 weeks, the overall analysis of variance indicated a 
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main effect of diet and a main effect of genotype on body weight, weight gain and adiposity (Fig. 
3.5C-E). Body weight at 24 weeks was significantly increased in LABKO mice fed either diet 
(Fig. 3.5A and C) The increase in weight gain over a 16-week period appeared to be greater in 
control diet-fed LABKO mice but the difference did not reach statistical significance while 
diabetogenic diet-fed LABKO mice had significantly increased weight gain (Fig. 3.5D). A two-
way ANCOVA was performed for 24-week body weight using 8-week body weight as the 
covariate and genotype and diet as the two factors in order to determine whether the increased 
body weight at 24 weeks in LABKO mice was predicted by elevated body weight at 8 weeks. The 
8-week body weight covariate was significantly associated with 24-week body weight (p=0.002) 
as was genotype (p=0.003) and diet (p<0.001), but there was no genotype by diet interaction 
(p=0.149).  Adiposity followed a similar pattern as 24-week body weight for both diet groups 
(Fig. 3.5E) Within diet, as there were no differences in lean mass between genotypes (data not 
shown), the increase in body weight and weight gain was due to increased adiposity. 
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Figure 3.5 
 
Figure 3.5. Body weight and composition of male mice fed a control diet (CD) or a 
diabetogenic diet (DD) for 16 weeks. n=5-18 per group. A) Body weight from week 8 to 24. B) 
Body weight prior to initiation of diets at week 8, F(2, 59)=8.981, p=0.0004. C) Body weight at 
the end of study at week 24, genotype F(2, 56)=15.12, p<0.0001; diet F(1, 56)=204.1, p<0.0001; 
interaction F(2, 56)=2.003, p=0.1444. D) Change in body weight from week 8 to week 24, 
genotype F(2, 56)=9.023, p=0.0004; diet F(1, 56)=228.7, p<0.0001; interaction F(2, 56)=2.032, 
p=0.1407. E) Percent adiposity at week 24, genotype F(2, 56)=8.202, p=0.0008; diet F(1, 
56)=95.17, p<0.0001; interaction F(2, 56)=3.521, p=0.0363. Effects of genotype are indicated by 
horizontal lines terminating in vertical lines. Effects of diet are indicated by brackets terminating 
in horizontal lines. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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The diabetogenic diet resulted in overall increased adipocyte size and the appearance of crown-
like structures (Fig. 3.6). Among groups fed the control diet, adipocyte area was similar between 
genotypes with a tendency for increased size in LABKO mice (Fig. 3.6A and B). This resulted in 
a greater number of larger adipocytes reflected by the rightward shift in the histogram (Fig. 3.6C). 
However, this genetic difference was lost in mice fed the diabetogenic diet despite both ABKO 
and LABKO mice having increased fat mass compared to controls (Fig. 3.5D, Fig.3. 6).  
Adipose inflammation appeared to increase the presence of crown-like structures in the 
diabetogenic diet-fed mice, but was not affected by genotype (Fig. 3.6A). Similarly, the 
diabetogenic diet increased the expression of both F4/80 (genotype F(2, 39)=0.4142, p=0.6637; 
diet F(1, 39)=63.71, p<0.0001; interaction F(2, 39)=0.4215, p=0.6590) and Mcp-1 (genotype F(2, 
39)=3.123, p=0.0552; diet F(1, 39)=19.12, p<0.0001; interaction F(2, 39)=1.555, p=0.2241) (data 
not shown). Mcp-1 expression appeared to be higher in both ABKO and LABKO mice, but was 
only significant in the LABKO group (Control: 3.266±0.291, LABKO: 8.767±3.976) (data not 
shown). 
To determine whether the increase in adiposity could be explained by increased adipogenesis or 
decreased lipolysis, markers of these processes were measured in control diet-fed mice. There 
was a significant increase in C/ebpβ expression in LABKO mice, but other measured genes of 
adipogenesis (Pparγ, C/ebpα, Zfp423) and lipolysis (Hsl, Pnpla2, Abhd5) were unchanged by 
genotype (Fig. 3.6D). 
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Figure 3.6 
 
Figure 3.6. Adipose histology, quantification and measure of adipogenesis and lipolysis in 
WAT at circadian time 0 in 24-week-old male mice fed a control diet (CD) or a diabetogenic 
diet (DD) for 16 weeks. A) Representative images of H&E stain from epididymal adipose. B) 
Adipocyte area, genotype F(2, 14)=1.392, p=0.281; diet F(1, 14)=6.985, p=0.0193; interaction 
F(2, 14)=1.599, p=0.2369. n=2-4 per group. C) Histogram of adipocyte count distribution of 
specified adipocyte area. D) Gene expression of adipogenic and lipolytic genes. For C/ebpβ, F(2, 
20)=5.893, p=0.0097. n=5-9 per group. Effects of genotype are indicated by horizontal lines 
terminating in vertical lines. Effects of diet are indicated by brackets terminating in horizontal 
lines. *p<0.05, **p<0.01. 
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Loss of glycemic control does not correspond with increased body weight and adiposity. 
To determine whether peripheral clocks play a role in the loss of glycemic control associated with 
obesity, fasting glucose, glucose tolerance and insulin sensitivity were measured in male mice 
challenged with a diabetogenic diet. There was a main effect of diet on fasting glucose but no 
effect of genotype in either diet (Fig. 3.7A and B). Similarly, there was a main effect of diet on 
blood glucose concentrations following an intraperitoneal injection of glucose but no differences 
between genotypes (Fig. 3.7C and D). Both ABKO and LABKO mice fed a diabetogenic diet had 
greater reductions in blood glucose following an intraperitoneal injection of insulin than control 
mice (Fig. 3.7E and F). To determine whether adipose tissue of ABKO and LABKO mice 
respond better to insulin, total and p-AKT were measured. Though p-AKT was increased in WAT 
of ABKO and LABKO mice, total AKT expression was increased as well. Therefore, there were 
no significant differences in p-AKT (Fig. 3.7G). 
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Figure 3.7 
 
Figure 3.7. Glycemic control in 24-week-old male mice fed a control diet (CD) or a 
diabetogenic diet (DD) for 16 weeks. n=5-18 per group. A) Fasting blood glucose 
concentrations from week 12 to 24. B) Fasting blood glucose concentrations following a 4-hour 
fast, genotype F(2, 56)=1.956, p=0.1509; diet F(1, 56)=8.497, p=0.0051; interaction F(2, 
56)=0.05681, p=0.9448. C) Glucose tolerance following a 4-hour fast in mice fed CD, genotype 
F(2, 28)=0.8944, p=0.4202; time F(4, 112)=75.99, p<0.0001; interaction F(8, 112)=1.436, 
p=0.1894, and in mice fed DD, genotype F(2, 28)=1.29, p=0.291; time F(4, 112)=80.27, 
p<0.0001; interaction F(8, 112)=1.909, p=0.0654. D) Area under the curve (AUC) calculated 
from glucose tolerance test, genotype F(2, 56)=0.3693, p=0.6929; diet F(1, 56)=18.25, p<0.0001; 
interaction F(2, 56)=1.989, p=0.1464. E) Insulin sensitivity following a 1-hour fast in mice fed 
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DD, genotype F(2, 28)=7.759, p=0.0021; time F(4, 112)=33.28, p<0.0001; interaction F(8, 
112)=3.42, p=0.0015. F) AUC calculated from insulin sensitivity test, F(2, 28)=7.768, p=0.0021. 
G) Western blot and densitometry analyses of total and p-AKT in WAT of mice on diabetogenic 
diet injected with insulin, F(2, 6)=3.495, p=0.0985. Effects of genotype are indicated by 
horizontal lines terminating in vertical lines. Effects of diet are indicated by brackets terminating 
in horizontal lines. *=Comparison between control and ABKO, #=Comparison between control 
and LABKO, +=Comparison between ABKO and LABKO for Figures 7B and D. *,#,+p<0.05, 
**p<0.01, ****p<0.0001. 
Disruptions in liver and adipose peripheral clocks increase hepatic cholesterol in LABKO mice. 
There was a main effect of diet on serum total cholesterol but no significant differences between 
genotypes in either diet groups. Serum triglycerides and non-esterified fatty acids (NEFAs) were 
not affected by diet or genotype (data not shown). However, it should be noted that mice were not 
fasted for these measures. As expected, there was a main effect of diet on liver weights. However, 
there were no differences in liver weights or percent liver weight between genotypes in either diet 
group (data not shown). Despite any lack of differences, ABKO mice appeared to have decreased 
lipid deposition in the liver compared to control and LABKO mice within the diabetogenic diet 
groups (Fig. 3.8A). There was a main effect of diet on hepatic total cholesterol and triglycerides 
(Fig. 3.8B and C). Within mice given a diabetogenic diet, LABKO mice had the highest level of 
hepatic total cholesterol (Fig. 3.8B). A similar pattern was observed for triglycerides, but these 
differences did not reach statistical significance (Fig. 3.8C). In an effort to explain the increase in 
hepatic cholesterol in LABKO mice fed a diabetogenic diet, genes involved in cholesterol 
synthesis and regulation were measured in liver. Hmgcr and Hmgcs, involved in cholesterol 
synthesis, exhibited similar patterns of expression with LABKO mice on control diet and both 
ABKO and LABKO mice on diabetogenic diet having increased expression (Fig. 3.8D). Sterol 
transporters, Abcg5 and Abcg8, were both suppressed by diet but no significant differences 
between genotypes were observed (Fig. 3.8D). Although genes involved in cholesterol uptake, 
Ldlr and Srb1, had the highest expression in LABKO mice on a control diet there were no 
differences in Ldlr and Srb1 expression between genotypes in mice on a diabetogenic diet (data 
not shown). Bile acid synthesis genes, Cyp7a1 and Cyp8b1, were unchanged by diet or genotype 
(data not shown). 
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Figure 3.8 
 
Figure 4.8. Liver histology, hepatic lipids and gene expression from liver isolated at 
circadian time 0 in 24-week-old male mice fed a control diet (CD) or a diabetogenic diet 
(DD) for 16 weeks. A) Representative images of H&E stain. B) Total cholesterol, genotype F(2, 
26)=5.095, p=0.0136; diet F(1, 26)=25.42, p<0.0001; interaction F(2, 26)=0.9054, p=0.4167. C) 
Triglycerides genotype F(2, 26)=2.519, p=0.1000; diet F(1, 26)=44.3, p<0.0001; interaction F(2, 
26)=0.3547, p=0.7047. n=4-7 per group. D) Gene expression of Hmgcr, genotype F(2, 39)=6.118, 
p=0.0049; diet F(1, 39)=1.268, p=0.267; interaction F(2, 39)=3.374, p=0.0445. E) Gene 
expression of Hmgcs, genotype F(2, 39)=3.582, p=0.0373; diet F(1, 39)=12.54, p=0.001; 
interaction F(2, 39)=2.471, p=0.0976. F) Gene expression of Abcg5, genotype F(2, 39)=0.8746, 
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p=0.4251; diet F(1, 39)=19.89, p<0.0001; interaction F(2, 39)=1.024, p=0.3685. G) Gene 
expression of Abcg8, genotype F(2, 39)=2.004, p=0.1484; diet F(1, 39)=18.92, p<0.0001; 
interaction F(2, 39)=1.747, p=0.1876. n=5-9 per group. Effects of genotype are indicated by 
horizontal lines terminating in vertical lines. Effects of diet are indicated by brackets terminating 
in horizontal lines. *p<0.05, **p<0.01, ****p<0.0001. 
Discussion 
Our study confirms and extends previous findings indicating that peripheral oscillators, 
particularly in adipose, modulate feeding and locomotor activity. The loss of Bmal1 in adipose 
tissue and the liver exacerbates obesity but no other metabolic co-morbidities. The central clock 
synchronizes the oscillations of peripheral clocks. However, an essential feature of peripheral 
clocks is the ability to be uncoupled from the central clock via entrainment by the feeding/fasting 
cycle [92, 201, 202]. Time-restricting food consumption to the rest phase results in obesity 
while food consumption solely during the active phase is protective against obesity [126-130]. In 
our study, we sought to determine the impact of disrupted adipose tissue and liver clocks on 
centrally-regulated functions related to metabolism such as feeding behavior and locomotor 
activity. It has previously been shown that deletion of Bmal1 from adipose alters plasma 
polyunsaturated fatty acid concentrations, leading to alterations in the hypothalamic regulation of 
feeding behavior [104]. We corroborated these findings and observed that ABKO mice exhibit 
impaired feeding patterns and have increased food intake during the light phase. In both studies, 
the aP2-Cre transgene was used for adipose deletion. AP2 is commonly used to drive the 
expression of Cre recombinase for adipose-specific deletion as it is abundantly expressed in 
adipose. However, AP2 is also expressed in other tissues such as macrophages, embryonic tissues 
and brain [203, 204]. In our study, we observed residual Bmal1 mRNA and protein expression in 
both adipose and liver. This is likely due to incomplete penetrance of Cre recombinase as well as 
the presence of other cell types expressing Bmal1. Deletion of Bmal1 from the liver and adipose 
tissue in LABKO mice also resulted in increases in food intake during the light phase as well as 
during the dark phase. ABKO mice tended to be more active, particularly during the light phase 
in our studies. However, a previous study did not observe any differences in locomotor activity 
with Bmal1 deletion from adipose tissue [104]. This discrepancy between studies is likely due to 
differences in environmental conditions or the diet used. Nonetheless, alterations in activity 
during both the light and dark phase in ABKO mice indicate that adipose Bmal1 plays a role in 
modulating physical activity and movement. Interestingly, increased activity was reversed in 
LABKO mice. Previous studies have demonstrated that liver-specific deletion of Bmal1 is 
insufficient to alter locomotor activity and feeding behavior [103]. Together, these findings 
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demonstrate that disrupting the liver clock in the setting of adipose clock disruption impacts 
physical activity. Thus, coordination of functional adipose and liver clocks is necessary to 
properly mediate centrally-regulated functions. Furthermore, the differences in food intake and 
activity between genotypes suggest tissue-specific roles of Bmal1. 
ABKO mice had increased overall food intake similar to that of LABKO mice but body weight 
and adiposity were not significantly increased like that of LABKO mice. This is likely due to the 
increased activity observed in ABKO but not in LABKO mice. Although we cannot rule out a 
direct role of peripheral Bmal1 in regulating energy metabolism, our findings suggest that 
changes in feeding behavior and activity in ABKO and LABKO mice are the primary regulators 
of body weight and composition.  
Blood glucose concentrations exhibit diurnal variations and several models of dysfunctional 
circadian rhythm exhibit impaired glycemic control [82, 105, 115]. Over a 24-hour period, 
ABKO mice with food access during the dark phase tended to have slightly elevated blood 
glucose concentrations compared to control and LABKO mice while the diurnal pattern remained 
similar between groups. Therefore, in the setting of restricted food availability to the dark phase, 
disrupting adipose and liver Bmal1 was insufficient to impair the diurnal pattern of blood glucose.  
Due to the high association between obesity and other features of MetS, we expected that in the 
presence of a diabetogenic diet, the disruption of Bmal1 in two metabolic tissues would 
exacerbate insulin resistance and fatty liver disease. Although LABKO mice were more obese 
than control mice, there was no further loss of glycemic control or evidence of increased hepatic 
inflammation and fibrosis in either ABKO or LABKO mice. Overall, the disruption of peripheral 
clocks from the liver and adipose tissue was insufficient to exacerbate metabolic disease beyond 
the development of obesity. One possibility for this observation may be explained by the effects a 
diet high in fat can have on circadian rhythms. A high-fat diet can lengthen the circadian period in 
mice prior to any body weight effect and attenuate diurnal feeding behavior and clock gene 
expression [205]. Consistent with these findings, we found that 16 weeks of a diabetogenic diet 
suppresses peak Bmal1 expression in white adipose tissue though protein expression was slightly 
increased. As this reflects expression at a single time point, the discrepancy may reflect a phase 
shift in BMAL1 expression or post-transcriptional regulation. Peak Bmal1 expression was not 
affected in the liver however. Others have demonstrated slight to significant attenuations in liver 
Bmal1 oscillations depending on the duration of high-fat feeding [205, 206]. It is likely that 
although disrupting multiple peripheral clocks indeed alters central behavior, these effects seem 
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to be overcome by the effects of a high-fat diet thereby muting any exacerbations in metabolic 
disease. 
Similar to the role of circadian rhythms in the development of obesity and insulin resistance, 
evidence suggest lipid homeostasis is dependent on circadian function. Clock-mutant mice have 
increased plasma triglycerides, cholesterol, and atherosclerotic lesions [207]. Additionally, a 
number of rhythmic transcripts involved in cholesterol synthesis and metabolism have been 
identified in the open access bioinformatics database, CircaDB. Hepatic cholesterol and 
triglycerides were divergently altered in ABKO and LABKO mice fed a diabetogenic diet, 
suggesting the involvement of liver Bmal1 in the regulation of cholesterol. Cholesterol synthesis, 
measured by transcript levels of Hmgcr and Hmgcs, tended to be increased in both ABKO and 
LABKO mice fed a diabetogenic diet. However, no additional changes in genes involved in 
cholesterol transport and bile acid synthesis that would explain the varying abundance of hepatic 
lipids were observed. It should be noted that transcript levels of Hmgcs and Cyp8b1 reach peak 
amplitude approximately at the beginning of the light cycle, Hmgcr, Ldlr, Cyp7a1, Abcg5 and 
Abcg8 at the beginning of the dark cycle and Srb1 at mid-light cycle [208]. Consequently, 
measuring gene expression throughout a 24-hour period would enhance the capability of 
identifying essential differences. 
A limitation of our study is the use of both male and female mice. Estradiol during development 
plays a role in diurnal rhythms and estrogen receptor beta is regulated by the clock machinery 
[209, 210]. Additionally, sexually dimorphic differences in clock gene expression in the SCN 
and locomotor activity in response to light-induced phase shifts by leptin is observed in mice 
[211]. To minimize the limiting effects of sex, only females were used for indirect calorimetry 
experiments while only males were used for the diet intervention portion of the study. 
Our study and others have demonstrated the selectivity of the clock’s influence on metabolism 
and the potential that exists in targeting circadian factors as a potential therapeutic for metabolic 
disease. Here we add knowledge to how disruptions in multiple peripheral clocks may 
differentially regulate behavior and influence the development of obesity. 
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CHAPTER 4: ROLE OF BILE ACID-FGF15/19 AXIS IN THE REGULATION OF ABCG5 
AND ABCG8 
Introduction 
Elevated cholesterol increases the risk of CVD by contributing to the development of 
atherosclerosis and is highly associated with NAFLD [212, 213]. The relationship between 
cholesterol and atherosclerotic CVD has been widely studied, leading to the development of lipid-
lowering agents that target a number of cholesterol-modulating pathways including cholesterol 
synthesis (HMG-CoA reductase inhibitors), cholesterol absorption (ezetimibe), and LDL receptor 
regulation (PSCK9 inhibitors).  More recently, emerging evidence implicates hepatic cholesterol 
in the pathogenesis of NAFLD and NASH, the more severe form of disease. Increased dietary 
cholesterol and fat act synergistically in wildtype mice to increase hepatic fat, inflammation, and 
fibrosis indicative of NASH [214]. In LDL receptor-deficient mice fed a high fat, high-
carbohydrate diet, the addition of cholesterol worsens dyslipidemia and hepatic steatosis as well 
as induces NASH-associated inflammation and fibrosis [74]. In humans, increased hepatic free 
cholesterol is detected in NAFLD [71]. We have previously observed that mice deficient of the 
cholesterol transporter, ABCG5 and ABCG8 (G5G8), have decreased biliary cholesterol 
secretion, increased hepatic cholesterol, and worsened obesity, insulin resistance, and NAFLD 
when fed a high-fat diet [149]. Conversely, overexpression of adenoviral G5G8 in obese db/db 
mice increases biliary cholesterol secretion and reduces triglycerides, insulin resistance, and ER 
stress [147]. These data suggest that G5G8 may be a promising target for accelerating cholesterol 
elimination and improving features of NAFLD. 
The majority of cholesterol elimination occurs through the conversion of cholesterol to bile acids 
(bile acid synthesis) and by direct clearance through the biliary pathway [157]. Of the cholesterol 
entering the bile, up to 90% is transported via the ABCG5 and ABCG8 (G5G8) heterodimer [143, 
215, 216]. Ursodiol (Urso) is a pharmacologic bile acid that has been found to increase G5G8 
protein abundance, biliary cholesterol secretion, and fecal neutral sterol elimination in mice 
[150]. Although the molecular mechanism(s) by which Urso regulates G5G8 is not clear, 
possibilities include the alleviation of ER stress and bile acid signaling.   
Fecal neutral sterol elimination is increased in mice receiving Urso and ezetimibe. However, the 
combination does not increase cholesterol synthesis, suggesting there is no increase in total sterol 
loss [150]. Rather, increases in ileal fibroblast growth factor 15 (Fgf15) and suppression of bile 
acid synthesis indicate a diversion of the cholesterol pool away from the bile acid synthesis 
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pathway to the biliary secretion pathway [150]. FGF15 in mice and FGF19 in humans 
(FGF15/19) are expressed in the enterocytes of the ileum, stimulated by farnesoid X receptor 
(FXR) in response to bile acids, and transported to the liver where it binds to its receptor, 
fibroblast growth factor receptor 4 (FGFR4), to suppress bile acid synthesis among other effects 
[163, 217, 218]. FXR agonists in clinical trials have shown promise for the treatment of NAFLD 
and NASH, presumably through effects mediated in part by FGF19 [170, 171]. FGF19 
administration improves parameters of obesity and insulin sensitivity in obese mice and is 
involved in regulating hepatic glycogen and fatty acid synthesis [173-175, 219]. However, it is 
unknown whether FGF15/19 plays a role in regulating G5G8 and biliary cholesterol secretion. 
Our study suggests that FGF15/19 increases G5G8 protein and promotes localization to the 
canalicular surface of hepatocytes. Furthermore, Urso causes a similar localization of G5G8 that 
appears to be dependent on FGF15/19 signaling via FGFR4 receptor. 
Methods 
Animal Husbandry and Procedures 
C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME). Mice heterozygous 
for the Abcg5 and Abcg8 (G5G8) mutant alleles were bred using trio matings to generate 
homozygous G5G8 knockout (KO) and wildtype (WT) littermates as previously described [149]. 
Mice were housed in individually ventilated cages in a temperature-controlled room maintained 
on a 14:10 light:dark cycle and had free access to water and standard rodent diet (Teklad 2918). 
Male mice 10-12 weeks of age were injected intraperitoneally with recombinant human FGF19 
protein (ProSpec CYT-700) at 1 μg/g body weight (BW) or PBS at 0 hours and 4 hours after 
lights-on. Mice were anesthetized under urethane 1g/kg BW at 8 hours after lights-on and basal 
bile was collected for 30 minutes by ligating the bile duct and cannulating the gallbladder. Bile 
flow was calculated gravimetrically assuming a density of 1 g/mL. Following exsanguination, 
tissues were dissected, frozen in liquid nitrogen, and stored at -80ºC until analysis. Blood was 
stored at 4ºC for four hours. After centrifugation at high speed for 10 minutes, serum was 
collected at stored at -80ºC until analyzed. A portion of liver was embedded in OCT compound 
for histology. 
Male and female mice 7 weeks of age were injected subcutaneously with FGFR4 antisense 
oligonucleotide (ASO) (Ionis Pharmaceuticals) 25 mg/kg BW twice weekly for a total of 5 
weeks. At the beginning of week 5, mice were fed either a control diet (Research Diets, Inc. AIN-
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76A) or a diet supplemented with 0.3% (w/w) ursodiol (Epic Pharma, LLC, NDC: 42806-503-01) 
for a total of 7 days. Basal bile and tissues were collected as described above. 
Real Time-PCR 
RNA was isolated from liver samples using RNA STAT-60 (Tel-Test, Inc.) and the RNeasy Mini 
Kit (Qiagen). The iScript cDNA Synthesis Kit (Bio-Rad) was used to synthesize 20 uL of cDNA 
from RNA 100 ng/uL. Relative changes in gene expression were measured by quantitative real 
time-PCR using SYBR Green and the 7900HT Fast Real Time-PCR System (Applied 
Biosystems). Gapdh was used as the normalization control for measured transcripts. 
Immunoblot Analysis 
Membrane protein preparations from frozen tissues, SDS-PAGE, and immunoblotting were 
conducted as previously reported [147, 149]. ABCG5 was detected in 40 μg of protein using a 
1:20,000 dilution of chicken anti-ABCG5 polyclonal antibody [147, 149]. ABCG8 was detected 
using a 1:100 dilution of monoclonal antibody [153]. Beta-actin was detected using a 1:50,000 
dilution of monoclonal antibody (Sigma-Aldrich A5441). 
Lipid Analysis 
Hepatic lipids were extracted from frozen liver (~100 mg) using the Folch method, dried in 
CHCl3 + 2% Triton and suspended in 1% Triton in water as previously reported [147]. 
Enzymatic, colorimetric assays (Wako Diagnostics) were used to measure free and total 
cholesterol from serum, hepatic lipid extracts, and bile as well as phospholipids from bile. Bile 
acids in bile were measured using an enzymatic assay that measures 3α-hydroxy bile acids as 
previously reported [220]. 
Immunofluorescence Microscopy 
Cryosections (8 μm) were cut, post-fixed in 4% PFA at room temperature for 30 min, then 
rehydrated in three changes of PBS. Sections were treated with 0.1% Triton X-100 for 15 min and 
then incubated in Buffer A (PBS + 1% bovine serum albumin (BSA) for 1 h at 22oC. Primary 
antibodies (ABCG5, 1:8000; ZO-1, 1:125) were diluted in Buffer A. Spotted sections were 
circumscribed with a wax pencil, overlaid with 100 μL of diluted antibody, and incubated 
overnight (4oC). Sections were then washed with three changes of PBS. Conjugated secondary 
antibodies directed against avian IgG (G5, Alexafluor 488) and rabbit IgG (ZO-1, Alexafluor 
568) were diluted in Buffer A (1 µg/mL) and incubated for 60 min (22oC).  Slides were washed 
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with 3 changes of PBS. Sections were spotted with aqueous mounting media containing DAPI 
and overlaid with glass coverslips.   
Sections were imaged with a Zeiss Axiovert 200IM microscope equipped with ApoTome and a 
63X oil immersion objective. Five optical sections (0.25 μm/section) in each channel (RGB) were 
captured in the Z plane and converted to a two dimensional image by Extended Focus calculation 
in the AxioVision imaging software suite. Channels were pseudocolored (ABCG5, green; ZO-1, 
red; DAPI, blue) and displayed individually and as merged RGB images.                                                                                          
Statistical Analysis 
Statistical analyses were conducted using GraphPad Prism (version 7.00). Data are presented as 
mean ± SEM with statistical significance defined as p<0.05. Unpaired t-tests were performed for 
comparisons between two groups. Two-way ANOVAs were performed for comparisons of 
groups defined by two factors and Bonferroni’s multiple comparisons tests were performed for 
post hoc analyses. 
Results 
FGF19 suppresses bile acid synthesis and increases hepatic G5G8 
In order to determine whether FGF19 regulates G5G8 protein expression, recombinant FGF19 (1 
μg/g BW) or carrier (PBS) was administered to mice at 0 and 4 hours after lights-on and tissues 
collected at 8 hours after lights-on. Mice injected with FGF19 had decreased expression of Fxr 
and increased expression of small heterodimer partner (Shp) in the liver (Figure 4.1A). SHP 
mediates suppression of Cyp7a1 through interactions with FGF15/19 [163]. Genes involved in 
bile acid synthesis, Cyp7a1, Cyp8b1, and Cyp27a1, were decreased with FGF19 administration 
(Figure 4.1A). The changes we observed were as expected based on previous reports and 
confirmed the efficacy of the recombinant FGF19 in the present study [163, 218, 221]. Abcb4 and 
Abcb11 transport phospholipids and bile salts, respectively, into bile and were unaffected 
following FGF19 administration (Figure 4.1A). Abcg8 mRNA increased by ~30% while ABCG5 
protein increased by ~50% and ABCG8 by ~200% (Figures 4.1A and B). 
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Figure 4.1 
 
Figure 4.1. FGF19 suppresses bile acid synthesis and increases hepatic G5G8. Mice were 
injected with PBS or FGF19 1 μg/g body weight at 0 and 4 hours after lights-on then euthanized 
at 8 hours. A: RT-PCR analysis of genes involved in bile acid synthesis and biliary cholesterol 
secretion in liver of mice injected with PBS (n=5) or FGF19 (n=7). B: Western blot analysis and 
densitometry of ABCG5 and ABCG8 protein expression in liver of mice injected with PBS (n=3) 
or FGF19 (n=4). Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
FGF19 increases biliary total lipid concentrations 
Consistent with our findings of increased G5G8 protein expression, biliary total cholesterol 
increased by nearly 50% following FGF19 administration (Figure 4.2A). There were also 
significant increases in biliary phospholipid and bile acid concentrations with FGF19 (Figures 
4.2B and C). Therefore, mice injected with FGF19 had increased total lipid concentrations in bile 
(Figure 4.2D). However, FGF19 administration did not alter basal bile flow measured 4 hours 
following the last injection (Figure 4.2E). The cholesterol saturation index (CSI) was calculated 
to determine the extent of cholesterol solubility in bile. While total lipid concentrations were 
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increased in bile of mice given FGF19, the CSI remained equal to that of mice receiving PBS 
(Figure 4.2F).  
Figure 4.2 
 
Figure 4.2. FGF19 increases biliary total lipid concentrations. Mice were injected with PBS or 
FGF19 1 μg/g body weight at 0 and 4 hours after lights-on then euthanized at 8 hours. A: Total 
lipids measured in bile of mice injected with PBS (n=6) or FGF19 (n=6). B: Phospholipids 
measured in bile of mice injected with PBS (n=6) or FGF19 (n=7). C: Bile acids measured in bile 
of mice injected with PBS (n=6) or FGF19 (n=6). D: Total cholesterol measured in bile of mice 
injected with PBS (n=6) or FGF19 (n=7). E: Bile flow rate normalized to liver weight (LW) of 
mice injected with PBS (n=6) or FGF19 (n=7). F: The cholesterol saturation index (CSI) of bile 
in mice injected with PBS (n=6) or FGF19 (n=6). Data are presented as mean ± SEM. *p<0.05, 
**p<0.01, ***p<0.001. 
FGF19 localizes G5G8 to the canalicular surface of hepatocytes 
Previously, we reported the development of a new antibody against ABCG5 which afforded us 
the opportunity to evaluate the effect of FGF19 on the localization of endogenous G5G8 [149]. 
Liver sections were imaged by immunofluorescence microscopy. Canalicular structures were 
delineated by an antibody against the tight junction protein, zonula occludens-1 (ZO-1) (Figures 
4.3A, D, G, and J). ABCG5 was observed in liver of control mice but not in G5G8 KO mice, 
verifying the specificity of the ABCG5 antibody (Figures 4.3B and E). In control mice injected 
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with PBS, G5G8 appeared to be discrete puncta that were dispersed in the cytosol of hepatocytes 
(Figure 4.3E). Administration of FGF19 or Urso co-localized ABCG5 with ZO-1 (Figures 4.3G-
L). These data suggest that FGF19 facilitates the mobilization of G5G8 to the apical surface of 
hepatocytes lining the bile canaliculi. 
Figure 4.3 
 
Figure 4.3. FGF19 localizes G5G8 to the canalicular surface of hepatocytes. 
Immunofluorescence microscopy of mouse ZO-1 (A, D, G, J) and ABCG5 (B, E, H, K) in liver of 
G5G8 KO (A, B, C), control (D, E, F), FGF19-injected (G, H, I), and Urso-supplemented (J, K, 
L) mice. 
FGF19 does not disrupt cholesterol homeostasis in the absence of G5G8 
We observed that FGF15/19 increases G5G8 while simultaneously decreasing bile acid synthesis, 
suggesting that cholesterol is diverted from the catabolic to the secretory pathway. In the absence 
of G5G8, free cholesterol was expected to accumulate in hepatocytes. Therefore, it was 
hypothesized that in the absence of G5G8, overexpression of FGF15/19 would disrupt cholesterol 
ABCG5ZO-1 Merge
G5G8 KO
Control
Urso
FGF19
57 
 
homeostasis in the liver. WT and G5G8 KO mice were injected with FGF19. G5G8 KO mice had 
decreased biliary total cholesterol but there were no differences in biliary phospholipid or bile 
acid concentrations (Figures 4.4A-C). Serum and hepatic cholesterol were measured to determine 
whether cholesterol would accumulate in G5G8 KO mice receiving FGF19. While there were no 
differences in serum total and hepatic total and free cholesterol, there was a slight but significant 
increase in serum free cholesterol in G5G8 KO mice (Figures 4.4D and E). Free cholesterol was 
measured in fast protein liquid chromatography (FPLC)-fractionated serum to determine its 
distribution in lipoprotein fractions. The FPLC profile did not reveal any major differences or the 
presence of LpX-like particles that would account for the increase in free cholesterol (not shown). 
Abcg5 and Abcg8 were confirmed to be significantly downregulated in G5G8 KO mice (Figure 
4.4F). Absence of G5G8 had no effect on gene expression in mice treated with FGF19 (Figure 
4.4F). 
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Figure 4.4 
 
Figure 4.4. FGF19 does not disrupt cholesterol homeostasis in the absence of G5G8. 
Wildtype (WT) and G5G8 knockout (KO) mice were injected with FGF19 1 μg/g body weight at 
0 and 4 hours after lights-on then euthanized at 8 hours. A: Total cholesterol measured in bile of 
WT and KO mice (n=4). B: Phospholipids measured in bile of WT and KO mice (n=4). C: Bile 
acids measured in bile of WT and KO mice (n=4). D: Total and free cholesterol measured in 
serum of WT and KO mice (n=4). E: Total and free cholesterol measured in liver of WT and KO 
mice (n=4). F: RT-PCR analysis of genes involved in cholesterol metabolism and bile acid 
synthesis in liver in WT and KO mice (n=4). Data are presented as mean ± SEM. *p<0.05, 
**p<0.01, ****p<0.0001. 
FGF15/19-FGFR4 signaling is required for Urso to localize G5G8 to the canalicular surface of 
hepatocytes 
Previous studies revealed that Urso can increase G5G8 resulting in increased biliary cholesterol 
secretion. Urso has similar effects on G5G8 abundance and localization as FGF19, but it is 
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unknown whether these effects are dependent on FGF19 signaling through its receptor, FGFR4. 
To address this question, mice injected with control or FGFR4 ASO were fed a control or Urso-
containing diet. In either the male or female group, there was no difference in body weight 
between control and Urso-fed mice receiving control or FGFR4 ASO (Figure 4.5A). Expression 
of Fgfr4 was similar between males and females within the control ASO treatment group; 
therefore, comparisons were conducted irrespective of sex (Figure 4.5B). Mice receiving FGFR4 
ASO had significantly decreased expression of Fgfr4, confirming the knockdown of Fgfr4 in the 
liver (Figure 4.5C).  Interestingly, there was also a slight reduction of Fgfr4 with Urso within the 
control ASO treatment group (Figure 4.5C).  
Figure 4.5 
 
Figure 4.5. FGF19-FGFR4 signaling is required for Urso to localize G5G8 to the canalicular 
surface of hepatocytes. Male and female mice were injected with control or FGFR4 ASO 25 
mg/kg body weight twice weekly for 5 weeks and fed standard or Urso 0.3%-supplemented diet 
for 7 days. A: Body weight measured post-treatment at 12 weeks of age (n=5). B: RT-PCR of 
Fgfr4 in liver of mice injected with control ASO (n=5). C: RT-PCR of Fgfr4 in liver of male and 
female mice injected with control of FGFR4 ASO (n=10). Data are presented as mean ± SEM. 
***p<0.001, ****p<0.0001. 
Immunofluorescence microscopy revealed that in mice receiving control ASO, Urso promoted 
co-localization of ABCG5 and ZO-1 on the canalicular surface of hepatocytes (Figure 4.6). In the 
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presence of FGFR4 ASO, the effect of Urso on the localization of ABCG5 was impaired (Figure 
4.6). 
Figure 4.6 
 
Figure 4.6. FGF15/19-FGFR4 signaling is required for Urso to localize G5G8 to the 
canalicular surface of hepatocytes. Immunofluorescence microscopy of mouse ZO-1 (A, D, G, 
J) and ABCG5 (B, E, H, K) in liver of mice receiving control ASO (A, B, C), FGFR4 ASO (D, E, 
F), Urso and control ASO (G, H, I), or Urso and FGFR4 ASO (J, K, L). 
Discussion 
The present study demonstrates that FGF19 upregulates and promotes canalicular localization of 
G5G8 in hepatocytes. However, treatment with FGF19 in the absence of G5G8 did not acutely 
disrupt cholesterol regulation in the liver, suggesting the involvement of G5G8-independent 
mechanisms for maintaining cholesterol homeostasis. Additionally, Urso regulates localization of 
G5G8 through an FGF15/19-FGFR4-dependent mechanism. Our findings suggest that biliary 
sterol elimination and bile acid synthesis share a common pathway mediated by FGF15/19-
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FGFR4 signaling. However, the mechanism(s) by which FGF15/19 regulates G5G8 awaits 
further investigation. 
The formation of bile involves the transport of bile acids, phospholipids, and cholesterol from 
hepatocytes into bile canaliculi. This process is tightly regulated in order to facilitate cholesterol 
solubilization in the form of mixed micelles. Increased biliary cholesterol concentrations relative 
to phospholipid and bile acid concentrations create supersaturated conditions that are favorable 
for gallstone formation [222]. Increased cholesterol gallstones are associated with polymorphisms 
in G5G8 that are thought to contribute to increased G5G8 activity [223, 224]. Therefore, it is 
plausible that biliary cholesterol secretion, mediated by G5G8, is regulated by bile acids in the 
enterohepatic circulation. During the fed state, bile acids are released from the gallbladder and 
bind to the nuclear receptor, FXR, to stimulate FGF15/19 in the small intestine [163]. FGF15/19 
enters the liver via the enterohepatic circulation and binds to the FGFR4-βKlotho receptor 
complex to inhibit Cyp7a1, suppressing bile acid synthesis [163]. Emptying of the gallbladder 
and subsequent repletion requires various signals that integrate the status of the intestine, liver, 
and gallbladder. We observed in the present study that FGF15/19 plays a role in regulating G5G8. 
This may be a mechanism by which enterohepatic bile acids mediate biliary cholesterol secretion. 
FGF15/19 has been found to promote gallbladder filling by increasing cyclic adenosine 
monophosphate (cAMP) [172]. Mice deficient of FGF15 have empty gallbladders while FGF19 
administration promotes gallbladder filling [172]. Interestingly, it has been demonstrated that 
localization of G5G8 to the canalicular surface involves cAMP signaling [225]. Both FGF19 and 
Urso induced expression of G5G8 at the site of bile canaliculi in the present study. Taken 
together, these data support the notion that in response to circulating bile acids, FGF15/19 
regulates biliary cholesterol secretion in a feed forward mechanism.  
Acute FGF19 administration suppressed bile acid synthesis and increased biliary total cholesterol. 
Therefore, we hypothesized that impairing biliary cholesterol secretion via G5G8 in the setting of 
increased FGF19 would disrupt hepatic cholesterol metabolism. Although serum free cholesterol 
was mildly increased in G5G8 KO mice, there were no changes in hepatic cholesterol or genes 
involved in cholesterol synthesis, transport, and bile acid synthesis. There were slight increases in 
Cyp7a1 and Cyp8b1 gene expression in G5G8 KO mice suggesting a possible compensatory 
response to promote non-G5G8-mediated cholesterol elimination, though these changes were not 
significant. Alternatively, there may be G5G8-independent, non-biliary pathways that are 
involved in maintaining cholesterol homeostasis. Supporting this notion, we have previously 
reported that Urso can increase fecal neutral sterols in G5G8 KO mice to a similar extent as in 
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wildtype mice [150]. Although we did not observe significant effects of acute FGF19 
administration in G5G8 KO mice in this study, further studies using a more chronic dosing 
regimen of FGF19 are warranted to assess the effect of persistently elevated FGF19.  
Urso is a hydrophilic bile acid that is used for the treatment of primary biliary cirrhosis and 
cholesterol gallstones. Urso facilitates the elimination of toxic bile acids that accumulate in 
hepatocytes and cholangiocytes as well as possess anti-apoptotic and anti-inflammatory 
properties [151]. Additionally, we have previously reported that Urso may be beneficial in liver 
diseases such as NAFLD and NASH by increasing G5G8 and biliary cholesterol secretion [150]. 
However, clinical data regarding the efficacy of Urso in NAFLD and NASH are inconsistent. 
While one study of standard dose Urso observed improvements in serum liver enzymes and 
steatosis, others found either no or slight improvements in serum liver enzymes with no 
improvements in liver histology with standard or high dose Urso [226-231]. The lack of efficacy 
observed in human studies may be explained, in part, by our findings in mice that Urso causes a 
simultaneous suppression of bile acid synthesis that minimizes the overall cholesterol elimination 
achieved via G5G8 [150]. The present study suggests that Urso regulates G5G8 by promoting 
canalicular localization and that this effect shares a common pathway with FGF15/19-mediated 
suppression of bile acid synthesis. 
Among the multiple effects of Urso, the alleviation of ER stress may be one mechanisms by 
which Urso regulates G5G8. The formation of functional G5G8 heterodimers requires N-linked 
glycosylation of both ABCG5 and ABCG8 within the ER prior to transport onto the canalicular 
surface of cells [152, 153]. Molecular chaperones, calnexin and calreticulin, facilitate folding of 
immature ABCG5 and ABCG8 in the ER and calreticulin stimulates the expression of G5G8 at 
the cell surface [154]. Proper G5G8 formation and trafficking may be impaired under conditions 
of ER stress such as obesity. Accordingly, decreased G5G8 in obese, insulin resistant ob/ob mice 
can be recused by overexpression of adenoviral GRP78, an ER chaperone [147]. Previous reports 
demonstrate that tauroursodeoxycholic acid (TUDCA) is a chemical chaperone that alleviates ER 
stress-induced cell apoptosis as well as insulin resistance and fatty liver in obese, diabetic mice 
[232, 233]. Furthermore, TUDCA increases G5G8 protein in livers of wildtype and db/db mice 
[148]. TUDCA is the hydrophilic, tauro-conjugated form of Urso and in mice, most bile acids are 
conjugated to taurine [234, 235]. 
Urso may also play a regulatory role in sterol homeostasis. In the setting of an expanded bile acid 
pool, bile acid synthesis decreases through negative feedback signaling by FGF15/19. The bile 
acid synthesis pathway is the major route by which cholesterol catabolism occurs. Therefore, 
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increases in bile acid synthesis require upregulation of biliary cholesterol secretion through G5G8 
in order to maintain hepatic sterol balance.  
Our current study extends knowledge on the dynamic role of FGF15/19 signaling in the 
simultaneous regulation of bile acid synthesis and biliary cholesterol secretion. Additionally, we 
observed that Urso mediates the localization of G5G8 to the canalicular surface through a 
FGF15/19-FGFR4-dependent mechanism. Although the mechanisms by which this effect occurs 
are unclear, it likely involves the regulation of multiple processes including ER stress and bile 
acid signaling. 
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CHAPTER 5: A FUTURE DIRECTION IN CLINICAL APPLICATION: EFFECT OF 
EZETIMIBE-URSODIOL COMBINATION THERAPY ON BIOMARKERS OF LIVER 
FUNCTION AND STEROL BALANCE IN SUBJECTS WITH NAFLD 
As the prevalence of NAFLD and NASH rises, the need for safe and effective therapies for 
treatment is becoming increasingly more urgent. A number of available pharmacologic agents 
including ezetimibe (EZ) and ursodiol (Urso) have been tested in clinical trials but have either 
failed or demonstrated minimal efficacy. EZ reduces intestinal absorption of dietary and biliary 
cholesterol by inhibiting NPC1L1 while Urso increases G5G8 and biliary cholesterol secretion. It 
has been demonstrated in multiple mouse models that increasing cholesterol elimination by 
promoting hepatic G5G8-mediated biliary secretion is dependent on intestinal absorption of 
cholesterol. In Ldlr KO mice, overexpression of G5G8 in both the intestine and liver increased 
biliary cholesterol and fecal neutral sterols while fractional absorption, hepatic cholesterol, LDL-
cholesterol, and VLDL-cholesterol were decreased [145]. However, overexpression of G5G8 
only in the liver in Ldlr KO mice increased biliary cholesterol secretion but decreased fractional 
absorption, LDL-cholesterol and VLDL-cholesterol only when intestinal absorption was inhibited 
by EZ [146]. Furthermore, adenoviral overexpression of G5G8 in the liver of db/db mice led to a 
paradoxical increase in plasma cholesterol that could only be suppressed in the presence of EZ 
[147]. These data suggest that concomitant regulation of biliary secretion and intestinal 
absorption of cholesterol is necessary for maintaining cholesterol homeostasis. 
In humans, several studies suggest that EZ may be effective for the treatment of NAFLD. In a 6-
month-long study in NASH patients with dyslipidemia, EZ improved liver enzymes, histology, 
and LDL-cholesterol [236]. EZ in combination with weight loss decreased intrahepatic lipids in 
obese patients [237]. EZ decreased alanine aminotransferase (ALT) after 12 months and steatosis 
after 24 months in newly-diagnosed NAFLD patients [237]. Urso has long been used in liver 
disease including NAFLD though results from clinical studies have been conflicting. Urso (13-15 
mg/kg) has been shown to improve liver enzymes but have no effect on histology [226-228]. In a 
6-month long study assessing a high dose of Urso (28-35 mg/kg), there were no changes in liver 
enzymes or histology [230]. However, a 12-month long study of high dose Urso yielded a 
decrease in ALT along with improvements in glycemic control [231]. As suggested by results 
from preclinical studies, the minimal effects of EZ and Urso monotherapy may be due to the 
interdependence of biliary secretion and intestinal absorption. Therefore, it is hypothesized that a 
combination therapy of EZ to inhibit intestinal absorption of cholesterol with Urso to 
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simultaneously promote biliary cholesterol secretion will increase cholesterol elimination, 
resulting in improvements in biomarkers of liver function and sterol balance in NAFLD. 
To test this hypothesis, a prospective, open-label, pre-/post-treatment, pilot study in subjects with 
NAFLD is proposed (Appendix 1). Enrolled subjects will undergo 6 months of intervention with 
EZ 10 mg daily and Urso 13-15 mg/kg daily with measurements conducted before and after 
treatment. The primary endpoints will be the decrease in ALT and ALT/aspartate 
aminiotransferase (AST) ratio and the secondary endpoints will be the decrease in hepatic fat 
fraction and changes in total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, fasting 
glucose and insulin, HbA1c, IL-8, IL-6, CK18, and plasma campesterol/lathosterol ratio. It is 
anticipated that after 6 months of EZ-Urso, ALT and ALT/AST ratio will be decreased. However, 
a limitation of the study is the possibility that these changes will not be observed in a small, pilot 
study. Nonetheless, useful information can be gathered from measures of hepatic fat fraction, 
glycemic control, inflammation, and plasma lipids. In preclinical studies, overexpression of 
G5G8 in obese, db/db mice decreased fasting glucose, triglycerides, and ER stress indicating that 
EZ-Urso may have significant effects on glycemic control [147]. Expanding the target patient 
population to include those with MetS and measuring hepatic fat fraction as the primary endpoint 
may optimize the potential to identify statistically significant differences pre- and post-treatment. 
Urso increases biliary cholesterol secretion, fecal neutral sterols, and G5G8 in a dose-dependent 
manner, and these effects are maintained with the addition of EZ in mice [150]. However, a 
negative sterol balance is not achieved, evidenced by a lack of a compensatory increase in 
cholesterol synthesis [150]. This is explained at least in part by a suppression in bile acid 
synthesis that is caused by the presence of Urso. Therefore, it is possible that EZ-Urso may not be 
effective in the treatment of NAFLD. However, several differences between mice and humans 
exist that suggest that the effects of EZ-Urso in mice may not translate into humans. In humans, 
EZ decreases fractional cholesterol absorption by approximately 50%, and the maximal reduction 
in LDL-cholesterol is 20% [238-240]. Mice have a significantly greater response to EZ with up to 
a 96% inhibition in intestinal cholesterol absorption [241]. The increased efficacy of EZ in mice 
may limit the effect of Urso on promoting biliary cholesterol secretion compared to humans. 
Additionally, there is conflicting data regarding the role of Urso as an FXR agonist. Urso has 
been considered to be a weak agonist [162, 242, 243]. In mice, Urso has been shown to increase 
ileal Fgf15 and decrease Cyp7a1 to suppress bile acid synthesis [150]. However, a recent study in 
humans demonstrated that short term Urso decreased FGF19 and FXR activation and stimulated 
bile acid synthesis, acting as an FXR antagonist [244]. Although Urso increases G5G8 in mice, 
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the effect in humans is unknown. Hepatic G5G8 abundance will not be directly measured in the 
proposed study, but the campesterol/lathosterol ratio will provide an indication of the 
effectiveness of EZ and Urso on cholesterol elimination. Presumably, lathosterol as a measure of 
cholesterol synthesis will increase to maintain sterol balance in response to increased cholesterol 
elimination. Chronic treatment with EZ alone can increase hepatic cholesterol synthesis [245]. 
Therefore, further studies comparing EZ and Urso monotherapies to the combination therapy are 
needed to determine relative efficacies. 
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CHAPTER 6: SUMMARY 
Imbalances in the regulation of glucose and lipid metabolism lead to the development of MetS. 
There are a multitude of molecular and biochemical pathways that are not specific to individual 
features of MetS but rather are interconnected. This dissertation focuses on the role of two 
distinct yet related aspects of metabolic regulation, circadian rhythms and the cholesterol-bile 
acid axis, in order to identify novel therapeutic targets for features of MetS. 
The existence of a relationship between disrupted circadian rhythms and metabolic disease is 
unequivocal as evidenced by a number of observational studies as well as animal and prospective 
human studies. In analyzing the role of the central clock in conditions of altered sleep/wake 
cycles, evidence indicates that asynchrony between the internal clock and centrally-mediated 
behaviors such as feeding and physical activity precipitates MetS and its associated phenotypes. 
Less is known about the significance of peripheral clocks, though increasing evidence supports 
the role of peripheral clock components as direct transcriptional regulators of glucose and lipid 
metabolism.  
In a mouse model of obesity, we conducted microarray analysis in order to identify potential 
genes of interest in adipose tissue that may be involved in the development of obesity. Of the 
genes that were significantly deregulated, genes associated with circadian rhythms including the 
clock-controlled PAR bZip family were the most overrepresented. During initial studies, we 
confirmed the expression of the PAR bZip genes in adipose tissue of mice and humans. 
Furthermore, we consistently observed a suppression of PAR bZip genes with obesity and insulin 
resistance. Measurements made during a single time point indicate a relationship between clock-
controlled genes and mediators of obesity in adipose tissue. However, whether the decreases in 
PAR bZip genes were a cause of obesity and insulin resistance or an associated outcome could 
not be determined from these studies. 
The PAR bZip transcription factors exhibit functional redundancy, and therefore mice require 
deletion of all three genes to have a significant impact on target genes. This adds a level of 
complexity in generating tissue-specific KO mice for studying the role of the PAR bZip family. 
In an effort to simplify procedures while maintaining our focus on the impact of disrupted 
peripheral clocks in the liver and adipose tissue, we generated and conducted a study in mice 
deficient of Bmal1 in adipose tissue alone (ABKO) and in both adipose tissue and liver 
(LABKO). The objective of this study was to determine the role of peripheral Bmal1 in the 
development of obesity and insulin resistance. Female ABKO and LABKO mice exhibited 
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alterations in feeding and activity patterns indicating that peripheral clocks mediate centrally-
regulated, diurnal functions. Male LABKO mice became more obese but no other significant 
obesity-related phenotypes were observed, even when challenged on a diabetogenic diet. A high-
fat diet has been shown to modulate locomotor activity periodicity as well as the expression of 
core clock and clock-controlled genes in the hypothalamus, liver, and adipose tissue. In our study, 
the effects of disrupted liver and adipose clocks were likely masked and confounded by the 
effects of a high-fat diet, which brings into question the impact of altering peripheral circadian 
rhythms in the setting of a high fat diet. Since a high-fat diet itself impairs circadian rhythmicity, 
it is difficult to delineate between the circadian- and non-circadian-related effects of the diet. It is 
likely that the macronutrient composition of a diet not only has a direct effect on clock genes and 
diurnal behaviors regulating metabolism but also has an impact on the degree of metabolic 
disease observed when peripheral circadian dysfunction precedes a high-fat diet. ABKO and 
LABKO mice also exhibited differences in hepatic cholesterol levels and expression of genes 
involved in cholesterol metabolism. Cholesterol and bile acid synthesis display diurnal patterns of 
activity and are transcriptionally-regulated by core clock genes [177-181]. Altered expression of 
cholesterol metabolic genes including Hmgcr and Srebp2 is associated with NAFLD [73]. The 
link between circadian rhythms and metabolism has revealed a novel approach of timing rather 
than simply restricting food intake for the treatment and/or prevention of metabolic diseases. In 
mice, a high-fat diet consumed at the beginning of the wake phase was less detrimental to body 
weight and glycemic control compared to a high-fat diet consumed at the end of the wake phase 
[127]. Similarly, a clinical study of overweight or obese individuals consuming more calories 
earlier in the day achieved greater weight loss and improved blood glucose levels compared to 
those consuming more during the latter part of the day [131]. Although these studies demonstrate 
compelling evidence supporting the timing of food intake as a therapeutic for metabolic diseases, 
it is unclear how impactful this strategy may be in humans in the setting of a standard American 
diet high in carbohydrates, fat, and cholesterol. Further clinical studies assessing the timing of 
diets with varying maconutrient compositions will provide additional knowledge on the 
magnitude of the effects of circadian rhythms on metabolism. 
Elevated hepatic free cholesterol has been implicated in NAFLD and NASH. Recent findings in 
mice have identified a potential combination drug therapy for the treatment of NAFLD. In these 
experiments, Urso-EZ promoted biliary cholesterol secretion by increasing G5G8 while 
simultaneously inhibiting intestinal cholesterol absorption. Although a compensatory increase in 
cholesterol synthesis was expected, signifying an increase in overall cholesterol elimination, no 
major changes were observed. Rather, there was a significant upregulation of Fgf15 
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corresponding with a suppression of bile acid synthesizing genes. It was hypothesized that the 
increase in G5G8 and decrease in bile acid synthesis by Urso were dependent mechanisms 
mediated by FGF15/19 signaling. In subsequent experiments, FGF19 and Urso were found to 
promote canalicular localization of G5G8. In the presence of FGFR4 ASO, this effect by Urso 
was abolished, indicating that the effects of Urso on G5G8 are dependent on FGF15/19 signaling. 
Urso regulates G5G8 in mice likely through multiple mechanisms involved in alleviating ER 
stress, inducing FXR, and signaling through the FGF15/19 pathway. Further studies in in vitro 
models expressing FGF15/19 and G5G8 are needed in order to differentiate between the 
regulation of G5G8 and bile acid synthesis. By understanding the mechanism(s) of Urso, 
therapeutic strategies to increase G5G8 without affecting bile acid synthesis can be explored for 
the treatment of NAFLD.   
The availability of Urso and EZ as FDA-approved drugs facilitates the translatability of the 
previously conducted preclinical study to humans. Although evidence in mice suggest that the 
effects of Urso-EZ may be mitigated by the suppression of bile acid synthesis, the impact on 
humans warrants further investigation. Species differences in drug response as well as conflicting 
results from trials assessing Urso and EZ monotherapy are all potential reasons why positive 
responses may still be observed in humans. The pilot study proposed in Chapter 5 may not yield 
statistically significant differences in the primary endpoint pre- and post-treatment, but it will still 
provide critical information regarding the underlying mechanisms by which Urso may be 
effective in the treatment of NAFLD. 
Although there are no FDA-approved drugs indicated for NAFLD and NASH currently, the 
potent FXR agonist, obeticholic acid (OCA), has been shown to be efficacious in NASH patients 
in clinical trials. An initial proof-of-concept study demonstrated an improvement in ALT, hepatic 
fibrosis, and insulin sensitivity as well as a reduction in body weight in NAFLD patients with 
T2DM after 6 weeks of treatment with the semi-synthetic bile acid [170]. The Farnesoid X 
Receptor Ligand Obeticholic Acid in NASH Treatment (FLINT) trial was a larger, multi-center 
study assessing the efficacy of OCA in NASH patients [171]. After 72 weeks of treatment, there 
was a significantly greater percentage of patients receiving OCA that had a decrease in NAFLD 
activity score by at least 2 points compared to those receiving placebo [171]. Although the effects 
of OCA on hepatic G5G8 in humans have not been formally tested, OCA and Urso are similar in 
that both induce choleresis and possess anti-apoptotic properties [246, 247]. However, FXR 
activation by OCA decreases bile acid pool size while Urso replaces endogenous bile acids and is 
incorporated into the bile acid pool [235, 248]. A decrease in the bile acid pool favors the 
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formation of cholesterol gallstones. Furthermore, increasing biliary cholesterol secretion by 
G5G8 causes a supersaturation of bile, leading to the precipitation of cholesterol crystals [249, 
250]. Conversely, previous studies in mice have suggested FXR activation may prevent 
cholesterol gallstone formation by inducing Abcb11 and Abcb4, transporters for bile acids and 
phospholipids, respectively [251]. On one hand, FXR activation by OCA may induce gallstones 
by 1) decreasing the bile acid pool size and 2) increasing biliary cholesterol secretion. On the 
other hand, FXR-mediated increases in ABCB11 and ABCB4 may prevent gallstones by 
lowering the cholesterol saturation index. Whether Urso is less likely to induce gallstone 
formation compared to OCA will depend on a combination of factors affecting bile acid pool size, 
G5G8 activity, and FXR activation. Therefore, studies comparing Urso to OCA need to be 
conducted in order to assess the effects of OCA on G5G8 and gallstone formation.  
In the FLINT study, OCA increased serum total cholesterol and LDL-cholesterol while 
decreasing HDL-cholesterol [171]. The increase in serum cholesterol was effectively managed by 
lipid-lowering therapy and resolved upon discontinuation of OCA [171]. The observed changes 
on cholesterol was likely due in part to the effects of FXR on suppressing bile acid synthesis. 
Additionally, FXR activation in mice has been shown to reduce HDL-cholesterol by inducing SR-
B1 and promoting RCT [252, 253]. Although it cannot be determined from these studies whether 
an increase in G5G8-mediated biliary cholesterol secretion and subsequent reabsorption of 
biliary-derived cholesterol could contribute to the increase in serum cholesterol, the addition of 
EZ may mitigate the increase in cholesterol if OCA has a similar effect on G5G8 as Urso. 
However, it is to be noted that FXR activation reduces intestinal cholesterol absorption, 
indicating that the overall effect of adding EZ may be minimized [253]. In addition to lowering 
serum cholesterol, EZ is effective in the prevention of cholesterol gallstones [254]. Therefore, 
studies comparing Urso to OCA both alone and in combination with EZ will determine whether 
1) OCA is more effective in improving biomarkers of NAFLD and NASH and 2) the addition of 
EZ is sufficient to offset the potential negative effects of OCA. Information gathered from these 
future studies will address critical questions regarding the safety and efficacy of Urso and OCA 
as treatments for NAFLD.   
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APPENDICES 
Appendix 1 
The effect of Ezetimibe-Ursodiol combination therapy on biomarkers of liver function and 
sterol balance in subjects with NAFLD 
Drug Identification: Zetia (Ezetimibe)/Ursodiol Combination 
 
                                         Date:     5 May 2015 
                                         Protocol Version 4 
 
Sponsor Principal Investigator:  Gregory Graf, PhD 
University of Kentucky Pharmaceutical Sciences 
345 Biological Pharmaceutical Complex 
489 S. Limestone 
Lexington, KY 40536-0595 
Gregory.Graf@uky.edu 
Phone: (859) 257-4749 
Fax:  (859) 257-7564 
 
 
 
 
 
CONFIDENTIAL STATEMENT 
This document contains confidential information, which should not be copied, referred to, 
released or published without written approval from Gregory Graf, PhD or the University of 
Kentucky.  Investigators are cautioned that the information in this protocol might be subject to 
change and revision.  Any conclusion regarding efficacy and safety must be considered 
provisional. 
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The effect of Ezetimibe-Ursodiol combination therapy on biomarkers of liver function and 
sterol balance in subjects with NAFLD  
I have read and understand this protocol, attachments, and Investigator Brochures for both Zetia 
and Ursodiol.  I agree to conduct the study as outlined in the protocol and to comply with all the 
terms and conditions set out therein.  I confirm that I will conduct the study in accordance with 
ICH GCP guidelines and the ethical principles of the Helsinki Declaration. 
 
Sponsor/Principal Investigator: 
 
Signature:  _______________________________  Date:  _________________ 
 
Printed Name:  ________________________________________ 
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Phone: (859) 257-4749 
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Phone: (859) 338-7825 
Fax:  (859) 323-6445 
Serious Adverse Event 
Reporting 
Merck’s 
Global Safety 
Fax:  (215) 993-1220 
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BACKGROUND AND RATIONALE 
Name and Description of Investigational Products 
This study will determine if two FDA approved drugs administered in combination will reduce 
biomarkers of nonalcoholic fatty liver disease (NAFLD).  Ezetimibe (EZ), marketed as “Zetia” is 
an inhibitor of cholesterol absorption that is indicated for cholesterol lowering.  Its mechanism of 
action is to block the Niemen Pick C 1 Like 1 protein (NPC1L1).  It is available in a single 
formulation (10 mg tablet) prescribed o.p.d.  Ursodiol (Urso) is marketed under multiple names 
by multiple suppliers including UrsoForte, a 500 mg tablet prescribed at 13-15 mg/kg/day, cf.  It 
is indicated for primary biliary cirrhosis.  The mechanism(s) of action of Urso are not fully 
understood, but are thought to be multifaceted and include opposing the effects of toxic bile 
acids, anti-apoptotic properties, and acting as a chemical chaperone among others.    
Background & Hypothesis 
Overweight and obesity is an epidemic that affects almost half of the US population at an estimated 
cost of $147 billion annually [255].  Obesity is strongly associated with the Metabolic Syndrome, 
a cluster of clinical phenotypes associated with increased risk of diabetes and heart disease.  It is 
now recognized that nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of 
Metabolic Syndrome [256].  Although more difficult to diagnose than diabetes or cardiovascular 
disease, current estimates for the incidence of NAFLD range from 17-33% and 5-17% for 
nonalcoholic steatohepatitis (NASH), the more severe expression of NAFLD.[256]  Current 
treatment of NAFLD is limited to lifestyle modification.  Other therapeutic approaches are often 
employed such as insulin sensitizing agents, anti-oxidants and anti-inflammatories, but none are 
particularly effective at reversing the disease [257, 258].  This pilot study will determine if there is 
sufficient evidence to pursue a combination therapy of EZ + Urso to effectively accelerate 
cholesterol elimination, reduce hepatic lipids and improve liver function tests.   
A growing body of literature supports an active role for cholesterol in the development of 
nonalcoholic fatty liver disease (NAFLD) and the progression to nonalcoholic steatohepatitis 
(NASH). Our previously published studies in preclinical models of diet-induced obesity indicate 
that reduced biliary cholesterol secretion accelerates the development of obesity and exacerbates 
hepatic steatosis and inflammation [149].  Conversely, our new preliminary data show that 
accelerating biliary cholesterol secretion through the ABCG5 ABCG8 sterol transporter (G5G8) 
reduces plasma glucose and triglycerides (TG) and restores insulin signaling in obese, db/db 
mice.  In both cases, changes in G5G8 activity and liver phenotypes correlated with alterations in 
markers of endoplasmic reticulum (ER) stress.  ER stress has been linked to hepatic insulin 
resistance and the upregulation of lipogenic, inflammatory, and apoptotic pathways in multiple 
cell types and in preclinical models of NAFLD [259]. 
Perhaps paradoxically, increasing G5G8-mediated biliary cholesterol secretion increases plasma 
and hepatic cholesterol, an effect blocked by co-administration of EZ.  Ezetimibe (EZ) is an 
inhibitor of cholesterol absorption and reduces delivery of cholesterol to both liver and bile [260].  
Similar to accelerated biliary secretion, the inhibition of cholesterol absorption with EZ improves 
liver function in preclinical models [261-263].  Our new preliminary data demonstrate that this 
effect of EZ is G5G8-dependent.  Thus, the effect of accelerated biliary cholesterol secretion is 
mitigated by intestinal absorption, and similarly, the effect of EZ is limited by G5G8.  These 
observations suggest that simultaneous acceleration of biliary secretion and inhibition of 
intestinal absorption will act cooperatively to promote cholesterol elimination from the body. 
Ursodiol (Urso) is a hydrophilic bile acid indicated for cholestasis and the dissolution of 
cholesterol gallstones, but it also acts as a molecular chaperone that alleviates ER stress, increases 
G5G8 and improves NAFLD in preclinical models [148, 264].    We hypothesize that EZ-Urso 
combination therapy will act cooperatively to achieve a “cholesterol drain” that promotes fecal 
elimination of cholesterol and alleviates clinical features of NAFLD (Fig 1).  
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Published & Preliminary Data in Preclinical 
Models 
The inclusion of cholesterol in a high fat, high 
sucrose diet increases the severity of NAFLD 
resulting in steatohepatitis in LDL receptor 
deficient mice [74].  In a mouse model of 
Alström Syndrome, the development of NAFLD 
was associated with the accumulation of hepatic 
free cholesterol due to an increase in hepatic 
uptake and a decrease in biliary elimination.7  In 
a mouse model of Alström Syndrome, the 
development of NAFLD was associated with the 
accumulation of hepatic free cholesterol due to 
an increase in hepatic uptake and a decrease in 
biliary elimination [265].  In this model, hepatic 
G5G8 was strongly repressed despite the 
accumulation of hepatic sterols.  We 
subsequently tested the hypothesis that the 
loss of G5G8 would contribute to NALFD 
[149].  Indeed, the loss of G5G8 resulted in 
accelerated loss of glycemic control and 
hepatic insulin resistance.  Liver weight was 
increased and hepatic lipid accumulation was 
substantially greater in G5G8 KO mice 
compared to wild-type controls (Fig 2).  The 
expression of inflammatory genes was 
increased as was the number of TUNEL and 
F4/80 positive cells.  These changes were 
associated with an increase in markers of ER-
stress (phopsho-eIF2) and suppression of 
insulin signaling (decreased phospho-Akt & 
serine phosphorylation of IRS1).  These data 
suggest that active biliary secretion opposes 
hepatic accumulation of cholesterol and TG 
and is important in the maintenance of insulin 
sensitivity.   
Ezetimibe (EZ) inhibits cholesterol absorption 
by blocking  Niemann-Pick C1-Like 1 
(NPC1L1), the primary transporter 
responsible for cholesterol absorption at the 
apical surface of enterocytes [266].  In 
addition, EZ has been shown to reduce insulin 
resistance and steatosis in both rats and mice 
[262, 263, 267].  However, the ability of EZ 
to promote cholesterol elimination from the 
body is dependent on G5G8 [268].  Therefore, 
we repeated this study in WT and G5G8 KO mice maintained on high fat diets containing EZ 
(0.005%).  Despite the presence of EZ, liver weight and lipids were increased in G5G8 deficient 
mice compared to wild-type controls (Fig 3).   The key implication of this observation is that the 
efficacy of EZ as a therapeutic in the treatment of NAFLD is dependent on G5G8 and biliary 
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cholesterol secretion.   
While these studies establish that biliary cholesterol secretion is essential for liver function in the 
setting of obesity, the therapeutically relevant question is whether this pathway can be targeted in 
the treatment of NAFLD. Therefore, we conducted an experiment to determine if accelerating 
biliary cholesterol secretion could correct liver dysfunction in a model of NAFLD.  Obese, db/db 
mice were infected with either a control virus or 
an adenovirus encoding G5G8 (AdG5G8).  
Expression of the mature, functional forms of 
G5 and G8 was confirmed by western blotting 
(Fig 4).  As expected, AdG5G8 increased biliary cholesterol and fecal neutral sterols. Differences 
in body weight and adiposity were not observed over the 72 hr treatment period.  AdG5G8 reduced 
fasting glucose and improved glucose tolerance in db/db mice (Fig 5).  There was also a decrease 
in fasting triglycerides and a suppression of SREBP and its lipogenic target genes. 
ER stress and activation of the integrated stress 
response (ISR) is thought to play a causative role in 
liver dysfunction in obese mice [232, 269].  
Phosphorylation of eiF2 by a series of stress-
activated kinases results in a cascade of signaling 
events that leads to reduced phosphorylation of 
protein kinase B (Akt), a key mediator of insulin 
signaling [270, 271].  Markers of ER stress were 
further increased obese G5G8 deficient mice 
compared to wild-type controls [149].  Therefore, we 
determined if AdG5G8 could reverse these effects.  
AdG5G8 reduced phospho-eiF2 and increased 
phospho-Akt (Fig 6).  Collectively, these published 
and preliminary data support a role for G5G8 
mediated biliary cholesterol secretion in the 
maintenance of hepatic insulin signaling, glycemic 
control and TG metabolism.  Further, they suggest 
therapeutics which accelerate biliary cholesterol 
secretion may be effective in the treatment of NAFLD 
and its more severe form, NASH. 
Increased biliary cholesterol secretion and fecal sterol 
elimination would presumably lower plasma 
cholesterol levels in db/db mice. However, we 
observed a paradoxical increase in plasma cholesterol following AdG5G8 administration (Fig 7).  
FPLC fractionation of serum indicates that the majority of cholesterol is associated with large 
77 
 
lipoprotein particles (fractions 5-8) such as VLDL or chylomicrons (CM).  These fractions are very 
low triglycerides and enriched in ApoB48 compared to mice treated with control virus (not shown).  
This suggested that the accumulation of these particles was due to reabsorption of secreted biliary 
cholesterol.  
Therefore, we administered AdG5G8 to mice 
in the absence and presence of EZ (Fig 8).  
When cholesterol absorption is inhibited, 
AdG5G8 does not generate large, cholesterol 
rich particles in plasma and total plasma 
cholesterol is reduced. These data indicate 
that in the presence of EZ, AdG5G8 promotes 
biliary secretion of cholesterol that is trapped 
within the proximal small intestine, fails to be 
re-absorbed and is ultimately lost in the feces. 
Similar observations were made in 
atherosclerosis studies in which a G5G8 
transgene expressed in both liver and intestine 
lowered LDL cholesterol and reduced lesion 
area whereas a liver specific transgene was ineffective in the absence of EZ [146, 272].  The key 
implication of our new and previously published observations is that the intestine mitigates the 
efficacy of increased biliary cholesterol secretion in the elimination of cholesterol in the feces.   
Clinical Studies with EZ or Urso Monotherapy 
A number of clinical trials have evaluated either EZ or Urso in the treatment of NAFLD or 
specifically NASH.  Yoneda et al. reported reductions in serum ALT, GGT, plasma triglycerides 
and hepatic fat (biopsy) in a 6-month pre-/post treatment open-label trial in 10 patients [273].  
High sensitivity CRP was also reduced, suggesting improvements in inflammation, but measures 
of insulin resistance were unchanged.  EZ in addition to weight loss was compared to weight loss 
alone in an obese, Australian cohort (BMI=33, n=15) [237].  EZ was effective at reducing 
intrahepatic lipids after adjusting for the effects of weight loss, but did not result in added benefit 
for other measures of NAFLD.  In a non-obese population (n=8), EZ reduced plasma ALT by 40% 
at 6 and 12 months, but failed to reduce hepatic fat as determined by ultrasound [274].  In the 
largest study to date (n=45) in a Japanese population, EZ reduced ALT at 12 months and resulted 
in modest, but significant, reductions in steatosis, ballooning, and other indices of NAFLD by 24 
months [274, 275].  Although limited in numbers of both studies and patients, EZ has shown 
promise in the treatment of NAFLD.  Results with Urso have been mixed. Low-dose Urso (13-15 
mg/kg/day) reduced some markers of inflammation including serum ALT, but failed to 
significantly improve NASH in two separate studies [226, 227].  High-dose Urso (28-32 
mg/kg/day) failed to reduced ALT at either 3 or 6 months in one trial (n=12) [230], but in a 
separate study lowered ALT levels by an average of 40% at 3, 6, 9 and 12 months and normalized 
ALT values in 25% of patients (ALT<35 IU/ml) compared to no reductions or normalizations in 
the placebo group [276].  In the latter study, Urso also reduced HbA1c and HOMA-IR values 
suggesting improved insulin sensitivity.  If our hypothesis is correct, the limited benefit of each of 
these agents is likely due to the interdependent nature of biliary cholesterol secretion and intestinal 
absorptive with respect to cholesterol elimination. 
Conclusions 
Our studies and others support an interdependence of biliary secretion and intestinal absorption 
for effective fecal cholesterol elimination.  As a consequence, monotherapies that reduce 
cholesterol absorption will be limited by biliary secretion rates.  Similarly, compounds that 
increase biliary secretion will be limited by intestinal reabsorption.  A key element of our 
hypothesis is that a combination therapy that simultaneously increases biliary secretion and 
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reduces cholesterol absorption will result in a “cholesterol drain” that actively promotes 
cholesterol elimination from the body.  No currently available therapeutic is indicated for the 
treatment of NAFLD.  The completion of this pilot study will determine if there is sufficient 
evidence to warrant larger and better-controlled trials to determine if EZ-Urso combination will 
promote a negative sterol balance, reduce hepatic lipids and improve biomarkers of liver function 
in subjects with NAFLD.  In addition, the fact that these agents are already FDA approved, have 
been used in large numbers of patients, and are well-tolerated greatly reduces the time required 
for this therapeutic approach to be tested in the NAFLD population should the clinical 
pharmacology goals be achieved.  Thus, the present study has to the potential to have an 
immediate impact in the development of therapeutic approaches in the treatment of NAFDL, 
including NASH.  
REGULATORY GUIDELINES   
This study will be performed in accordance with US 21 Code of Federal Regulations Parts: 
50, Protection of Human Subjects; 
54, Financial Disclosure by Clinical Investigators and 
56, Institutional Review Boards 
 
RESEARCH OBJECTIVES 
Aims 
Determine if ezetimibe-ursodiol combination therapy (EZ-Urso) reduces hepatic fat, improves 
liver function tests and reduces markers of inflammation in subjects with NAFLD. Subjects 
diagnosed with NAFLD will be recruited to participate in an open label, pre-post treatment 6-
month clinical trial to determine if EZ-Urso combination therapy provides benefit in subjects with 
NAFLD.  Pre- and post-treatment measures of liver enzymes, steatosis by MRI quantification, 
inflammatory cytokines, apoptotic markers and plasma lipids will be determined.    
Determine the extent to which a “cholesterol drain” is achieved and associates with markers of 
NAFLD and obesity-related liver phenotypes.  The extent of cholesterol loss is directly reflected 
by the rate of cholesterol synthesis.  Pre- and post-treatment plasma lathosterol, a late 
intermediate in the cholesterol synthesis pathway, will be determined by GC-MS. A reduction in 
plasma campesterol, a marker of sterol absorption, and a lowering of the campesterol/lathosterol 
ratio are also reflective of a greater dependence on de novo synthesis to maintain cellular sterol 
levels in tissues.  The extent to which each of these associates with key measures of the severity 
of NAFLD will be determined.  Similarly, associations with plasma glucose, insulin, and HOMA-
IR will be determined to assess insulin resistance, which is strongly associated with the 
development of NAFLD.  
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INVESTIGATIONAL PLAN 
Description of Overall Study Design 
The study will be conducted as a prospective open label trial with 
pre- and post-treatment measures for all dependent variables.  This 
trial will enroll subjects with a clinical diagnosis of nonalcoholic 
fatty liver disease (NAFLD) by magnetic resonance imaging 
(MRI), computed tomography (CT) or ultrasound, including those 
diagnosed with nonalcoholic steatohepatitis (NASH). Subjects will 
be consented, blood collected and a MRI conducted on the first 
visit.  Subjects will be advised on the proper use of the 
pharmacotherapy and given the first three month’s supply of EZ 
and Urso. For the remaining three months, study drug will be 
delivered by US mail along with return packaging for the prior 
three month’s study medication in order to monitor compliance.  
Subjects will be called routinely to encourage compliance, 
retention, and monitor side effects or adverse events.  After six 
months of pharmacotherapy, subjects will return for a follow-up 
assessment of plasma parameters, MRI and a post-study 
questionnaire.  
Duration of Subject Enrollment:  6 months 
Duration of Study:  18 months 
Dosing Rationale 
No study to date has assessed EZ-Urso combination therapy in the treatment of NAFLD or 
NASH.  Our data in preclinical models suggest that combination therapy will be more effective 
than either single agent.    Although high-dose Urso is required to reduce ALT as a monotherapy, 
noncompliance is a significant concern.  Side effects at this dose included diarrhea and abdominal 
discomfort in a significant number of subjects [276].  In addition, currently available formulations 
require 6-9 tablets daily for subjects between 64-72 inches tall and BMIs ranging from 25 to 50.  
Based on these factors, EZ-Urso combination therapy will include EZ in its standard formulation 
(10 mg/day) and Urso (13-15 mg/kg/day).   
Safety Analysis   
Subjects will be monitored for adverse events through scheduled phone calls once a month.  
Subjects experiencing severe adverse events will be told to discontinue the study medications 
immediately and contact their physician. Mild to moderate adverse events will be reviewed by Dr. 
Grigorian to determine appropriate actions to ensure subject safety. Adverse events will be 
documented and reported in accordance with IRB, and Merck. Subjects will be informed that they 
may withdraw from the study at any time. 
 
SUBJECT POPULATION:   
Recruitment Method 
Subjects will be recruited either through pre-screening by UK HealthCare Hepatology or through 
referring physicians. Fliers containing information about the study and contact information will 
be distributed to UK HealthCare Hepatology and to outside physicians’ offices. The flier will also 
contain a checklist for Dr.  Grigorian and other referring physicians to use for pre-screening. 
Subjects seen by Dr. Grigorian at UK HealthCare Hepatology will be pre-screened during their 
normally scheduled routine appointment to determine if they meet the study eligibility 
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requirements. Referring physicians will be asked to inform subjects deemed potentially eligible 
using the pre-screen checklist about the study and to provide the subject with the completed 
checklist to keep if they decide to enroll in the study. All potential subjects, both from UK 
HealthCare Hepatology and outside physicians’ offices, will contact the study coordinator listed 
on the flier to set up the first appointment which will take place at the Clinical Services Core 
(CSC) facility.   
Selection of Subjects 
Twelve individuals will be enrolled of any gender, race or ethnicities who meet the 
inclusion/exclusion criteria outlined in Table 1.  Subjects will be between the age of 18 and 75 
years with normal renal function, alanine aminotransferase (ALT) in excess of 50% of the normal 
range and an ALT/aspartate aminotransferase (AST) ratio greater than 1.0 who are typically 
referred to the hepatologist by their primary care physician.  Hepatic steatosis is generally 
confirmed by either MRI, CT or ultrasound, but a clinical diagnosis of NASH requires liver 
biopsy and analysis by a pathologist.  Subjects with advanced liver disease with cirrhosis will not 
be recruited as the mechanism of action of the proposed therapeutics is unlikely to provide benefit 
in these subjects.  Having a diagnosis of secondary steatosis or other liver diseases and women 
who are pregnant or breastfeeding will be excluded.  Subjects reporting alcohol intake at levels 
reported to promote liver disease will be excluded.  A critical element of the trial is the precise 
determination of hepatic fat fractions prior to and after pharmacotherapy.  Thus, individuals too 
large for the available research MRI instrument, with known claustrophobia or medical devices or 
conditions incompatible with MRI will be excluded. Individuals from vulnerable populations will 
not be recruited.    
Inclusion/Exclusion Criteria  
Table 1 
Inclusion Exclusion 
18-75 yrs  Normal ALT within last 6 mo 
ALT >1.5 normal (>55 F, 60 M)   
ALT/AST ratio >1.0 Advanced fibrosis based on 1) biopsy, if 
available (Stage 3 or 4 NAFLD), 2) imaging, 
or 3) lab (platelet count <150,000) 
 Alcohol (>20g/day F, >30g/day M) 
Steatosis (MRI, CT or 
Ultrasound) 
2o steatosis, other liver disease 
Normal kidney function (CrCl 
>30mL/min) 
Rx (Urso, EZ, Vit E, fish oils, TZD,  insulin, 
sulfonylureas, HMG-CoA reductase inhibitors) 
  
 Pregnancy/Breastfeeding 
 BMI > 50, largest body circ >160cm, 
claustrophobia, other incompatibilities listed in 
MRI screening form  
 Hypersensitivity to Ezetimibe or ursodiol 
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Concomitants Medications/Treatments to Avoid 
Individuals already taking either EZ or Urso will not be included.  In addition, individuals taking 
therapeutics with reported benefits or complications in the treatment of NAFLD/NASH (vitamin 
E, fish oils), thiazoladinediones (TZDs),  insulin, sulfonylureas, HMG-CoA reductase inhibitors) 
will also be excluded as these may confound the interpretation of the results. 
Subject Withdrawal Criteria 
Voluntary withdrawal: Subjects will be asked to contact the study coordinator in the event that 
voluntary withdrawal from the study is desired. The study coordinator will document the reason 
for withdrawal and schedule a follow-up if withdrawal is due to an adverse event. 
PI-determined withdrawal: If the subject no longer meets inclusion/exclusion criteria or 
experiences a serious adverse event or suspected unexpected serious adverse reaction, the subject 
will be withdrawn from the study. For serious adverse events or suspected unexpected serious 
adverse reactions, any necessary follow-up will be conducted. 
If a subject withdraws or is withdrawn from the study, no additional data will be collected and no 
replacement will be enrolled. The study design accounts for a 25% dropout rate with a minimum 
of 9 subjects needed to reach statistical significance. 
 
STUDY PROCEDURES/EXAMINATIONS 
Initial Contact 
Interested potential subjects will contact the study coordinator and pre-screening will be 
conducted to determine if the potential subject meets criteria for age, alcohol consumption, 
concomitant medications, weight loss, pregnancy/breastfeeding, MRI, and hypersensitivity to the 
study drugs. If the participant is determined eligible, the study coordinator will set up an initial 
appointment (Visit 1) with the CSC in order to obtain consent. If applicable, subjects will be 
reminded at this time to bring the pre-screen checklist completed by their physician to the 
appointment. Additionally, subjects will be asked to present to this visit after a 12 hour fast.   
Visit 1 
Eligibility will be confirmed and informed consent will be obtained. Demographics and contact 
information including name, age, gender, race, phone number, email address, mailing address, 
availability, and referring physician will be obtained or confirmed if information was already 
provided during the initial contact. Subjects will be assigned a unique identification number at 
this point.  Weight will be obtained to determine ursodiol dosing. Data to be collected from the 
chart review include ALT, AST, GGT, lipid panel (total cholesterol, LDL, HDL, TG), and 
HbA1c. Subjects will be given a 3-month supply of their study medication and counseled on each 
medication. Subjects will be expected to keep a daily log of when medication was taken to ensure 
compliance. This log will be provided to the subject at this time. Subjects will be told that about 
7-10 days prior to their completion of the 3-month supply, another 3-month supply of their study 
medication will be mailed to them along with a daily log and a pre-paid package. Subjects are to 
mail back their medication bottles any remaining medication they did not take and their study 
diary in this pre-paid package. The procedure for reporting adverse effects will be explained. 
During this time, the study coordinator will schedule the next appointment for the subject (Visit 
7).  
Visits 1 and 7 
Subjects will present to each visit after a 12 hour fast. Medical history and medication history will 
be obtained. Vital signs (BP, HR), height, weight, waist and hip circumference, and the largest 
body circumference will be measured. This information will be used for determining waist to hip 
ratio and to confirm subject is compatible with the MRI machine. Blood will be drawn via 
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peripheral venipuncture by a trained phlebotomist. A total of 25 mL of blood will be collected 
into green PST, gold SST, and purple tubes for both standard and non-standard labs listed below 
in Table 2. After the clinic visit ,subjects will be asked to return to undergo an MRI at the UK 
Magnetic Resonance Imaging and Spectroscopy Center (MRISC). Subjects will be given 
directions to the MRISC and $25 cash compensation. Subjects will be asked to finish consuming 
any food at least 3.5 hours prior to the MRI appointment. The study coordinator will confirm 
subjects’ contact information in case a phone call is warranted between the time the subject 
leaves the clinic and returns to the MRISC. At this time, subjects will be allowed to leave the 
premises until the MRI appointment. Upon completion of the MRI visit, subjects will be given an 
additional $25 cash compensation for a total of $50 cash compensation per visit.  
Study Flow Chart 
 
Screening Treatment at Home 
Follow-
up 
Procedure Visit 1 
Visit 
2 
Visit 
3 
Visit 
4 
Visit 
5 
Visit 
6 Visit 7 
Telephone Call 
Informed  Consent X       
Demographics X       
Medical History X      X 
Medication History X      X 
Inclusion/Exclusion X       
Height/Weight X      X 
Waist and Hip 
Measurement 
X     
 
X 
Blood Pressure and 
Heart Rate 
X     
 
X 
Clinical Labs X      X 
Study Labs X      X 
MRI X      X 
Questionnaire       X 
Adverse Events X X X X X X X 
Study Drug issued1 X   X    
Daily Log issued1 X   X    
Study Drug compliance2    X   X 
1 = First 3-month’s supply of study drug will be given to the participant at the on-site study visit 
1.  The last 3-month’s supply will be sent via US mail directly to the participant.  The package 
will include an envelope with paid postage for return shipment of the previous 3-month’s 
medications. 
2 = Compliance will be monitored at mid-point and end of study via pill counts and daily log. 
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Dose Titration 
Ursodiol dosing will be titrated up the final dose of 13-15mg/kg/day over a one week period. 
Subjects will take ursodiol 500mg/day for three days then 1000mg/day for four days then 13-
15mg/kg/day from thereafter. This will be done to increase the tolerability of adverse effects. 
Magnetic Resonance Imaging (MRI) 
MRIs for all subjects will be obtained through the UK Magnetic Resonance Imaging and 
Spectroscopy Center (MRISC) in order to more accurately determine the extent of hepatic 
steatosis.  Beyond being a noninvasive procedure, a key advantage of MRI for hepatic fat 
determination over biopsy is that multiple areas of the liver can be analyzed.  Thus, we employ a 
noninvasive approach that better estimates the extent of steatosis throughout the liver. In addition, 
we can monitor changes in hepatic fat fractions pre- and post-treatment. MRI exams will be 
conducted by Dr. Peter Hardy, PhD, a Research Assistant Professor in the Division of 
Radiological and Medical Physics and Dr. James Lee, MD, an Assistant Professor in Radiology.  
Briefly, a 20mm
3
 voxel will be placed at four independent locations (upper and lower right & left 
lobe) of the liver avoiding major vascular structures, liver edge or bile ducts.  STEAM single 
voxel proton spectroscopy will be performed.   TR will be prolonged to minimize T1 effect and 
multiple and short TEs will be performed to limit the effects of J-coupling and estimate T2.  
Spectra will be analyzed and area under the curve will be calculated and recorded by our Peter 
Hardy and James Lee.  Hepatic fat in each subject will be calculated as the mean fat fraction from 
the four scans.   
Shipment of Drug 
Subjects will be given a 3-month supply of medication during their initial visit. Approximately 7-
10 days prior to the end of month 3, study personnel will mail the remaining 3 month’s supply of 
medication to the subject along with a daily log. This shipment will also include a pre-paid 
package in which subjects will use to mail back empty bottles and any unused medication. These 
packages will be mailed to the IDS pharmacy. 
IDS Mailing Address 
 Stephen Sitzlar 
 University of Kentucky 
 1000 S. Limestone Street, Rm A03.101 Pavilion A 
 Lexington, KY 40536 
Telephone Calls and Follow-up 
Medical and medication history will be updated as needed.  Phone interviews will be conducted 
monthly to monitor compliance as well as known side effects of each medication and any 
unexpected side effects or adverse events. Subjects will be contacted 5-7 days before each clinic 
visit as a reminder of their upcoming appointment. Following 6 months of pharmacotherapy, 
subjects will return to the CSC facility for a blood draw, scheduled MRI and completion of a 
post-study questionnaire. 
Laboratory Blood Sampling 
Blood obtained from subjects at each visit will be taken to both the UK HealthCare clinical 
laboratory and to the study laboratory of Dr. Graf located in the Biological Pharmaceutical 
Building for measurements of labs listed in Table 2. Two green PST tubes, one gold SST tube, 
and one purple tube will be delivered to the UK HealthCare clinical laboratory while remaining 
plasma will be divided into aliquots and transported to the study laboratory of Dr. Graf where the 
samples will be stored at -80ºC until use. The non-standard of care labs that will be performed in 
the laboratory of Dr. Graf include measurement of inflammatory markers (interleukin-8, -6, 
tumor necrosis factor α) and a marker of apoptosis (CK18).  Plasma lipids will be extracted and 
analyzed by gas chromatography-mass spectrometry for the determination of intermediate 
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metabolites of cholesterol synthesis (lathosterol) as well as phytosterols (campesterol, sitosterol, 
stigmasterol) to estimate rates of cholesterol synthesis and absorption before and after 
pharmacotherapy.   
Any remaining aliquots of plasma will remain in the study laboratory of Dr. Graf for long-term 
storage.  This will be done so that if new biomarkers of NAFLD/NASH emerge, these samples 
may be analyzed in the future; this will be included with informed consent.   
Table 2 
Lab Standard of care Visit 1 Visit 7 
ALT X X X 
AST X X X 
GGT  X X 
Lipid profile  X X 
Insulin  X X 
Glucose  X X 
HbA1c  X X 
TNFα  X X 
IL-8  X X 
IL-6  X X 
CK18  X X 
Sterols  X X 
 
DRUG SUBSTANCE  
Ezetimibe 
ZETIA (ezetimibe, IND: 52,791) is in a class of lipid-lowering compounds that selectively inhibits 
the intestinal absorption of cholesterol and related phytosterols. The chemical name of ezetimibe 
is 1-(4-fluorophenyl)3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-
azetidinone. The empirical formula is C24H21F2NO3. Its molecular weight is 409.4 and its 
structural formula is: 
 
Ezetimibe is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and 
acetone and practically insoluble in water. Ezetimibe has a melting point of about 163°C and is 
stable at ambient temperature. ZETIA is available as a tablet for oral administration containing 10 
mg of ezetimibe and the following inactive ingredients: croscarmellose sodium NF, lactose 
monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, povidone USP, and 
sodium lauryl sulfate NF. 
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Name and address of Manufacturer:  
Merck Sharp & Dohme Corp. 
126 E. Lincoln Avenue 
MS: RY34-A238 
Rahway, NJ 07065-0900 
 
Ursodiol 
URSO 250 (ursodiol, 250 mg) is available as a film-coated tablet for oral administration. URSO 
Forte (ursodiol, 500 mg) is available as a scored film-coated tablet for oral administration. 
Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring bile acid found in small 
quantities in normal human bile and in larger quantities in the biles of certain species of bears. It 
is a bitter-tasting white powder consisting of crystalline particles freely soluble in ethanol and 
glacial acetic acid, slightly soluble in chloroform, sparingly soluble in ether, and practically 
insoluble in water. The chemical name of ursodiol is 3α,7ß-dihydroxy-5ß-cholan-24-oic (C24 
H40 O4). Ursodiol has a molecular weight of 392.56. Its structure is shown below: 
 
 
 
 
 
 
 
Inactive ingredients: microcrystalline cellulose, povidone, sodium starch glycolate, magnesium 
stearate, ethylcellulose, dibutyl sebacate, carnauba wax, hydroxypropyl methylcellulose, PEG 
3350, PEG 8000, cetyl alcohol, sodium lauryl sulfate and hydrogen peroxide. 
Name and address of Manufacturer:  
Forest Research Institute 
Harborside Financial Center 
Plaza V, Suite 1900 
Jersey City, NJ 07311 
 
INVESTIGATIONAL DRUG ACCOUNTABILITY 
Both drugs in this study (EZ and Urso) will be stored in the Investigational Drug Service (IDS) 
pharmacy during the duration of the study. Merck will directly ship the required amount of EZ to the 
IDS pharmacy where IDS staff will maintain proper storage and security of drug. Urso will be 
purchased from Forest, properly stored, and secured by IDS pharmacy. Both drugs will be packaged 
and labeled by IDS pharmacy staff. The subject’s initial supply of medication will be dispensed from 
the IDS pharmacy to either the study coordinator or other study personnel who will then deliver the 
supply to the subject.   Subjects will be instructed to return any unused drug via mail (see section 
Shipment of Drug). Any unused drug that is returned to IDS will be properly disposed of on-site by 
study personnel. This will be documented in the case report form (CRF). 
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ADVERSE EVENTS 
Reporting Procedures for Exchange of Adverse Event Information 
Adverse Event or AE shall mean any untoward medical occurrence in a Study subject who is 
administered the Study Drug regardless of whether or not a causal relationship with the Study Drug 
exists.  By way of example and without limitation, an AE can be any unfavorable and unintended 
sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with 
the use of the Study Drug. 
“Serious Adverse Event” or “SAE” shall mean any untoward medical occurrence in a Study subject 
who is administered the Study Drug that results in death, a life-threatening drug experience, requires 
inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant 
disability/incapacity, or is a congenital anomaly/birth defect that occurs in the offspring of a patient 
taking the drug, cancer, or is a new cancer if the cancer is the condition of the study, or overdose.  
Other important medical events that may jeopardize the subject or may require intervention to 
prevent one of the outcomes listed previously should also be considered “serious.” 
“Suspected Unexpected Serious Adverse Reaction” or “SUSAR” shall mean any Serious Adverse 
Event, the nature, severity or frequency of which is not consistent with information in the most 
current investigator’s brochure, or with respect to a marketed product the most current Summary of 
Product Characteristics (SPC) or Package Insert. 
Serious Adverse Event and Suspected Unexpected Serious Adverse Reaction, Potential Incident, or 
Incident Reporting:  Principal Investigator shall forward to Merck’s Global Safety (“Merck GS”) 
group any SAE, SUSAR or Incident information, including, but not limited to, all initial and follow-
up information involving any Study subject in the Study.  Notification shall be in the form of a 
completed CIOMS I/MedWatch (or other mutually agreed upon format) within 24 hours of learning 
of the information.  This information shall be transmitted to Merck GS using the contact information 
provided below or such other modified contact information as provided by Merck in writing.  All 
information shall be transmitted in the English language and contain the reporter’s name and the 
Study subject identifier code.   SUSAR information will be reported unblinded if the Study Drug has 
been blinded in the Study.   
 Merck may define certain Non-Serious Events of Interest.  If any Non-Serious Events of Interest 
are defined, Merck will provide such information in writing to Principal Investigator at the time 
of Protocol approval, execution of the study contract or anytime thereafter.  Reporting of any 
defined Non-Serious Events of Interest will be handled in the same manner as SAEs unless 
mutually agreed otherwise in writing by the parties.   
 All reports of Study Drug exposure during pregnancy or lactation whether associated with an AE 
or not, must be reported to Merck GS in accordance with the timelines and contact information 
for an SAE.  Principal Investigator shall follow pregnancies to term to obtain the outcome of the 
pregnancy.  The outcome of the pregnancy shall be forwarded to Merck GS. 
 Institution and Principal Investigator shall fully comply with all of their respective reporting 
obligations to the applicable regulatory authorities with respect to any AE, SAE or SUSAR that 
arises from the Study. 
 SAE reports and any other relevant safety information are to be forwarded to Merck GS FAX 
number:  (215) 993-1220. 
In the event Principal Investigator or Institution becomes aware of a defect or possible defect in the 
Study Drug provided under this Agreement, Institution and Principal Investigator agree to notify 
Merck within one business day of first becoming aware of the defect or possible defect.   
Principal Investigator agrees to notify Merck within twenty-four (24) hours in the event that the FDA 
or any other regulatory authority notifies the Study site of a pending inspection that concerns the 
Study or Institution’s ability to perform clinical research.  In addition, Principal Investigator will 
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forward to Merck any written communication received as a result of the inspection within twenty-
four (24) hours of receipt of such communication and agrees to allow Merck to assist in responding 
to any citations involving the Study Drug.  Such responses shall be made as soon as possible under 
the circumstances or within any earlier deadline set by the issuing regulatory authority. Principal 
Investigator shall also provide to Merck a complete description of documents and any 
correspondence provided to any inspector.  In the event the FDA or other regulatory authority 
requests or requires any action to be taken to address any citations, Principal Investigator and 
Institution agree, after consultation with Merck, to take such action as necessary to address such 
citations. 
A copy of all 15 Day Reports and Annual Progress Reports are to be submitted as required by the 
applicable regulatory authority by the Principal Investigator.  Principal Investigator agrees to cross 
reference this submission according to local regulations, to the Study Drug number (IND, CSA, etc) 
at the time of submission.  Additionally Principal Investigator agrees to submit a copy of these 
reports to Merck (Attn: Global Safety; FAX 215-993-1220) at the time of submission to the 
appropriate regulatory agency. 
Merck may provide the Principal Investigator and Institution, at Study initiation and on an ongoing 
basis, with information regarding the Study Drug, including but not limited to safety information.  
The Principal Investigator and Institution agree to hold this information in confidence. 
Adverse Event Follow-up 
All AEs, including clinically significant changes in physical examinations findings, or isolated 
clinically significant laboratory findings must be followed until the event resolves, the condition 
stabilizes, the event is otherwise explained, or the subject is lost to follow-up.  If resolved or 
stabilized, a resolution date should be documented on the case report form (CRF). 
Adverse events ongoing at the final visit or early termination visit will be followed until that 
adverse event is resolved. 
Pregnancy 
Pregnancy is an exclusion criterion for this study.  Female subjects must be instructed that if up to 
9 months after study drug administration she suspects she may be pregnant, she is to immediately 
contact the Research Coordinator who will schedule a serum pregnancy test within 48 hr to 
confirm pregnancy.  Pregnancy will be followed until resolution (i.e., termination [voluntary or 
spontaneous] or birth) to assess for pregnancy-associated AEs or SAEs such as congenital 
anomaly. 
 Reproductive Risks:  It is not known whether receiving the study drug used in this study 
are harmful to an unborn child.  Pregnancy after administration of either Ezetimibe or 
Ursodiol may involve risks to the mother, and her embryo or fetus.  Therefore, females 
who are capable of reproducing, must use effective contraceptive methods.  These 
methods must be used from the time of screening until the end of the study.  Examples of 
effective birth control are:  hormonal contraceptives (the pill, implant, transdermal patch, 
or injection), barrier methods (condom with spermicide, diaphragm with spermicide), 
IUD, or a male partner who has had a vasectomy. 
 Lactating women:  It is not known whether either of the study drugs or its metabolites are 
excreted in human milk.  Because many drugs are excreted in human milk, women who 
are breastfeeding will be excluded from the study. 
 
POTENTIAL RISK:   
Blood Draws 
The risks associated with blood draws include pain, bruising, soreness and possible infection at 
the site of blood withdrawal, as well as possible fainting.   
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MRI 
The risks associated with MRI include anxiety and possible discomforts from lying on one’s 
back, but are otherwise minimal as no contrast reagents will be used.   
Study Drug 
Both EZ and Urso have been used in large numbers of patients for a number of years and are 
well-tolerated.   
 Side effects listed for Ezetimibe when administered alone include upper respiratory tract 
infection, diarrhea, arthralgia, sinusitis, and pain in extremity and occurred in excess of 
2% of placebo treated subjects. 
 Side effects of Ursodiol include diarrhea, elevated creatinine, elevated blood glucose, 
leukopenia, peptic ulcer, skin rash, and thrombocytopenia.  These adverse reactions 
occurred at similar rates in placebo treated subjects. 
All participants will be monitored for side effects through routine calls from the research 
coordinator.  Subject safety will be monitored according to GCP guidelines.  Any changes to the 
risk/benefit ratio will be reported accordingly to IRB and FDA regulations. 
Privacy/Social 
The only other risk is possible loss of privacy or social distress from the examination (height, 
weight, waist and hip circumference and blood pressure) and medical record review. All 
subjects will be assigned a study identification number. These risks are deemed minimal.   
Only the Principal Investigator, Chief Physician, the CCTS CSC research nurses, and the study 
coordinator will have access to the subjects’ identities and private information.  The study 
coordinator will create a unique identification number for each enrolled subject during the first 
CSC visit.  The tubes of blood collected will only be identified by the individual’s assigned 
unique identification number. All information collected on the subject (age, height, weight, waist 
and hip circumference, blood pressure, heart rate, fasting lipid panel, glucose, liver tests, and 
medication list) will only be identified by the unique identification number assigned. Plasma will 
be collected and stored temporarily in the Biochemical Analysis Laboratory and permanently in 
the Graf Laboratory. Plasma samples and subject data will be associated through the unique 
identification number.  All electronic information is encrypted and stored on secure server with 
password protection (see data management plan).  
 
BENEFIT VS. RISK   
The study is designed to determine if the EZ-Urso combination therapy provides benefit for 
subjects with NAFLD. Should this combination prove efficacious, the condition of these subjects 
will improve.  Subjects will receive results of clinical labs that are standard of care in NAFLD, 
but not other labs that are of experimental value.  Subjects will receive cash compensation for 
their time but not enough to be coercive. In addition, volunteers may receive personal 
satisfaction from participating in a study that is designed to improve a health condition that 
directly affects them.    
The risks to the subject are minimal. The procedures to be performed are limited to blood 
collection, MRI and the administration of two well-tolerated therapeutics.  All procedures will 
be performed in the CCTS CSC using skilled nurses, a hospital environment, and sterile 
procedures. MRIs will be performed by Dr. Peter Hardy, PhD and Dr. James Lee, MD. To 
protect privacy, all data will only be identified by the assigned unique study number, and no 
identifying information will be collected.   
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STATISTICAL ANALYSIS 
Statistical Methods 
Clinical and biochemical measures in pre and post-treatment samples will be analyzed using a 
paired t-test.  Linear regression will be used to determine relationships between changes in 
indices of cholesterol synthesis and absorption (plasma lathosterol, campesterol, & 
campesterol/lathosterol ratio) and changes in clinical and biochemical measures (e.g.  
lathosterol vs.  ALT).  Differences will be considered significant at p < 0.05. 
A reduction in plasma ALT to within 50% of the normal range (<50IU/L) will be considered as 
clinically relevant (i.e. reduced to 75 IU/L).  Using previously published data from the chief 
physician’s studies, ALT levels in subjects with NASH are expected to be ~106 ± 65 [227].  
Using a type 1 error rate of 5% and a sample size of 9, the type 2 error rate will be 50% 
Any deviation from the planned analyses will be done in consult with the biostatistics core within 
the UK CCTS and reported to the IRB. 
Primary Endpoints  
The primary endpoints of this study will include the reduction in ALT and reduction in ALT/AST 
ratio.  
Secondary Endpoints   
Secondary endpoints will include reduction in hepatic fat fraction, changes in GGT, total 
cholesterol, LDL, HDL, triglycerides, fasting glucose, fasting insulin, HbA1c, IL-8, IL-6, CK18, 
and differences in plasma lipids.  
 
STUDY MANAGEMENT 
IRB Approval 
This study must have initial and at least annual approval from an Institutional Review Board 
(IRB) responsible for approving human subject research.  Furthermore, screening and enrollment 
of subjects into the trial will not commence until Investigator receives the IRB approval letter.  In 
addition, a copy of the IRB approval letter must be filed on-site in the investigator’s study binder.  
When appropriate, amendments to the protocol must be submitted for IRB review and approval 
before being implemented. 
Informed Consent 
 Study enrollment should not begin until the Investigator has received an approved and 
validated informed consent from the IRB. 
 All subjects enrolling in the study: 
1.  Will be informed of the investigational nature of the study 
2. Must be given a copy of the Informed Consent Form 
3. Must be given the opportunity to ask any questions regarding the study treatment 
4. Will have voluntarily and willingly signed the Informed Consent Form prior to 
initiation of any study related test/procedure.   
Protocol Adherence 
The Investigator agrees to conduct the study in accordance with this protocol.  Prior to beginning 
the study, the Investigator(s) must sign both the Investigator Agreement and the protocol 
signature page. 
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An Investigator must not make any changes to the study without first receiving written approval 
from the Principal Investigator and IRB, except when necessary to eliminate apparent immediate 
hazard to a subject. 
Study Monitoring and Auditing 
Study monitoring will be carried out in compliance with FDA regulation (21 CFR 812) and all 
GCP guidelines. 
Data Recording and Record Retention 
1. All data will be recorded on electronic Case Report Forms for each subject enrolled in the 
study as well as in the subject records. 
2. The Investigator will ensure that the medical records are made available for review by the 
study monitor or governmental regulatory bodies as required. 
3. All subject study records are to be maintained in a secure storage facility until notified by 
the Principal Investigator that the forms may be discarded.  This includes the following: 
a) Case Report Forms, source documentation, signed informed consents and enrollment 
logs 
b) Drug Accountability Records and shipment receipts of all drug shipped to the study 
site 
c) Correspondence with the IRB or Ethics Committee, Principal Investigator, FDA, 
monitor, or other investigators 
d) Study protocol and any amendments issued 
e) Protocol and informed consent approvals from the IRB 
f) Investigator agreements and curricula vitae of Investigator(s), and the site personnel 
signature form 
g) Laboratory certificates, if applicable 
Data from the analyses of human samples will be managed using Research Electronic Data 
Capture (REDCap), which is provided through the UK CCTS.  REDCap is a secure web-based 
application for building and managing online databases. The application is trademarked by the 
Vanderbilt CTSA. Vanderbilt developed a Consortium of institutions to share this research and 
data capture tool. Users are engaged in a Regulatory and Software Validation Committee, which 
includes compliance with 21 CFR Part 11, HIPAA, and other regulations.  The University of 
Kentucky REDCap software was installed in the Institute for Pharmaceutical Outcomes & Policy 
in 2008 and is located in 180 BioPharm Complex (BPC). The web server and the database server 
are located on separate servers behind a firewall with in-house control with UK's campus 
network. In addition, in order to maintain secure communications, the web server has a secured 
security license (SSL) and is located on https://redcap.rdmc.org/redcap/.  Research data is stored 
locally and is backed up daily using MySQL Administrator software using the Windows Server 
2008 R2 edition. Accounts are created using domain accounts generated by UK used for 
authentication purposes. This login process requires individual password protection for 
investigators. Dr. Graf will assign users to the REDCap project and define permissions for each 
user. User rights that may be issued include the ability to create calendar events, import or export 
data, build reports, lock or unlock records when entry is completed, create records, rename 
records, edit or delete records, and determine if an electronic signature is required for certain 
events. In addition, each user can be given an expiration date which will remove access to that 
individual user. REDCap maintains a built-in audit trail that logs all user activity and pages 
viewed. The logging record can be viewed by those with proper user rights. When investigators 
are logged onto REDCap to enter data, a vulnerability to hacking the account while open is of 
concern; however, all data is encrypted when transmitted to the REDCap server. Portable devices 
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are not at risk because nothing is downloaded onto the device. A secure web based connection is 
used for all data collection. Data storage on portable devices is not a security concern for 
REDCap administration, but appropriate measures will be taken when exporting data from 
REDCap. To assist investigators, REDCap has an email function that offers greater security for 
large attachments that contain sensitive data. Each recipient receives an email containing a unique 
downloaded URL, along with a second follow up email with the password for downloading the 
files. The file is stored securely and removed from the server upon the specified expiration date.  
Data and Safety Monitoring 
Monitoring for adverse events will be conducted in real-time by the study investigators and 
study coordinators. Risks involved with this study are considered greater than minimal risk.  For 
this reason, we will utilize the standing independent Data Safety Monitoring Board (DSMB) as 
chartered by the Center for Clinical and Translational Science (CCTS).  The DSMB will meet 
semiannually or as needed, and will review subject recruitment, AE’s, side effects, laboratory 
results, dropouts, protocol violations, and inclusion/exclusion criteria.  More frequent meetings 
will take place if side effects or other problems are prevalent.    
All procedures will be conducted by well-trained nursing staff or physicians.  Once subjects begin 
the pharmacotherapy phase of the trial, patient safety will be monitored through routine phone 
calls by the clinical research coordinator.  Incidental significant MRI findings or reported 
unexpected and known side effects will be recorded and regularly reported to Drs. Grigorian and 
Graf at monthly research staff meetings.  Any serious side effects or adverse events will be 
immediately reported to the chief physician who will take appropriate actions to ensure there is 
no compromise of patient care or safety.  These subjects may be removed from the study 
depending on the nature of the event.      
Interim reviews  
The PI will ensure that the IRB is notified within the timeframe set by the IRB of any AEs and 
SAEs, protocol deviation/violation notification.  The PI will ensure that the IRB is immediately 
made aware of any protocol amendments, study suspension/termination, safety reporting by the 
sponsor.  
This protocol will be continuously monitored in real-time by the principal investigator and study 
coordinator for adverse events (AEs).  
AEs will be graded according to intensity. Mild: Discomfort noticed but no disruption of normal 
daily activity. Moderate: Discomfort sufficient to reduce or affect normal daily activity. Severe: 
Incapacitating with inability to work or perform normal daily activity. 
The attribution scale for AE reporting will be as follows. Probable: AE is related to the procedure 
or drug (e.g. infection from a fat biopsy). Possible: AE follows the procedure or drug within a 
reasonable period (within 7 days), but may have been produced by the subject’s clinical state or 
other factors (e.g. rash 3 days following the FSIGT). Remote: AE does not follow the procedure 
or drug within a reasonable period and could readily have been produced by the subject’s clinical 
state or other factors. Unrelated: AE is judged to be clearly due to extraneous causes and does not 
meet the above criteria. 
Plan for unexpected adverse event (AE) reporting 
Serious AEs will be reported to Human Subjects/IRB within 48 hr, and will also be reported to 
Merck, within 24 hours of the Investigator becoming aware of the event. Unanticipated events 
will be reported to the IRB no later than 15 days after the event. Annual reporting of adverse 
events will be reported to the University of Kentucky Institutional Review Board, and Merck. 
Monitoring of adverse events 
As described in the research plan, subjects who are treated with EZ-Urso combination therapy 
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will have a total of two clinical visits and 5 telephone contacts. Adverse events will be monitored 
via exams, vital signs, review of subject’s medical chart, phone interviews and documented. Each 
visit will be documented with a progress note in the research chart. 
 
SUBJECT CONFIDENTIALITY   
The Investigator and the Principal Investigator affirm a subject’s right to protection against 
invasion of privacy.  In compliance with United States federal regulations, the Principal 
Investigator requires the Investigator(s) to permit, when necessary, representatives from the FDA 
or other regulatory authorities to review and/or copy any medical records relevant to the study in 
accordance with local laws.  Should direct access to medical records require a waiver or 
authorization separate from the subject’s statement of informed consent, it is the responsibility of 
the Investigator to obtain such permission in writing from the appropriate individual. 
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Appendix 2 
Abbreviations 
4S: Scandinavian simvastatin survival study 
ABCA1: ATP binding cassette subfamily A, member 1 
ABCB11: ATP binding cassette, subfamily B, member 11 
ABCB4: ATP binding cassette, subfamily B, member 4 
ABCD2: ATP binding cassette, subfamily D, member 2 
ABCG5: ATP binding cassette subfamily G, member 5 
ABCG8: ATP binding cassette subfamily G, member 8 
ABKO: adipose-Bmal1 knockout mice 
ACAT2: acetyl-CoA actyltransferase 2 
Ad-Cre: adenoviral vectors contained Cre recombinase 
Ad-Empty: adenoviral vectors containing no insert 
ALT: alanine aminotransferase 
APOA1: apolipoprotein A1 
APOB: apolipoprotein B 
APOCIII: apolipoprotein CIII 
APOE: apolipoprotein E 
ASBT: apical sodium-dependent bile acid transporter 
ASO: antisense oligonucleotide 
AST: aspartate aminotransferase 
ATGL: adipose triglyceride lipase 
BMAL1: aryl hydrocarbon receptor nuclear translocator-like protein 1 
BMI: body mass index 
CA: cholic acid 
cAMP: cyclic adenosine monophosphate 
CD: control diet 
CDCA: chenodeoxycholic acid 
CETP: cholesteryl ester transfer protein 
ChREBP: carbohydrate responsive element binding protein 
CLOCK: circadian locomotor output cycles kaput 
CRY: cryptochrome 
CSI: cholesterol saturation index 
CVD: cardiovascular disease 
CYP27A1: sterol 27-hydroxylase 
CYP7A1: cholesterol 7α-hydroxylase 
CYP7B1: 25-hydroxycholesterol 7α-hydroxylase 
CYP8B1: sterol 12α-hydroxylase 
DAVID: Database for Annotation, Visualization and Integrate Discovery 
Db/db: leptin receptor-deficient mice 
DBP: d site albumin promotor binding protein 
DD: diabetogenic diet 
EE: energy expenditure 
ER: endoplasmic reticulum 
EZ: ezetimibe 
FAA: food anticipatory activity 
FABP-4: fatty acid binding protein 
FFA: free fatty acid 
FGF15: fibroblast growth factor 15 
FGF15/19: FGF15 and FGF19 
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FGFR4: fibroblast growth factor receptor 4 
FLINT: Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment 
FOXO1: forkhead box protein O1 
FPLC: fast protein liquid chromatography 
FXR: farnesoid X receptor 
FXRE: FXR response element 
G5G8: ABCG5 ABCG8 
GTT: glucose tolerance test 
HDL: high density lipoprotein 
HLF: hepatic leukemia factor 
HMG-CoA: 3-hydroxy-3-methylglutary CoA 
HMGCR: HMG-CoA reductase 
HSL: hormone sensitive lipase 
IL-1α: interleukin 1 alpha 
IL-10: interleukin 10 
IL-6: interleukin 6 
IMPROVE-IT: Vytorin efficacy international trial 
INSIG1: insulin-induced protein 1 
INSIG2: insulin-induced protein 2 
IR: insulin resistant 
IRS-1: insulin receptor substrate 
IS: insulin sensitive 
IST: insulin sensitivity test 
KO: knockout 
LABKO: liver- and adipose-Bmal1 knockout mice 
LCAT: lecithin:cholesterol acyltransferase 
LDL: low density lipoprotein 
LDLR: low density lipoprotein receptor 
LPL: lipoprotein lipase 
LXRα: liver X receptor alpha 
MetS: metabolic syndrome 
MTP: microsomal triglyceride transfer protein 
NAFLD: nonalcoholic fatty liver disease 
NASH: nonalcoholic steatohepatitis 
NEFA: non-esterified fatty acid 
NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells 
NPC1L1: Niemann-Pick C1-like 1 
Ob/ob: leptin-deficient mice 
OCA: obeticholic acid 
OSTα/β: organic solute transporter alpha/beta 
PAR bZip: proline- and acid-rich basic region leucine zipper 
PEPCK: phosphoenolpyruvate carboxykinase 
PER: period 
PGC1α: PPARG coactivator 1 alpha 
PPARα: peroxisome proliferator activated receptor alpha 
PPARγ: peroxisome proliferator activated receptor gamma 
RCT: reverse cholesterol transport 
REE: resting energy expenditure 
RER: respiratory exchange ratio 
REV-ERBα: nuclear receptor subfamily 1, group D, member 1 
RORα: Retinoic acid receptor-related orphan receptor alpha 
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RORE: retinoic acid-related orphan receptor response element 
RXR: retinoid X receptor 
SCAP: SREBP cleavage-activating protein 
SCN: suprachiasmatic nucleus 
SHP: small heterodimer partner 
SR-B1: scavenger receptor B1 
SREBP-1c: sterol regulatory element binding protein 1c 
SREBP-2: sterol regulatory element binding protein 2 
T2DM: type 2 diabetes mellitus 
τ: tau or period 
TEF: thyrotroph embryonic factor 
TLR2: toll like receptor 2 
TLR4: toll like receptor 4 
TNF-α: tumor necrosis factor alpha 
TUDCA: tauroursodeoxycholic acid 
Urso: ursodiol 
VLDL: very low density lipoprotein 
WAT: white adipose tissue 
WT: wildtype 
ZO-1: zona occludens-1 
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